Biodexa Pharmaceuticals (BDRX) F-1 18 Mar 24 Registration statement (foreign) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2023
Entity Addresses [Line Items]
Document Type	F-1
Amendment Flag	false
Entity Registrant Name	Biodexa Pharmaceuticals plc
Entity Central Index Key	0001643918
Entity Incorporation, State or Country Code	X0
Entity Address, Address Line One	Caspian Point
Entity Address, Address Line Two	Caspian Way
Entity Address, City or Town	Cardiff
Entity Address, Country	GB
Entity Address, Postal Zip Code	CF10 4DQ
Country Region	+44
City Area Code	29
Local Phone Number	20480 180
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	850 Library Ave.
Entity Address, Address Line Two	Suite 204
Entity Address, City or Town	Newark
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19711
City Area Code	(302)
Local Phone Number	738-6680
Contact Personnel Name	Donald J. Puglisi

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Profit or loss [abstract]
Revenue			£ 699	£ 578	£ 180
Grant revenue					163
Total revenue	£ 298	£ 468	699	578	343
Other income		16	22	24	12
Research and development costs	(2,251)	(2,413)	(5,111)	(4,654)	(6,068)
Impairment of intangible assets					(12,369)
Administrative costs	(2,291)	(1,849)	(4,542)	(2,946)	(4,958)
Loss from operations	(4,244)	(3,778)	(8,932)	(6,998)	(23,040)
Finance income	410	404	497	936	1
Finance expense	(22)	(24)	(53)	(44)	(431)
Loss before tax	(3,856)	(3,398)	(8,488)	(6,106)	(23,470)
Taxation	288	337	832	646	1,281
Loss for the year attributable to the owners of the parent	(3,568)	(3,061)	(7,656)	(5,460)	(22,189)
Items that will or may be reclassified subsequently to profit or loss:
Total other comprehensive gain net of tax					508
Exchange gains arising on translation of foreign operations					508
Total other comprehensive income net of tax					508
Total comprehensive loss attributable to the owners of the parent	£ (3,568)	£ (3,061)	£ (7,656)	£ (5,460)	£ (21,681)
Loss per share
Basic and diluted loss per ordinary share	£ (4)	£ (62)	£ (1.55)	£ (1.36)	£ (10.36)

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - GBP (£) £ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Non-current assets
Property, plant and equipment	£ 693	£ 831	£ 1,152	£ 542
Intangible assets		6
Intangible assets	5	6
Total Non-Current Assets	698	837	1,152	542
Current assets
Trade and other receivables	903	1,006	1,034	572
Taxation	1,134	846	670	1,157
Cash and cash equivalents	5,227	2,836	10,057	7,546
Total Current Assets	7,264	4,688	11,761	9,275
Total assets	7,962	5,525	12,913	9,817
Non-current liabilities
Borrowings	380	463	620	60
Provisions				50
Total Non-Current Liabilities	380	463	620	110
Current liabilities
Trade and other payables	1,755	1,447	1,092	1,230
Borrowings	164	161	146	200
Provisions		207	50
Derivative financial liability	364	85	553	1,559
Total current Liabilities	2,283	1,900	1,841	2,989
Total liabilities	2,663	2,363	2,461	3,099
Issued capital and reserves attributable to owners of the parent
Share capital	5,341	1,108	1,098	1,063
Share premium	84,653	83,667	83,434	74,364
Merger reserve	53,003	53,003	53,003	53,003
Warrant reserve	1,275	720	720	720
Accumulated deficit	(138,973)	(135,336)	(127,803)	(122,432)
Total equity	5,299	3,162	10,452	6,718
Total equity and liabilities	£ 7,962	£ 5,525	£ 12,913	£ 9,817

CONSOLDATED STATEMENTS OF CASH

CONSOLDATED STATEMENTS OF CASH FLOWS - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Cash flows from operating activities
Loss for the year	£ (3,568)	£ (3,061)	£ (7,656)		£ (5,460)		£ (22,189)
Adjustments for:
Depreciation of property, plant and equipment	72	96	174		213		1,089
Depreciation of right of use asset	70	86	166		190		118
Amortisation of intangible fixed assets	1		3				10
Loss/(Profit) on disposal of fixed assets		2	14		(39)		(226)
Impairment of intangible assets							12,369
Impairment of loan			207
Finance income	(410)	(404)	(497)		(936)		(1)
Finance expense	22	24	53		44		431
Share-based payment charge/(credit)	15	100	123	[1]	89	[1]	(404)	[1]
Taxation	(288)	(337)	(832)		(646)		(1,281)
Foreign exchange (gains)/losses			(1)		(3)		387
Cash flows from operating activities before changes in working capital	(4,086)	(3,494)	(8,246)		(6,548)		(9,697)
Decrease/(Increase) in trade and other receivables	103	(224)	7		(487)		493
Increase/(Decrease) in trade and other payables	309	187	356		(130)		(2,004)
Increase/(Decrease) in provisions	(207)	(8)	(157)				(47)
Cash used in operations	(3,881)	(3,539)	(7,726)		(7,165)		(11,255)
Taxes received			678		1,157		1,954
Net cash used in operating activities	(3,881)	(3,539)	(7,048)		(6,008)		(9,301)
Investing activities
Purchases of property, plant and equipment	(4)	(33)	(62)		(320)		(209)
Proceeds from disposal of fixed assets		9	20		42		143
Long term deposit for guarantee for Government loan							2,639
Loan granted			(207)
Interest received	24	7	29				1
Net cash (used in)/generated from investing activities	20	(17)	(220)		(278)		2,574
Financing activities
Interest paid	(7)	(5)	(18)		(15)		(34)
Receipts from sub-lessee on onerous lease							45
Amounts paid on lease liabilities	(95)	(73)	(178)		(112)		(258)
Repayment of Government grants on closure of Spanish operation							(229)
(Repayment)/Proceeds from Government loan					(103)		(6,182)
Share issues including warrants, net of costs	6,354		243		9,035		9,742
Net cash generated from financing activities	6,252	(78)	47		8,805		3,084
Net increase/(decrease) in cash and cash equivalents	2,391	(3,634)	(7,221)		2,519		(3,643)
Cash and cash equivalents at beginning of year	2,836	10,057	10,057		7,546		10,928
Exchange (losses)/gains on cash and cash equivalents					(8)		261
Cash and cash equivalents at end of year	£ 5,227	£ 6,423	£ 2,836		£ 10,057		£ 7,546
[1]credit recognised in 2020 due to employees leaving the company and the subsequent reversal of the cumulative share based payment charge relating to share options under the 2014 Biodexa Pharmaceuticals plc Enterprise Management Incentive Scheme.

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - GBP (£) £ in Thousands	Share Capital [Member]	Share premium [member]	Merger reserve [member]	Warrant reserve [member]	Foreign Exchange Reserve [Member]	Retained earnings [member]	Total
At 1 January 2020 at Dec. 31, 2019	£ 1,023	£ 65,879	£ 53,003		£ (508)	£ (99,839)	£ 19,558
IfrsStatementLineItems [Line Items]
Loss for the year						(22,189)	(22,189)
Total comprehensive loss					508	(22,189)	(21,681)
Transactions with owners
Shares issued on 27 July 2020	21	5,729					5,750
Costs associated with share issue on 27 July 2020		(489)					(489)
Share-based payment credit						(404)	(404)
Total contribution by and distributions to owners	40	8,485		720		(404)	8,841
Foreign exchange translation					508		508
Shares issued with warrants on 18 May 2020 – notes 16,23	16	2,527		720			3,263
Costs associated with shares issued with warrants on 18 May 2020		(544)					(544)
Shares issued on 19 August 2020	3	1,278					1,281
Costs associated with share issue on 19 August 2020		(16)					(16)
At 31 December 2020 at Dec. 31, 2020	1,063	74,364	53,003	720		(122,432)	6,718
IfrsStatementLineItems [Line Items]
Loss for the year						(5,460)	(5,460)
Total comprehensive loss						(5,460)	(5,460)
Transactions with owners
Costs associated with share issue on 27 July 2020		(1,046)					(1,046)
Share-based payment credit						89	89
Total contribution by and distributions to owners	35	9,070				89	9,194
Foreign exchange translation
Shares issued on 19 February 2021		161					161
Costs associated with share issue on 19 February 2021		(10)					(10)
Shares issued on 6 July 2021	35	9,965					10,000
At 31 December 2020 at Dec. 31, 2021	1,098	83,434	53,003	720		(127,803)	10,452
IfrsStatementLineItems [Line Items]
Loss for the year						(3,061)	(3,061)
Total comprehensive loss						(3,061)	(3,061)
Transactions with owners
Shares issued on 27 July 2020
Exercise of warrants on 22 March 2022
Share-based payment credit						100	100
Total contribution by and distributions to owners						100	100
At 31 December 2020 at Jun. 30, 2022	1,098	83,434	53,003	720		(130,764)	7,491
At 1 January 2020 at Dec. 31, 2021	1,098	83,434	53,003	720		(127,803)	10,452
IfrsStatementLineItems [Line Items]
Loss for the year						(7,656)	(7,656)
Total comprehensive loss						(7,656)	(7,656)
Transactions with owners
Share-based payment credit						123	123
Total contribution by and distributions to owners	10	233				123	366
Foreign exchange translation
Exercise of warrants on 22 March 2022
Shares issued with warrants on 18 May 2020 – notes 16,23	10	311					321
Costs associated with shares issued with warrants on 18 May 2020		(78)					(78)
At 31 December 2020 at Dec. 31, 2022	1,108	83,667	53,003	720		(135,336)	3,162
IfrsStatementLineItems [Line Items]
Loss for the year						(3,568)	(3,568)
Total comprehensive loss						(3,568)	(3,568)
Transactions with owners
Shares issued on 27 July 2020	65	99		4,803			4,967
Costs associated with share issue on 15 February 2023		(29)		(874)			(903)
Costs associated with share issue on 27 July 2020	2,214	(1,404)		1,214			2,024
Costs associated with share issue on 26 May 2023				(317)		(210)	(527)
Exercise of pre-funded warrants during period	1,244	1,024		(2,266)			2
Exercise of warrants on 22 March 2022	710	1,296		(2,005)			1
Share-based payment credit						141	141
Total contribution by and distributions to owners	4,233	986		555		(69)	5,705
At 31 December 2020 at Jun. 30, 2023	£ 5,341	£ 84,653	£ 53,003	£ 1,275		£ (138,973)	£ 5,299

Basis of preparation

Basis of preparation	6 Months Ended
	Jun. 30, 2023
Basis Of Preparation
Basis of preparation	1. Basis of preparation The unaudited interim consolidated financial information for the six months ended 30 June 2023 has been prepared following the recognition and measurement principles of the International Financial Reporting Standards, International Accounting Standards and Interpretations (collectively IFRS) issued by the International Accounting Standards Board (IASB), in accordance with International Accounting Standard 34 Interim Financial Reporting (‘IAS 34’). The interim consolidated financial information does not include all the information and disclosures required in the annual financial information and should be read in conjunction with the audited financial statements for the year ended 31 December 2022. The condensed interim financial information has not been audited. The comparative financial information for the six months ended 30 June 2022 and the year ended 31 December 2022 in this interim financial information does not constitute statutory accounts for that year. The statutory accounts for 31 December 2022 have been delivered to the UK Registrar of Companies. The auditor’s report on those accounts was unqualified and did not contain a statement under section 498(2) or 498(3) of the Companies Act 2006. The auditor’s report did draw attention to a material uncertainty related to going concern and the requirement, as of the date of the report, for additional funding to be raised by the Company by the fourth quarter of 2023. Going Concern We have experienced net losses and significant cash outflows from cash used in operating activities over the past years as we have developed our portfolio. For the six months to June 30, 2023, we incurred a consolidated loss from operations of £ 3.57 3.06 3.88 3.54 138.97 Our future viability is dependent on our ability to raise cash from financing activities to finance our development plans until commercialisation, generate cash from operating activities and to successfully obtain regulatory approval to allow marketing of our development products. Our failure to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. Our consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at June 30, 2023, we had cash and cash equivalents of £ 5.23 We have prepared cash flow forecasts and considered the cash flow requirement for the next three years including the period 12 months from the date of approval of this interim financial information. These forecasts show that further financing will be required before the first quarter of 2024 assuming, inter alia, that certain development programs and other operating activities continue as currently planned. If we raise additional funds through the issuance of debt securities or additional equity securities, it could result in dilution to our existing shareholders, increased fixed payment obligations and these securities may have rights senior to those of our ordinary shares (including the ADSs) and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects. In our opinion, the environment for financing of small and micro-cap biotech companies is as challenging as it has been since the financial crisis of 2008-10. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by Biodexa are likely to be dilutive. We continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any alternative courses of action to finance the Company would be successful. This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt upon our ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to us which are actionable before our cash resources run out then we will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would stated at net realizable value and all liabilities would be accelerated to current liabilities. We believe there are adequate options and time available to secure additional financing for the Company and after considering the uncertainties, we consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the timing of clinical trials. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. If we lack sufficient capital to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected.

Finance income and expense

Finance income and expense	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Finance income and expense	2. Finance income and expense Schedule of finance income Six months unaudited £’000 Six months unaudited £’000 Finance income Interest received on bank deposits 24 6 Gain on equity settled derivative financial liability 386 398 Total finance income 410 404 The gain on the equity settled derivative financial liability in 1H23 and 1H22 arose as a result of the fall in the Biodexa share price. Six months unaudited £’000 Six months unaudited £’000 Finance expense Interest expense on lease liabilities 15 24 Other loans 7 - Total finance expense 22 24	6 Finance income and expense Schedule of finance income 2022 £’000 2021 £’000 2020 £’000 Finance income Interest received on bank deposits 29 – 1 Gain on equity settled derivative financial liability 468 936 – Total finance income 497 936 1 2022 £’000 2021 £’000 2020 £’000 Finance expense Interest expense on lease liabilities 43 36 20 Other loans 10 8 14 Loss on equity settled derivative financial liability – – 397 Total finance expense 53 44 431 The gain/(loss) on the equity settled derivative financial liability in 2022, 2021 and 2020 arose as a result of the movement in share price (note 19).

Taxation

Taxation	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Taxation	3. Taxation Income tax is recognised or provided at amounts expected to be recovered or to be paid using the tax rates and tax laws that have been enacted or substantively enacted at the Group Statement of Financial Position date. Research and development tax credits are recognised on an accruals basis and are included as an income tax credit under current assets. The research and development tax credit recognised is based on management’s estimate of the expected tax claim for the period and is recorded within taxation under the Small and Medium-sized Enterprise Scheme. Schedule of components of income tax expense (benefit) Six months unaudited £’000 Six months unaudited £’000 Income tax credit 288 337	7 Taxation Schedule of components of income tax expense (benefit) 2022 £’000 2021 £’000 2020 £’000 Current tax credit Current tax credited to the income statement 825 646 1,144 Taxation payable in respect of foreign subsidiary – – (21 ) Adjustment in respect of prior year 7 – 158 Current tax credit 832 646 1,281 Deferred tax credit Reversal of temporary differences – – – Total tax credit 832 646 1,281 The reasons for the difference between the actual tax charge for the year and the standard rate of corporation tax in the United Kingdom applied to losses for the year are as follows: Schedule of difference between actual tax charge and the standard rate of corporation tax 2022 £’000 2021 £’000 2020 £’000 Loss before tax (8,488 ) (6,106 ) (23,470 ) Expected tax credit based on the standard rate of United Kingdom corporation tax at the domestic rate of 19% (2021: 19%; 2020: 19%) (1,613 ) (1,160 ) (4,459 ) Expenses not deductible for tax purposes 392 75 596 Income not taxable (4 ) (2 ) (75 ) Adjustment in respect of prior period (7 ) – (158 ) Surrender of tax losses for R&D tax refund (357 ) (280 ) (491 ) Deferred tax not recognised 757 721 3,306 Total tax credited to the income statement (832 ) (646 ) (1,281 ) The taxation credit arises on the enhanced research and development tax credits accrued for the respective periods. An adjustment has been recognised in 2022 in respect of the prior period of £7k (2021: £Nil; 2020: £158k), this is as a result of a more detailed review of cost classification prior to the submission of tax returns to HMRC.

Loss per share

Loss per share	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Loss per share	4. Loss per share Basic loss per share amounts are calculated by dividing the net loss for the period from continuing operations, attributable to ordinary equity holders of the parent company, by the weighted average number of ordinary shares outstanding during the period. As the Group made a loss for the period the diluted loss per share is equal to the basic loss per share. Schedule of loss per share Six months unaudited £’000 Six months unaudited £’000 Numerator Loss used in basic EPS and diluted EPS: (3,568 ) (3,061 ) Denominator Weighted average number of ordinary shares used in basic EPS 99,191,082 4,923,828 Basic and diluted loss per share: (4 )p (62 )p At a General Meeting on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result, the par value of the Ordinary Shares was changed from £0.001 per share to £ 0.02 At a General Meeting on 14 June 2023, shareholders approved the subdivision and redesignation of the Company’s Issued Ordinary Shares of £ 0.02 On 15 February 2023 the company completed a private placement for the sale of (i)8,125 ADSs (3,250,200 Ordinary Shares), (ii) 32,327 ADSs (12,931,020 Ordinary Shares) issuable upon the exercise of Series A warrants, (iii) 48,491 ADSs (19,396,530 Ordinary Shares) issuable upon the exercise of Series B warrants, and (iv) 155,461 ADSs (62,184,525 Ordinary Shares) issuable upon the exercise of pre-funded warrants, subject to certain reset provisions set forth in the Pre-Funded Warrants, at an initial purchase price of $185.60 per ADS, for aggregate gross proceeds of approximately $6.0 million. In addition, in connection with the February Private Placement the Company entered into a Waiver to the Securities Purchase Agreement (‘SPA’), dated 13 December 2022 between the Company and Armistice Capital Master Fund Ltd. (‘Armistice’), as amended on 16 December 2022, providing for a permanent waiver of certain equity issuance prohibitions and participation rights under the SPA. The Company agreed to, subject to receipt of shareholder approval at the General Meeting on 24 March 2023, issue to Armistice 1,562 625,000 The Series A and Series B warrants are exercisable on an ‘alternative cashless basis’ effectively allowing the holders to exercise for nil consideration. All resolutions were passed at the General Meeting on 24 March 2023. On 26 May 2023 the company completed a Registered Direct Offering for the sale of (i) 276,699 ADSs (110,679,610 Ordinary Shares), (ii) 415,043 ADSs (166,017,300 Ordinary Shares) issuable upon the exercise of Series C warrants, and (iii) 276,689 ADSs (110,675,600 Ordinary Shares) issuable upon the exercise of Series C warrants, at an initial price per ADS of $12.00, for aggregate gross proceeds of $3.32 million. The issuance of the Series C warrants and Series D warrants issuable was subject to shareholder approval at a general meeting on 14 June 2023. The Series C warrants are exercisable on an ‘alternative cashless basis’ effectively allowing the holders to exercise for nil consideration. All resolutions were passed at the General Meeting on 14 June 2023. The Company has considered the guidance set out in IAS 33 in calculating the denominator in connection with the issuance of Series A, Series B, Series C, Pre-funded and Investor warrants. Management have recognised the warrants from the date of grant rather than the date of issue of the corresponding Ordinary Shares when calculating the denominator. The Group has made a loss in the current and previous periods presented, and therefore the options and warrants are anti-dilutive. As a result, diluted earnings per share is presented on the same basis as basic earning per share. *The above ADS numbers reflect the ADS ratio change effected on 5 July 2023.	8 Loss per share Schedule of loss per share 2022 £’000 2021 £’000 2020 £’000 Numerator Loss used in basic EPS and diluted EPS: Continuing operations (7,656 ) (5,460 ) (22,189 ) Denominator Weighted average number of ordinary shares used in basic EPS: 4,941,793 4,027,345 2,142,000 Basic and diluted loss per share: Continuing operations – £ (1.55 ) (1.36 ) (10.36 ) At a General Meeting on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result the par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. The denominator has been calculated to reflect the share consolidation. The Group has made a loss in the current and previous years presented, and therefore the options and warrants are anti-dilutive. As a result, diluted earnings per share is presented on the same basis for all periods shown.

Borrowings

Borrowings	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Borrowings	5. Borrowings Schedule of borrowings As at 30 £’000 As at 31 £’000 Current Lease liabilities 164 161 Total 164 161 Non-current Lease liabilities 380 463 Total 380 463 Book values approximate to fair value at 30 June 2023 and 31 December 2022. Obligations under finance leases are secured by a fixed charge over the fixed assets to which they relate. During the period the finance lease was satisfied.	17 Borrowings Schedule of borrowings 2020 £’000 2021 £’000 2020 £’000 Current Lease liabilities 161 146 93 Government and research loans – – 107 Total 161 146 200 Non-current Lease liabilities 463 620 60 Total 463 620 60 During 2021 a euro denominated government and research loan of £103k (2020: £6.2m) was repaid. This amount includes £ nil (2020: £1.2m) of government grants, which is included in the amounts disclosed in note 16. This amount translated at year end rate was £107k (2020: £4.8m). Book values approximate to fair value at 31 December 2022, 2021 and 2020. Obligations under finance leases are secured by a fixed charge over the fixed assets to which they relate. Government loans in Spain MPE previously had four Spanish government loans, three were repaid in 2020 with the final loan repaid in February 2021 prior to the liquidation of MPE. Three of the loans were provided for the finance of research, technical innovation and the construction of their laboratory. The loans were term loans which carried an interest rate below the market rate and were repayable over periods through to 2024. As a result of the Group’s decision on 31 March 2020 to terminate further in-house development of MTD201 and the subsequent closure of its dedicated manufacturing facilities in Bilbao two of these loans were repaid in 2020, with the final loan being repaid in 2021. The fourth loan received by MPE in September 2019 for € 6.6 2.9 The loans carried default interest rates in the event of scheduled repayments not being met. On initial recognition, the loans are discounted at a market rate of interest with the credit being classified as a grant within deferred revenue. The deferred grant revenue is released to the consolidated statement of comprehensive income within research and development costs in the period to which the expenditure is recognised. The deferred revenue element of the government loans is designated within note 16 as deferred revenue and Government grants, the gross contractual repayment of the loans is disclosed in note 20. As a result of the repayment of the loans these were fully amortised during 2020.

Provision

Provision	6 Months Ended
	Jun. 30, 2023
Provision
Provision	6. Provision Schedule of provisions As at 30 £’000 As at 31 £’000 Opening provision at 1 January 207 50 Utilisation of provision (207 ) (43 ) Provision recognised during the period - 200 - 207 On 19 December 2022 the Company entered into a Promissory Note and Security Agreement with Bioasis to assist in the short term with Bioasis’ working capital requirements. Under the agreement the Company agreed to advance Bioasis up to US$ 750,000 The Company advanced US$ 250,000 250,000 Management considers recovery of the debt to be uncertain and in 2022 recognised an impairment provision of £ 207,000 207,000 On 3 February 2023 Bioasis announced they were ‘urgently exploring and evaluating all financing and strategic alternatives that may be available to address its liquidity requirements’ which triggered an event of default. As a result of this the 3rd payment under the agreement was not made. On 5 March 2023 Bioasis were served with a notice of an event of default. On 20 June 2023 Bioasis announced the suspension of operations. In 2023 the provision was utilised against the advance made to Bioasis in January 2023.

Derivative financial liability

Derivative financial liability – current	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Derivative Financial Liability Current
Derivative financial liability – current	7. Derivative financial liability – current Schedule of derivative financial liability As at 30 £’000 As at 31 £’000 At 1 January 85 553 Warrants issued 665 - Gain recognised in finance income within the consolidated statement of comprehensive income (386 ) (468 ) 364 85 Equity settled derivative financial liability is a liability that is not to be settled for cash. During the period the following warrants were exercised: No warrants recognised as equity settled derivatives were exercised in 2023 or 2022. The Company issues warrants in the ADSs of the Company as part of registered direct offerings and private placements in the US. The number of ADSs to be issued when exercised is fixed, however the exercise price is denominated in US Dollars being different to the functional currency of the Company. Therefore, the warrants are classified as equity settled derivative financial liabilities recognised at fair value through the profit and loss account (‘FVTPL’). The financial liability is valued using the Black-Scholes model in 2023, in previous periods the Monte Carlo model was used. The change in methodology is as result of the Company de-listing from AIM in 2023 and no longer needing to consider foreign exchange movements in fair value calculation. Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the ‘finance income’ or ‘finance expense’ lines item in the income statement. A key input in the valuation of the instrument is the Company share price. Details of the warrants are as follows: The below ADS numbers reflect the ADS ratio change effected on 5 July 2023. May 2023 warrants In June 2023 the Company issued 276,689 May 2020 warrants In May 2020 the Company issued 838 October 2019 warrants In October 2019 the Company issued 392 May 2020 and October 2019 warrant re-price On 13 December 2022 the Company entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd (‘Armistice’) to re-price previously issued ADS warrants issued to Armistice to $ 320 10,000 3,280 3,300 Schedule of warrants outstanding ADS Warrants Original price New price per Equivalent Ordinary Number October 2019 warrants 375 $10,000 $320 150,000 May 2020 warrants 406 $3,280 $320 162,400 * Number and original price of warrants have been adjusted to reflect the share consolidation and ratio change of ADS’s to ordinary shares that occurred on 2 March 2020 and 24 March 2023 and the ratio change of ADS’s to ordinary shares on 26 September 2022 and 5 July 2023. DARA warrants and share options The Group also assumed fully vested warrants and share options on the acquisition of DARA Biosciences, Inc. (which took place in 2015). The number of ordinary shares to be issued when exercised is fixed, however the exercise prices are denominated in US Dollars. The warrants are classified equity settled derivative financial liabilities and accounted for in the same way as those detailed above. The financial liability is valued using the Black-Scholes option pricing model. The exercise price of the outstanding options is $1,903.40. The following table details the outstanding warrants and options recognised as equity settled derivative financial liabilities as at 30 June 2023, 31 December 2022 and also the movement in the period: Schedule of warrants and options recognised At 1 Lapsed At 31 2022 Granted Lapsed Exercised At 30 June ADSs May 2023 grant ‘D’ warrants – – – 276,689 – – 276,689 May 2020 grant 838 – 838 – – – 838 October 2019 grant 392 – 392 – – – 392 Ordinary Shares DARA Warrants 204 (204) – – – – – DARA Options 138 – 138 (4) – 134 Fair value hierarchy The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique: Level 1: quoted (unadjusted) prices in active markets for identical assets and liabilities; Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data. The fair value of the Group’s derivative financial liability is measured at fair value on a recurring basis. The following table gives information about how the fair value of this financial liability is determined. Schedule of consolidated financial assets and liabilities at fair value Financial Fair value as at 30 June 2023 Fair value as 2022 Fair value Valuation Significant unobservable input(s) Relationship of Equity settled financial derivative liability – June 2023 £ 364,000 - Level 3 2023 - Black-Scholes Model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life of 4.98 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.13% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability – May 2020 Warrants – £48,000 Level 3 2023 – Black- Scholes Model 2022 - Monte Carlo simulation model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.38 years determined using the remaining life of the share options The shorter the expected life the lower the fair value. Risk-free rate of 4.68% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability – October 2019 Warrants – £37,000 Level 3 2023 – Black- Scholes Model 2022 - Monte Carlo simulation model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.00 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.87% determined using the expected life assumptions. The higher the risk-free rate Total £364,000 £85,000 Changing the unobservable risk-free rate input to the valuation model by 10% higher while all other variables were held constant, would not impact the carrying amount of shares (2022: nil). There were no transfers between Level 1 and 2 in the period. The financial liability measured at fair value on Level 3 fair value measurement represents consideration relating to warrants issued in June 2023, May 2020 and October 2019 as part of Private Placements and Registered Direct offerings.
Derivative financial liability – current		19 Derivative financial liability – current Schedule of derivative financial liability 2022 £’000 2021 £’000 2020 £’000 Equity settled derivative financial liability At 1 January 553 1,559 664 Warrants issued – – 997 Transfer to share premium on exercise of warrants – (70 ) (499 ) (Gain)/loss recognised in finance (income)/expense within the consolidated statement of comprehensive income (468 ) (936 ) 397 At 31 December 85 553 1,559 Equity settled derivative financial liability is a liability that is not to be settled for cash. May 2020 warrants In May 2020 the Company issued 477,255 warrants in the ordinary share capital of the Company as part of a registered direct offering in the US. The number of ordinary shares to be issued when exercised is fixed, however the exercise price is denominated in US Dollars being different to the functional currency of the Company. Therefore, the warrants are classified as equity settled derivative financial liabilities recognised at fair value through the profit and loss account (‘FVTPL’). The financial liability is valued using the Monte Carlo model. Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the ‘finance income’ or ‘finance expense’ lines item in the income statement. Fair value is determined in the manner described in note 20. A key input in the valuation of the instrument is the Company share price. October 2019 warrants In October 2019 the Company issued 157,495 warrants in the ordinary share capital of the Company as part of a registered direct offering in the US. The number of ordinary shares to be issued when exercised is fixed, however the exercise price is denominated in US Dollars. The warrants are classified equity settled derivative financial liabilities and accounted for in the same way as those issued in May 2020. The financial liability is valued using the Monte Carlo model. Warrant re-price On 13 December 2022 the Company entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd (‘Armistice’) to re-price previously issued ADR warrants issued to Armistice to $4 per ADR. The impact of the re-pricing is shown in the table below: The warrant exercise price per ADR for the remaining warrants remains unchanged as follows: October 2019 warrants at $125.00 per ADR; May 2020 warrants at $41.00 and $41.25 per ADR. Schedule of warrant exercise price ADR Warrants Equivalent Ordinary Number* Original Price New Price per Number October 2019 ADR warrants 30,000 $ 125.00 $ 4.00 150,000 May 2020 ADR warrants 32,550 $ 41.00 $ 4.00 162,750 Number and original price of warrants have been adjusted to reflect the share consolidation and ratio change of ADR’s to ordinary shares that occurred on 2 March 2020, the ratio change of ADR’s to ordinary shares on 26 September 2022 and the share consolidation and ratio change of ADR’s to ordinary shares that occurred on 24 March 2023. DARA warrants and share options The Group also assumed fully vested warrants and share options on the acquisition of DARA Biosciences, Inc. (which took place in 2015). The number of ordinary shares to be issued when exercised is fixed, however the exercise prices are denominated in US Dollars. The warrants are classified equity settled derivative financial liabilities and accounted for in the same way as those detailed above. The financial liability is valued using the Black-Scholes option pricing model. The exercise price of the warrants and options is $61.03 and $95.17 respectively. During 2022 all remaining warrants expired. The following table details the outstanding warrants over ordinary shares as at 31 December and also the movement in the year: Schedule of warrants outstanding At 1 Granted Exercised At 31 Lapsed Exercised At 31 Lapsed At 31 May 2020 grant – 477,255 (125,000 ) 352,255 – (15,340 ) 336,915 – 336,915 October 19 grant 157,495 – – 157,495 – – 157,495 – 157,495 DARA Warrants 231 – – 231 (27 ) – 204 (204 ) – DARA Options 138 – – 138 – – 138 – 138 Number of warrants have been adjusted to reflect the share consolidation and ratio change of ADR’s to ordinary shares that occurred on 2 March 2020, the ratio change of ADR’s to ordinary shares on 26 September 2022 and the share consolidation and ratio change of ADR’s to ordinary shares that occurred on 24 March 2023.

Share capital and reserves

Share capital and reserves	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Share capital and reserves	8. Share capital and reserves Schedule of detailed information about share capital Authorised, allotted and As at 30 June Number As at 30 June £ As at 31 Number As at 31 £ Ordinary shares of 277,971,722 277,972 5,417,137 108,343 ‘A’ Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 ‘B’ Deferred shares of £0.001 4,063,321,418 4,063,321 – – Total 5,341,294 1,108,344 At a General Meeting on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result, the par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. The above table reflects the share consolidation in the comparative figures. At a General Meeting on 14 June 2023, shareholders approved the subdivision and redesignation of the Company’s Issued Ordinary Shares of £0.02 each into to one Ordinary Share of £0.001 each and 19 ‘B’ Deferred Shares of £0.001 each. The ‘B’ Deferred Shares have limited rights and are effectively valueless. The previously issued Deferred Shares were redesignated ‘A’ Deferred Shares. On 26 May 2023 the Company entered into private placement as set out in note 4. As no share premium was recognised in relation to this transaction the transaction costs allocated to the initial issue of shares have been charged to retained earnings. During the period the Company entered into two private placements as set out in note 4. The pre-funded, Series A, Series B, Series C and Investor warrants have been accounted for as equity warrants and the fair value on recognition allocated to the warrant reserve, net of transaction costs. On exercise of the warrants the fair value has been transferred to share capital and share premium. Ordinary and deferred shares were recorded as equity. Rights attaching to the shares of Biodexa Pharmaceuticals PLC Shares classified as equity The holders of ordinary shares in the capital of the Company have the following rights: (a) to receive notice of, to attend and to vote at all general meetings of the Company, in which case shareholders shall have one vote for each share of which he is the holder; and, (b) to receive such dividend as is declared by the Board on each share held. The holders of deferred shares in the capital of the Company: (a) shall not be entitled to receive notice of or to attend or speak at any general meeting of the Company or to vote on any resolution to be proposed at any general meeting of the Company; and (b) shall not be entitled to receive any dividend or other distribution of out of the profits of the Company. In the event of a distribution of assets, the deferred shareholders shall receive the nominal amount paid up on such share after the holder of each ordinary share shall have received (in cash or specie) the amount paid up or credited as paid up on such ordinary share together with an additional payment of £100 per share. The Company has the authority to purchase the deferred shares and may require the holder of the deferred shares to sell them for a price not exceeding 1p for all the deferred shares. Schedule Of Ordinary and Deferred Shares 2023 Ordinary Number ‘A’ Number ‘B’ Deferred Share £ Total £’000 At 1 January 2023 5,417,137 1,000,001 - 15 February 2023 Private Placements 3,250,200 - - 0.0505 164 26 May 2023 Registered Direct Offering 110,679,610 - - 0.0097 1,076 April – June 2023 Exercise February 2023 pre-funded warrants 62,184,525 - - 0.0505 3,139 March 2023 Exercise Series ‘A’ warrants 12,931,020 - - 0.0505 653 March 2023 Exercise Series ‘B’ warrants 19,396,530 - - 0.0505 979 15 June 2023 Exercise Investor warrants 625,000 - - 0.0505 32 14 June 2023 Share sub-division and re-designation - - 4,063,321,418 n/a n/a 30 June 2023 Exercise ‘C’ warrants 63,487,700 - - 0.0097 617 At 30 June 2023 (unaudited) 277,971,722 1,000,001 4,063,321,418 2022 At 1 January 2022 4,923,420 1,000,001 - 22 March 2022 Exercise of warrants 1 - - 200.000 - 3 May 2022 Share issue to SIPP trustee* 1,250 - - 0.001 - 19 December 2022 Registered Direct Offering 492,466 - - 0.6660 321 At 31 December 2022 5,417,137 1,000,001 - *Share issued to Biodexa Pharmaceuticals PLC employee benefit trust	22 Share capital Schedule of detailed information about share capital Authorised, allotted and fully 2022 Number 2022 £ 2021 Number 2021 £ 2020 Number 2020 £ At 31 December Ordinary shares of 5,417,137 108,343 4,923,420 98,468 3,153,694 63,074 Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 Total 1,108,344 1,098,469 1,063,075 At a General Meeting on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result the par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. At the same time, the ratio of the Company’s Ordinary Shares to ADSs was changed from each ADS representing 25 Ordinary Shares to each ADS representing 5 Ordinary Shares. The above table reflects the share consolidation. In accordance with the Articles of Association for the Company adopted on 13 November 2014, the share capital of the Company consists of an unlimited number of ordinary shares of nominal value £0.001 each. Ordinary and deferred shares were recorded as equity. Rights attaching to the shares following the incorporation of Biodexa Pharmaceuticals plc Shares classified as equity The holders of ordinary shares in the capital of the Company have the following rights: (a) to receive notice of, to attend and to vote at all general meetings of the Company, in which case shareholders shall have one vote for each share of which he is the holder; and, (b) to receive such dividend as is declared by the Board on each share held. The holders of deferred shares in the capital of the Company: (a) shall not be entitled to receive notice of or to attend or speak at any general meeting of the Company or to vote on any resolution to be proposed at any general meeting of the Company; and (b) shall not be entitled to receive any dividend or other distribution of out of the profits of the Company. In the event of a distribution of assets, the deferred shareholders shall receive the nominal amount paid up on such share after the holder of each ordinary share shall have received (in cash or specie) the amount paid up or credited as paid up on such ordinary share together with an additional payment of £100 per share. The Company has the authority to purchase the deferred shares and may require the holder of the deferred shares to sell them for a price not exceeding 1p for all the deferred shares. Schedule Of Ordinary and Deferred Shares Ordinary Number Deferred Number Share £ Total £’000 At 1 January 2020 1,174,752 1,000,001 2020 18 May 2020 Placing & Registered Direct Offering 787,878 5.4000 4,255 27 July 2020 Placing 1,064,814 5.4000 5,750 19 August 2020 Exercise of warrants 125,000 6.2642 783 30 September 2020 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – At 31 December 2020 3,153,694 1,000,001 19 February 2021 Exercise of warrants 15,340 5.9600 91 6 July 2021 Placing 1,754,386 5.7000 10,000 At 31 December 2021 4,923,420 1,000,001 22 March 2022 Exercise of warrants 1 200.0000 – 3 May 2022 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – 19? December 2022 Registered Direct Offering 492,466 0.6660 321 At 31 December 2022 5,417,137 1,000,001

Related party transaction

Related party transaction	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Related party transaction	9. Related party transaction The Directors consider there to be no related party transactions during the periods reported other than Directors Remuneration.	27 Related party transactions Trading Transactions The Directors consider BioConnection BV to be a related party by virtue of the fact that there is a common Director with the Company and the Director is identified as having significant influence over the entity. 2019 was the first year where this relationship existed. During the year Group companies entered into the following transactions with related parties who are not members of the Group. Schedule of related party transactions Purchase of good Amounts owed by related parties 2022 €’000 2021 €’000 2020 €’000 2022 €’000 2021 €£’000 2020 €’000 BioConnection BV – – 296 – – – During 2019 Midatech Pharma (Espana) SL entered into a commercial contract with BioConnection BV in connection with the Group’s MTD201 program, this contract was subsequently terminated in 2020 as a result of the termination of the program. The Group has not made any allowances for bad or doubtful debts in respect of related party debtors nor has any guarantee been given or received during 2022, 2021 or 2020 regarding related party transactions.

Contingent liabilities

Contingent liabilities	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Contingent liabilities	10. Contingent liabilities The Company entered into an Arrangement Agreement with Bioasis on 13 December 2022 as amended on 18 December 2022. Under the agreement the Company agreed to acquire the entire issued share capital of Bioasis for consideration of, in aggregate, approximately C$7.4 million (c£4.4 million). The agreement was subject to shareholder approval. Under the agreement the Company agreed to reimburse Bioasis US$ 225,000 225,000 On 23 January 2023 at the General Meeting to approve the Arrangement Agreement none of the special resolutions were passed and, accordingly, the acquisition of Bioasis did not proceed. On 23 January Bioasis terminated the Arrangement Agreement and requested reimbursement of US$ 225,000	28 Contingent liabilities The Company entered into an Arrangement Agreement with Bioasis on 13th December 2022 as amended on 18 December 2022. Under the agreement the Company agreed to acquire the entire issued share capital of Bioasis for consideration of, in aggregate, approximately C$ 7.4 225,000 225,000 On 23 January 2023 at the General Meeting to approve the Arrangement Agreement none of the special resolutions were passed and, accordingly, the acquisition of Bioasis did not proceed. On 23 January Bioasis terminated the Arrangement Agreement and requested reimbursement of US$225,000 expenses relating to the transaction, to date these expenses have not been paid. The Group had no contingent liabilities at 31 December 2021 and 31 December 2020.

Events after the reporting date

Events after the reporting date	6 Months Ended
	Jun. 30, 2023
Notes and other explanatory information [abstract]
Events after the reporting date	11. Events after the reporting date On 5 July 2023, and in an effort to bring the ADS price into compliance with NASDAQ’s minimum bid price per share requirement, we effected a ratio change in the number of Ordinary Shares represented by our ADSs from five Ordinary Shares per ADS to 400

Accounting policies

Accounting policies	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Accounting policies	1 Accounting policies General information Biodexa Pharmaceuticals plc (the ‘Company’) is a company registered and domiciled in England and Wales. The Company was incorporated on 12 September 2014. The Company is a public limited company, whose ordinary shares have been admitted to trading on AIM (‘AIM’), which is a submarket of the London Stock Exchange, since 8 December 2014 until the admission of the Company’s ordinary shares to trading on AIM was cancelled on 26 April 2023. In addition, since 4 December 2015 the Company has American Depository Receipts (‘ADRs’) registered with the US Securities and Exchange Commission (‘SEC’) and is listed on the NASDAQ Capital Market. The financial statements were approved and authorised for issue by the Board of Directors on 28 April 2023. On 27 March 2023 the Company changed its name to Biodexa Pharmaceuticals plc from Midatech Pharma plc. Basis of preparation The Group was formed on 31 October 2014 when the Company entered into an agreement to acquire the entire share capital of Midatech Limited and its wholly owned subsidiaries through the issue equivalent of shares in the Company which took place on 13 November 2014. The financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IASB). The principal accounting policies adopted in the preparation of the financial statements are set out below. The policies have been consistently applied to all the periods presented. The consolidated financial statements have been prepared on a historical cost basis, except for the following item (refer to individual accounting policies for details): - Certain financial instruments – fair value through profit or loss. Adoption of new and revised standards New standards, interpretations and amendments effective from 1 January 2022 The Group reviewed the new standards, interpretations and amendments effective from 1 January 2022 and deemed none were applicable to the annual financial statements for the year ended 31 December 2022. New standards, interpretations and amendments not yet effective There are a number of standards, amendments to standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the group has decided not to adopt early. The Group reviewed the new standards, interpretations and amendments effective from 1 January 2023 and 1 January 2024 and deemed none have an impact on the group. Basis for consolidation The Group financial statements consolidate those of the parent company and all of its subsidiaries. The parent controls a subsidiary if it has power over the investee to significantly direct the activities, exposure, or rights to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor’s returns. All subsidiaries have a reporting date of 31 December. All transactions and balances between Group companies are eliminated on consolidation, including unrealised gains and losses on transactions between Group companies. Where unrealised losses on intra-Group asset sales are reversed on consolidation, the underlying asset is also tested for impairment from a Group perspective. Amounts reported in the financial statements of subsidiaries have been adjusted where necessary to ensure consistency with the accounting policies adopted by the Group. The consolidated financial statements consist of the results of the following entities: Schedule of entities Entity Summary description Biodexa Pharmaceuticals plc Ultimate holding company Midatech Limited Trading company Midatech Pharma (Espana) SL (formerly Midatech Biogune SL) Liquidated - 2021 PharMida AG Dormant Midatech Pharma (Wales) Limited (formerly Q Chip Limited) Trading company Midatech Pharma Pty Dissolved - 2020 Biodexa Limited (formerly Bioadexa Pharmaceuticals Limited) Dormant – incorporated October 2022 Going concern The Group and Company are subject to a number of risks similar to those of other development and early-commercial stage pharmaceutical companies. These risks include, amongst others, generation of revenue from the development portfolio and risks associated with research, development, testing and obtaining related regulatory approvals of our pipeline products. Ultimately, the attainment of profitable operations is dependent on future uncertain events which include obtaining adequate financing to fulfill our commercial and development activities and generating a level of revenue adequate to support our cost structure. We have experienced net losses and significant cash outflows from cash used in operating activities over the past years as we develop our portfolio. For the year ended 31 December 2022, the Group incurred a consolidated loss from operations of £7.7 million and negative cash flows from operating activities of £7.0 million. As of 31 December 2022, the Group had an accumulated deficit of £135.3 million. Our future viability is dependent on our ability to raise cash from financing activities to finance our development plans until commercialisation, generate cash from operating activities and to successfully obtain regulatory approval to allow marketing of our development products. Our failure to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue its business strategies. Our consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at 31 December 2022, we had cash and cash equivalents of £2.8 million. On 9 February 2023 the Company completed a Private Placement in which it raised US$5.2 million (approximately £4.3 million), after deducting the placement agent’s fees and other estimated expenses. We forecast that the Group currently has enough cash to fund its planned operations into the fourth quarter of 2023. We believe we currently have enough cash to fund our planned operations into the fourth quarter of 2023. Failure to secure additional funding before the fourth quarter of 2023 could result in the Company being placed into administration. We have prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period twelve months from the date of approval of the consolidated financial statements. These forecasts show that further financing will be required during the course of the next 12 months assuming, inter alia, that certain development programs and other operating activities continue as currently planned. In our opinion, the environment for financing of small and micro-cap biotech companies is as challenging as it has been since the financial crisis of 2008-2010. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, any attendant financings by Biodexa are likely to be dilutive. We and our advisors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group, including fundraising and the partnering of assets and technologies of the Company. The alternatives being considered are all at an early stage and are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any of the alternative courses of action to finance the Company will be successful. This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt about our ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to current liabilities. As a result of the foregoing, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended 31 December 2022 with respect to this uncertainty. We believe there are adequate options and time and available to secure additional financing for the Company and after considering the uncertainties, we considered it is appropriate to continue to adopt the going concern basis in preparing these financial information. Our ability to continue as a going concern is dependent upon our ability to obtain additional capital and/or dispose of assets, for which there can be no assurance we will be able to do on a timely basis, on favourable terms or at all. Revenue Revenue is accounted for in line with principles of IFRS 15 ‘Revenue from contracts with customers’ Supply of Research and Development Services Revenue from the supply of services is subject to specific agreement. This is recognised over the contract term, proportionate to the progress in overall satisfaction of the performance obligations (the services performed by the Group), measured by cost incurred to date out of total estimate of costs. The primary input of substantially all work performed under these arrangements is labour. There is normally a direct relationship between costs incurred and the proportion of the contract performed to date. Where the Group supplies services to a client it generally bills an agreed percentage in advance of the commencement of any work and the balance on completion. Invoices to clients are payable under normal commercial terms. Grant revenue Where grant income is received, which is not a direct re-imbursement of related costs, revenue is recognised at the point at which the conditions have been met, this has been recognised within grant revenue. Where grants are received as a re-imbursement of directly related costs they are credited to research and development expense in the same period as the expenditure towards which they are intended to contribute. The Group previously received government loans that had a below-market rate of interest. These loans were recognised and measured in accordance with IFRS 9. The benefit of the below-market rate of interest was measured as the difference between the initial carrying value of the loan discounted at a market rate of interest and the proceeds received. The difference was held within deferred revenue as a government grant and released as a credit to grant income or to research and development expense in line with the expenditure to which it related. In a situation where the proceeds were invested in plant and equipment, the deferred revenue was credited to research and development within the income statement in line with the depreciation of the acquired asset. Business combinations and externally acquired intangible assets Business combinations are accounted for using the acquisition method at the acquisition date, which is the date at which the Group obtains control over the entity. The cost of an acquisition is measured as the amount of the consideration transferred to the seller, measured at the acquisition date fair value, and the amount of any non-controlling interest in the acquiree. The Group measures goodwill initially at cost at the acquisition date, being: · the fair value of the consideration transferred to the seller, plus; · the amount of any non-controlling interest in the acquiree, plus; · if the business combination is achieved in stages, the fair value of the existing equity interest in the acquiree re-measured at the acquisition date, less; · the fair value of the net identifiable assets acquired and assumed liabilities. Acquisition costs incurred are expensed and included in administrative costs. Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration, whether it is an asset or liability, will be recognised through the consolidated statement of comprehensive income. If the contingent consideration is classified as equity, it is not re-measured. An intangible asset, which is an identifiable non-monetary asset without physical substance, is recognised to the extent that it is probable that the expected future economic benefits attributable to the asset will flow to the Group and that its cost can be measured reliably. The asset is deemed to be identifiable when it is separable or when it arises from contractual or other legal rights. Externally acquired intangible assets other than goodwill are initially recognised at cost and subsequently amortised on a straight-line basis over their useful economic lives where they are in use. Goodwill is stated at cost less any accumulated impairment losses. The amounts ascribed to intangibles recognised on business combinations are arrived at by using appropriate valuation techniques. In-process research and development (‘IPRD’) programmes acquired in business combinations are recognised as assets even if subsequent expenditure is written off because the criteria specified in the policy for development costs below are not met. IPRD is subject to annual impairment testing until the completion or abandonment of the related project. No further costs are capitalised in respect of this IPRD unless they meet the criteria for research and development capitalisation as set out below. As per IFRS 3, once the research and development of each defined project is completed, the carrying value of the acquired IPRD is reclassified as a finite-lived asset and amortised over its useful life. The significant intangibles recognised by the Group and their useful economic lives are as follows: Schedule of intangibles assets useful economic lives Goodwill – Indefinite life IPRD – In process, not yet amortising IT and website costs – 4 years The useful economic life of IPRD will be determined when the in-process research projects are completed. Internally generated intangible assets (development costs) Expenditure on the research phase of an internal project is recognised as an expense in the period in which it is incurred. Development costs incurred on specific projects are capitalised when all the following conditions are satisfied: · completion of the asset is technically feasible so that it will be available for use or sale; · the Group intends to complete the asset and use or sell it; · the Group has the ability to use or sell the asset and the asset will generate probable future economic benefits (over and above cost); · there are adequate technical, financial and other resources to complete the development and to use or sell the asset; and · the expenditure attributable to the asset during its development can be measured reliably. All internal activities related to the research and development of new projects are continuously monitored by the Directors. The Directors consider that the criteria to capitalise development expenditure are not met for a product prior to that product receiving regulatory approval in at least one country. Development expenditure not satisfying the above criteria, and expenditure on the research phase of internal projects are included in research and development costs recognised in the Consolidated Statement of Comprehensive Income as incurred. No projects have yet reached the point of capitalisation. Impairment of non-financial assets Assets that have an indefinite useful life, for example goodwill, or intangible assets not ready for use, such as IPRD, are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). The Group at 31 December 2022 had only one cash generating unit (2021: one, 2020: one), as set out in note 12. Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of impairment at each reporting date. Impairment charges are included in profit or loss, except, where applicable, to the extent they reverse gains previously recognised in other comprehensive income. An impairment loss recognised for goodwill is not reversed. Patents and trademarks The costs incurred in establishing patents and trademarks are either expensed in accordance with the corresponding treatment of the development expenditure for the product to which they relate or capitalised if the development expenditure to which they relate has reached the point of capitalisation as an intangible asset. Foreign currency Transactions entered into by subsidiary entities in a currency other than the currency of the primary economic environment, in which they operate, are recorded at the rates ruling when the transactions occur. Foreign currency monetary assets and liabilities are translated at the rates ruling at the reporting date. Exchange differences arising on the retranslation of unsettled monetary assets and liabilities are recognised immediately in profit or loss. The presentational currency of the Group is Pounds Sterling. Foreign subsidiaries use the local currencies of the country where the operate. On consolidation, the results of overseas operations are translated into Pounds Sterling at rates approximating to those ruling when the transactions took place. All assets and liabilities of overseas operations, including goodwill arising on the acquisition of those operations, are translated at the rate ruling at the reporting date. Exchange differences arising on translating the opening net assets at opening rate and the results of overseas operations at actual rate are recognised in other comprehensive income and accumulated in the foreign exchange reserve. Exchange differences recognised in the profit or loss of Group entities on the translation of long-term monetary items forming part of the Group’s net investment in the overseas operation concerned are reclassified to other comprehensive income and accumulated in the foreign exchange reserve on consolidation. On disposal of a foreign operation, the cumulative exchange differences recognised in the foreign exchange reserve relating to that operation up to the date of disposal are transferred to the consolidated statement of comprehensive income as part of the gain or loss on disposal. Financial assets and liabilities Assets at amortised cost The Group does not have any financial assets which it would classify as fair value through profit or loss. Therefore, all financial assets are classed as assets at amortised cost as defined below. These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise principally through the provision of goods and services to customers (e.g. trade receivables), but also incorporate other types of contractual monetary asset. They are initially recognised at fair value plus transaction costs that are directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment. For impairment provisions, the Group applies the IFRS 9 simplified approach to measure expected credit losses using a lifetime expected credit loss provision for trade receivables to measure expected credit losses on a collective basis. Trade receivables are grouped based on a similar credit risk and ageing The expected loss rates are based on the Group’s historic credit losses experienced over the three-year period prior to the period end. The historic loss rates are then adjusted for current and forward-looking information on macroeconomic factors. The Group’s assets at amortised costs comprise trade and other receivables and cash and cash equivalents in the consolidated statement of financial position. Cash and cash equivalents include cash in hand, deposits held at call with original maturities of three months or less. Financial liabilities The Group classifies its financial liabilities into one of two categories, depending on the purpose for which the liability was acquired. Fair value through profit and loss (‘FVTPL’) The Group has outstanding warrants in the ordinary share capital of the company. The number of ordinary shares to be issued when exercised is fixed, however the exercise price is denominated in US Dollars being different to the functional currency of the parent company. Therefore, the warrants are classified as equity settled derivative financial liabilities recognised at fair value through the profit and loss account. The financial liability is valued using the either the Monte Carlo model or the Black-Scholes option pricing model. Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the ‘finance income’ or ‘finance expense’ lines item in the income statement. Fair value is determined in the manner described in note 19. Other financial liabilities include the following items: · Borrowings are initially recognised at fair value net of any transaction costs directly attributable to the issue of the instrument. Such interest-bearing liabilities are subsequently measured at amortised cost using the effective interest rate method, which ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried in the consolidated statement of financial position. Interest expense in this context includes initial transaction costs and premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding. · Government loans received on favourable terms below market rate are discounted at a market rate of interest. The difference between the present value of the loan and the proceeds is held as a government grant within deferred revenue and is released to research and development expenditure or grant income in line with when the asset or expenditure is recognised in the income statement. · Trade payables and other short-term monetary liabilities are initially recognised at fair value and subsequently carried at amortised cost using the effective interest method. Share capital Financial instruments issued by the Group are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Group has two classes of share in existence: · ordinary shares of £ 0.001 · deferred shares of £1 each are classified as equity instruments. Retirement benefits: defined contribution schemes Contributions to defined contribution pension schemes are charged to the consolidated statement of comprehensive income in the year to which they relate. Provisions Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Share-based payments The Group operates a number of equity-settled, share-based compensation plans, under which the entity receives services from employees as consideration for equity instruments (options) of the Group. The fair value of the employee services received in exchange for the grant of the options is recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted: · including any market performance conditions (including the share price); · excluding the impact of any service and non-market performance vesting conditions (for example, remaining an employee of the entity over a specified time period); and · including the impact of any non-vesting conditions (for example, the requirement for employees to save). Non-market performance and service conditions are included in assumptions about the number of options that are expected to vest. The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. Where vesting conditions are accelerated on the occurrence of a specified event, such as a change in control or initial public offering, such remaining unvested charge is accelerated to the income statement. In addition, in some circumstances employees may provide services in advance of the grant date and therefore the grant date fair value is estimated for the purposes of recognising the expense during the period between service commencement period and grant date. At the end of each reporting period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting conditions. It recognises the impact of the revision to original estimates, if any, in the income statement, with a corresponding adjustment to equity. When the options are exercised, the Company issues new shares. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium. Leases Identifying Leases The Group accounts for a contract, or a portion of a contract, as a lease when it conveys the right to use an asset for a period of time in exchange for consideration. Leases are those contracts that satisfy the following criteria: (a) There is an identified asset; (b) The Group obtains substantially all the economic benefits from use of the asset; and (c) The Group has the right to direct use of the asset. The Group considers whether the supplier has substantive substitution rights. If the supplier does have those rights, the contract is not identified as giving rise to a lease. In determining whether the Group obtains substantially all the economic benefits from use of the asset, the Group considers only the economic benefits that arise from the use of the asset, not those incidental to legal ownership or other potential benefits. In determining whether the Group has the right to direct use of the asset, the Group considers whether it directs how and for what purpose the asset is used throughout the period of use. If there are no significant decisions to be made because they are pre-determined due to the nature of the asset, the Group considers whether it was involved in the design of the asset in a way that predetermines how and for what purpose the asset will be used throughout the period of use. If the contract or portion of a contract does not satisfy these criteria, the Group applies other applicable IFRSs rather than IFRS 16. All leases are accounted for by recognising a right-of-use asset and a lease liability except for: · Leases of low value assets; and · Leases with a duration of 12 months or less. Lease liabilities are measured at the present value of the contractual payments due to the lessor over the lease term, with the discount rate determined by reference to the group’s incremental borrowing rate on commencement of the lease. Right of use assets are initially measured at the amount of the lease liability, reduced for any lease incentives received, and increased for lease payments made at or before commencement of the lease. The Group has taken advantage of the practical expedient to ignore the requirement to separate non-lease components and instead account for the entire contract as a single lease. Subsequent to initial measurement lease liabilities increase as a result of interest charged at a constant rate on the balance outstanding and are reduced for lease payments made. Right-of-use assets are amortised on a straight-line basis over the remaining term of the lease. When the group revises its estimate of the term of any lease (because, for example, it re-assesses the probability of a lessee extension or termination option being exercised), it adjusts the carrying amount of the lease liability to reflect the payments to make over the revised term, which are discounted using a revised discount rate. An equivalent adjustment is made to the carrying value of the right-of-use asset, with the revised carrying amount being amortised over the remaining (revised) lease term. If the carrying amount of the right-of-use asset is adjusted to zero, any further reduction is recognised in profit or loss. Nature of leasing activities (in the capacity as lessee) As at 31 December 2022 the Group had one property lease in place in the UK. Taxation Tax is recognised in the Comprehensive Statement of Income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax credit is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the country where the Company operates and generates income. Deferred taxation Deferred tax assets and liabilities are recognised where the carrying amount of an asset or liability in the consolidated statement of financial position differs from its tax base, except for differences arising on: · the initial recognition of goodwill; · the initial recognition of an asset or liability in a transaction which is not a business combination and at the time · investments in subsidiaries and jointly controlled entities where the Group is able to control the timing of the reversal of the difference and it is probable that the difference will not reverse in the foreseeable future. Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profit will be available against which the difference can be utilised. The amount of the asset or liability is determined using tax rates that have been enacted or substantively enacted by the reporting date and are expected to apply when the deferred tax assets or liabilities are recovered or settled. Property, plant and equipment Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses. Depreciation is provided on all items of property, plant and equipment so as to write off their carrying value over their expected useful economic lives. It is provided at the following rates: Schedule of depreciation rates of property, plant and equipment Fixtures and fittings – 20%- 25% per annum straight line Leasehold improvements – the shorter of 10% per annum straight line or over the lease term Computer equipment – 25% per annum straight line Laboratory equipment – 15% – 25% per annum straight line Right of use asset – Economic life of contractual relationship

Critical accounting estimates a

Critical accounting estimates and judgements	12 Months Ended
	Dec. 31, 2022
Critical Accounting Estimates And Judgements
Critical accounting estimates and judgements	2 Critical accounting estimates and judgements The preparation of these consolidated financial statements requires the Group to make estimates, assumptions and judgments that can have a significant impact on the reported amounts of assets and liabilities, revenue and expenses and related disclosure of contingent assets and liabilities, at the respective dates of our financial statements. The Group bases its estimates, assumptions and judgments on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Management evaluates estimates, assumptions and judgments on a regular basis and makes changes accordingly, and discusses critical accounting estimates with the board of Directors. The following are considered to be critical accounting estimates: Impairment of goodwill and intangible assets not yet ready for use Goodwill and intangibles not yet ready for use are tested for impairment at the cash generating unit level on an annual basis at the year end and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a cash generating unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. The fair value of each cash generating unit or asset is estimated using the income approach, on a discounted cash flow methodology. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, including for revenues and development costs, estimation of the long term rate of growth for the business, estimation of the useful life over which cash flows will occur and determination of our weighted-average cost of capital. The carrying value of goodwill was £Nil (2021: £Nil; 2020: £Nil) and intangibles not yet ready for use was £Nil (2021: £Nil; 2020:£Nil) as at 31 December 2022 (note 11). The estimates used to calculate the fair value of a cash generating unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each such unit. In March 2020 the Group undertook a Strategic Review to re-evaluate its priorities in the context of available resources. The Board concluded that the Company was unlikely to conclude a license transaction or raise sufficient funds to continue the required remaining investment in MTD201 on a timely basis. The Board therefore decided to terminate further in-house development of the MTD201 programme with immediate effect and, in line with that decision, to close the Company’s MTD201 dedicated manufacturing facilities in Bilbao and offer redundancy to all 42 employees. As a result of the decision to terminate this program the Group recognised an impairment charge of £2.3m in the year to 31 December 2020 against goodwill and an impairment charge against the IPRD of the Midatech Pharma (Wales) Ltd cash generating unit of £9.3m. See note 12. In June 2020 the Group received a letter from Secura Bio Inc., the licensor of Panobinostat, the active ingredient in the Group’s MTX110 development program, purporting to terminate our license. As a result of this purported termination an impairment charge of £0.8m was recognised in the year to 31 December 2020 against the acquired IPRD in relation to MTX110. See note 11. Share-based payments The Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on the grant date. The Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that have to be met as conditions to vesting. The resulting cost of an equity incentive award is recognised as expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognised over the vesting period using the straight-line method and classified in the consolidated statements of comprehensive income. The assumptions used for estimating fair value for share-based payment transactions are disclosed in note 25 to our consolidated financial statements and are estimated as follows: · volatility is estimated based on the average annualised volatility of a number of publicly traded peer companies in the biotech sector; · the estimated life of the option is estimated to be until the first exercise period, which is typically the month after the option vests; and · the dividend return is estimated by reference to our historical dividend payments. Currently, this is estimated to be zero as no dividend has been paid in the prior periods. Financial liabilities Fair value through profit and loss (‘FVTPL’) The Group has outstanding warrants in the ordinary share capital of the Company. The number of ordinary shares to be issued when exercised is fixed, however the exercise price is denominated in US Dollars being different to the functional currency of the parent company. Therefore, the warrants are classified as equity settled derivative financial liabilities recognised at fair value through the profit and loss account. The financial liability is valued using the either the Monte Carlo model or the Black-Scholes option pricing model. Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the ‘finance income’ or ‘finance expense’ lines item in the income statement. Fair value is determined in the manner described in note 19. The following are considered to be critical accounting judgments: Revenue Supply of Research and Development Services There are significant management judgements and estimates involved in the recognition of revenue from the supply of services. Revenue on services is recognised over the contract term, proportionate to the progress in overall satisfaction of the performance obligations (the services performed by the Group), measured by cost incurred to date out of total estimate of costs. The Company’s R&D collaboration agreements require the delivery of services within 12 months. Income taxes Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Judgment is required to determine the amount of deferred tax assets that can be recognised based upon the likely timing and the level of future taxable profits together with future tax planning strategies. In 2022, there were approximately £ 71.6 67.2 63.2 Going Concern We have has experienced net losses and significant cash outflows from cash used in operating activities over the past years as it develops its portfolio. For the year ended 31 December 2022, the Group incurred a consolidated loss from operations of £ 7.7 7.0 135.3 Our future viability is dependent on our ability to raise cash from financing activities to finance our development plans until commercialisation, to generate cash from operating activities and to successfully obtain regulatory approval to allow marketing of our development products. Our failure to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. Our consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at 31 December 2022, we had cash and cash equivalents of £ 2.8 We have prepared cash flow forecasts and considered the cash flow requirement for the Company for our next three years including the period twelve months from the date of the approval of the financial statements. These forecasts show that further financing will be required during the course of the next 12 months assuming, inter alia, that certain development programs and other operating activities continue as currently planned. In our opinion, the environment for financing of small and micro-cap biotech companies is as challenging as it has been since the financial crisis of 2008-2010. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, any attendant financings by Biodexa are likely to be dilutive. We and our advisors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group, including fundraising and the partnering of assets and technologies of the Company. The alternatives being considered are all at an early stage and are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any of the alternative courses of action to finance the Company will be successful. This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt about our ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would stated at net realizable value and all liabilities would be accelerated to current liabilities. As a result of the foregoing, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended 31 December 2022 with respect to this uncertainty. We believe there are adequate options and time and available to secure additional financing for the Company and after considering the uncertainties, we considered it is appropriate to continue to adopt the going concern basis in preparing these financial information. Our ability to continue as a going concern is dependent upon our ability to obtain additional capital and/or dispose of assets, for which there can be no assurance we will be able to do on a timely basis, on favourable terms or at all.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Revenue	3 Revenue Revenue from contracts with customers Geographical analysis of revenue by destination of customer Schedule of revenue by geographical analysis 2022 £’000 2021 £’000 2020 £’000 Revenue: United Kingdom – – 4 Belgium 699 578 114 Rest of the World – – 62 699 578 180 All revenue came from the sale of services in 2022, 2021 and 2020. It is derived entirely from the Company’s R&D collaboration agreements. It is recognised over the contract term proportionate to the progress in overall satisfaction of the performance obligations. Schedule of performance obligations Contractual Assets Contractual Liabilities 2022 £’000 2021 £’000 2020 £’000 2022 £’000 2021 £’000 2020 £’000 At 1 January – 71 – – (68 ) – Transfers in the period from contract assets to trade receivables – (71 ) – – – – Amounts included in contract liabilities that was recognised as revenue during the period – – – – (68 ) – Excess of revenue recognised over cash – – 71 – – – Cash received in advance of performance and not recognised as revenue during the period – – – (197 ) – (68 ) At 31 December – – 71 (197 ) – (68 ) The Company’s R&D collaboration agreements are for the delivery of services within the next 12 months for which the practical expedient in paragraph 121 (a) of IFRS15 applies. In 2022, all revenue came from 1 customer (2021: 1 customer; 2020: 3 customers). Schedule of commercial segment 2022 £’000 2021 £’000 2020 £’000 Customer A 100 % 100 % 64 % Customer B – – 34 % Customer C – – 2 % The Group contains one reportable operating segment, Pipeline Research and Development (‘Pipeline R&D’). This segment seeks to develop products using the Group’s nanomedicine and sustained release technology platforms. All the reconciliations required for segmental reporting can be found in the primary statements. The accounting policies of the reportable segments are consistent with the Group’s accounting policies described in note 1.

Loss from operations

Loss from operations	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Loss from operations	4 Loss from operations Schedule of loss from operations Note 2022 £’000 2021 £’000 2020 £’000 Loss from operations is stated after charging/(crediting): Depreciation of property, plant and equipment - Research and development costs 9 162 198 1,064 - Administrative costs 9 12 15 25 Depreciation of right of use asset - Research and development costs 9 151 165 110 - Administrative costs 9 15 25 8 Amortisation of intangible assets – software - Research and development costs 11 3 – 8 - Administrative costs 11 – – 2 Impairment of intangible assets 11 – – 12,369 Impairment of financial asset 14 207 – – Provision against future loss on loan agreement 18 207 – – Fees payable to the Company’s auditor for the audit of the parent Company financial statements 106 88 87 Fees payable to the Company’s auditors for the audits of the subsidiary financial statements 44 44 43 Fees payable to the Company’s auditor for: – Audit related services 70 – 7 Fees payable to the Company’s previous auditor for the audit of the parent Company financial statements – – 15 Fees payable to the Company’s previous auditor for: - Audit related services 67 41 171 Foreign exchange loss 9 12 96 Profit/(Loss) 14 (42 ) (226 ) Equity settled share-based payment* 123 89 (404 ) * credit recognised in 2020 due to employees leaving the company and the subsequent reversal of the cumulative share based payment charge relating to share options under the 2014 Biodexa Pharmaceuticals plc Enterprise Management Incentive Scheme.

Staff costs

Staff costs	12 Months Ended
	Dec. 31, 2022
Staff Costs
Staff costs	5 Staff costs Staff costs (including Directors) comprise: Schedule of staff costs 2022 £’000 2021 £’000 2020 £’000 Wages and salaries 2,033 1,354 2,727 Defined contribution pension cost (note 24) 98 71 75 Social security contributions and similar taxes 269 152 397 Share-based payment charge/(credit) 123 89 (404 ) Staff costs gross 2,523 1,666 2,795 Employee numbers The average number of staff employed by the Group during the financial year amounted to: Schedule for average number of employed staff 2022 2021 2020 Research and development 22 15 31 General and administration 5 5 9 27 20 40 Key management personnel compensation Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, including the Directors of the Company listed on page 25, including the Chief Executive Officer and Chief Scientific Officer. Schedule of Management Personnel Compensation 2022 £’000 2021 £’000 2020 £’000 Short term employee benefits 668 658 472 Post-employment benefits 21 27 24 Termination benefits – – 30 Share-based payment 53 61 (472 ) Total 742 746 54 None of the Directors have exercised share options during the year (2021: nil, 2020: nil). During the year no Directors (2021:1; 2020: 2) participated in a defined contribution pension scheme. Pension contributions in the above note include those of the Chief Scientific Officer.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Property, plant and equipment	9 Property, plant and equipment Schedule of detailed information about property, plant and equipment Fixtures and fittings £’000 Leasehold improvements £’000 Computer equipment £’000 Laboratory equipment £’000 Right of use asset £’000 Total £’000 Cost At 1 January 2020 248 2,038 403 3,738 1,124 7,551 Additions – 58 16 135 – 209 Effect of modification to lease terms – – – – (678 ) (678 ) Disposal (202 ) (2,184 ) (185 ) (2,323 ) (316 ) (5,210 ) Exchange differences 7 92 2 112 58 271 At 31 December 2020 53 4 236 1,662 188 2,143 Additions 57 53 16 194 720 1,040 Transfer – – – (155 ) 155 – Effect of modification to lease terms – – – – (24 ) (24 ) Disposal (50 ) (4 ) (10 ) (138 ) (164 ) (366 ) At 31 December 2021 60 53 242 1,563 875 2,793 Additions 3 – 14 45 – 62 Transfer to intangibles – – (122 ) – – (122 ) Disposal – – (46 ) (174 ) (51 ) (271 ) At 31 December 2022 63 53 88 1,434 824 2,462 Fixtures and fittings £’000 Leasehold improvements £’000 Computer equipment £’000 Laboratory equipment £’000 Right of use asset £’000 Total £’000 Accumulated depreciation At 1 January 2020 235 1,794 332 2,740 296 5,397 Charge for the year 9 310 50 720 118 1,207 Disposal (202 ) (2,183 ) (185 ) (2,300 ) (316 ) (5,186 ) Exchange differences 7 81 2 79 14 183 At 31 December 2020 49 2 199 1,239 112 1,601 Transfer – – – (74 ) 74 – Charge for the year 8 5 22 178 190 403 Disposal (50 ) (3 ) (8 ) (138 ) (164 ) (363 ) At 31 December 2021 7 4 213 1,205 212 1,641 Transfer to intangibles – – (113 ) – – (113 ) Charge for the year 12 11 12 139 166 340 Disposal – – (41 ) (155 ) (41 ) (237 ) At 31 December 2022 19 15 71 1,189 337 1,631 Net book value At 31 December 2022 44 38 17 245 487 831 At 31 December 2021 53 49 29 358 663 1,152 At 31 December 2020 4 2 37 423 76 542 As at 31 December right of use asset consisted of leasehold improvements of £485k (2021: £619k; 2020: £76k) and laboratory equipment of £2k (2021: £44k; 2020: £nil). On 1 January 2022 software previously disclosed within computer equipment was transferred to intangible assets.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Leases	10 Leases Schedule of market rental rates Lease Liabilities 2022 £’000 2021 £’000 2020 £’000 At 1 January 766 76 907 Additions – 720 – Transfer – 77 – Effect of modification to lease terms – (24 ) (788 ) Interest expenses 36 29 15 Lease payments (178 ) (112 ) (105 ) Exchange differences – – 47 At 31 December 624 766 76 The right of use asset is disclosed in note 9. In April 2021 the Group signed an agreement to lease new premises in Cardiff, Wales, to house its corporate offices and laboratories. The agreement to lease allowed the Group to carry out the Cat A works and fit out prior to completion of the lease and its occupation in August 2021. The lease agreed was for a 5 year period with no break clause. The lease was recognised as a right of use asset in 2021. The recognition in 2021 of the right of use asset and corresponding lease liability were a non cash investing and financing transaction. In May 2021 the Group provided notice to terminate its property lease on its historical building in Cardiff. The lease required 6 month’s notice. During 2020 as a result of the closure of the Group’s operations in Spain two property leases were terminated early, this impacted both the right of use asset and the lease liability. Low value leases expensed in year: Low value leases expensed in year 2022 £’000 2021 £’000 2020 £’000 Low value leases expensed 3 2 10 3 2 10 Total cash outflow for leases in 2022 was £181k (2021: £114k; 2020: £115k).

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Intangible assets	11 Intangible assets Schedule of reconciliation of changes in intangible assets and goodwill In-process £’000 Goodwill £’000 IT/Website £’000 Total £’000 Cost At 1 January 2020 13,378 2,291 35 15,704 Disposal – – (36 ) (36 ) Foreign exchange – – 1 1 At 31 December 2020 13,378 2,291 – 15,669 At 31 December 2021 13,378 2,291 – 15,669 Transfer from property, plant and equipment – – 122 122 Disposal – – (12 ) (12 ) At 31 December 2022 13,378 2,291 110 15,779 In-process research and development £’000 Goodwill £’000 IT/Website Costs £’000 Total £’000 Accumulated amortisation and impairment At 1 January 2020 3,300 – 25 3,325 Amortisation charge for the year – – 10 10 Disposal – – (36 ) (36 ) Impairment 10,078 2,291 – 12,369 Foreign exchange – – 1 1 At 31 December 2020 13,378 2,291 – 15,669 At 31 December 2021 13,378 2,291 – 15,669 Amortisation charge for the year – – 3 3 Transfer from property, plant and equipment – – 113 113 Disposal – – (12 ) (12 ) At 31 December 2022 13,378 2,291 104 15,773 Net book value At 31 December 2022 – – 6 6 At 31 December 2021 – – – – At 31 December 2020 – – – – In 2020 an impairment charge of £0.8m was recorded in relation to the acquire IPRD on MTX110. The impairment was as a result of the termination of a License Agreement between the Company and Secura Bio Inc. Pursuant to the License Agreement, Midatech Limited was granted a non-exclusive worldwide, sub-licensable license to certain patents of Panobinostat, the active pharmaceutical ingredient of the Company’s development product MTX110.

Impairment testing

Impairment testing	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Impairment testing	12 Impairment testing As a result of the Board’s decision to terminate its MTD201 program in March 2020 an impairment charge of £ 11.6 9.3 2.3

Subsidiaries

Subsidiaries	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Subsidiaries	13 Subsidiaries The subsidiaries of the Company, all of which are 100% owned as at 31 December 2022, either directly or through subsidiaries where indicated, and have been included in these financial statements in accordance with the details set out in the basis of preparation and basis of consolidation note 1, are as follows: Schedule of subsidiaries Name Registered Office Nature of Business Notes Midatech Limited 1 Caspian Point, Caspian Way, Cardiff, Trading company PharMida AG c/o Kellerhals, Hirschgässlein 11, 4051 Basel, Switzerland Dormant (a) (b) Midatech Pharma (Wales) Limited 1 Caspian Point, Caspian Way, Cardiff, Trading company Biodexa Limited (formerly Biodexa Pharmaceuticals Limited) 1 Caspian Point, Caspian Way, Cardiff, Dormant Notes: (a) Wholly owned subsidiary of Midatech Limited. (b) PharMida AG became dormant in January 2016.

Trade and other receivables

Trade and other receivables	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Trade and other receivables	14 Trade and other receivables Schedule of trade and other receivables 2022 £’000 2021 £’000 2020 £’000 Trade receivables 329 33 95 Prepayments 376 607 258 Other receivables 301 394 219 Total trade and other receivables 1,006 1,034 572 Less: non-current portion – – – Current portion 1,006 1,034 572 The Group has applied the practical expedient permitted by IFRS 15 to not disclose the transaction price allocated to performance obligations unsatisfied (or partially unsatisfied) as of the end of the reporting period as contracts typically have an original expected duration of a year or less. Book values approximate to fair value at 31 December 2022, 2021 and 2020. Expected Credit Loss Given the short-term nature of the Group’s trade receivables and accrued income, which are mainly due from large national or multinational companies, the Group's assessment of expected credit losses includes provisions for specific clients and receivables where the contractual cash flow is deemed at risk. Considerations include the current economic environment along with historical and forward-looking information. No assumptions or estimating techniques are applied in considering these. Additional provisions are made based on the assessment of recoverability of aged receivables over one year where sufficient evidence of recoverability is not evident. Trade and other receivables contain one impaired asset in 2022, as detailed below. In 2021 and 2020 Trade and other receivables did not contain an impaired asset. The Group does hold security in 2022 as detailed above against one asset, in 2021 and 2020 it did not hold any collateral as security. The maximum exposure to credit risk at the consolidated statement of financial position date is the fair value of each class of receivable. The Company recognises a default on a financial asset when the counter party announces they have limited resources to satisfy the debt. Bioasis Loans On 13 December 2022 the Company entered into an Arrangement Agreement with Bioasis Technologies Inc (‘Bioasis’) under which the Company would acquire the entire issued share capital of Bioasis, the agreement entered into was subject to shareholder approval. In addition to this, on 19 December 2022 the Company entered into a Promissory Note and Security Agreement with Bioasis to assist in the short term with Bioasis’ working capital requirements. Under the agreement the Company agreed to advance Bioasis up to US$750,000 in 3 tranches payable on 19 December 2022, 3 January 2023 and 6 February 2023. The loan is repayable on the earliest of the following: a) The occurrence of an event of default; b) The closing date (as defined in the Arrangement Agreement for the proposed acquisition of Bioasis); or c) 30 June 2023. The promissory note is subject to interest at a rate equal to 2% per month or, from and after the Bioasis maturity date, at a default rate of 15% per annum. Under the Security Agreement the Company was made a secured creditor. The Company advanced US$250,000 to Bioasis in the year to 31 December 2022. A further advance of US$250,000 was made to Bioasis on 3 January 2023. Management considers recovery of the debt to be uncertain and have therefore recognised an impairment provision of £207,000 in the year against the advance made to Bioasis in December 2022. On 3 February 2023 Bioasis announced they were ‘urgently exploring and evaluating all financing and strategic alternatives that may be available to address its liquidity requirements’ which triggered an event of default. As a result of this the 3rd payment under the agreement was not made in the post year end period. On 5 March 2023 Bioasis were served with notice of an event of default.

Cash and cash equivalents and c

Cash and cash equivalents and cash flow supporting notes	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Cash and cash equivalents and cash flow supporting notes	15 Cash and cash equivalents and cash flow supporting notes Cash and cash equivalents for purposes of the consolidated statement of cash flows comprises: Schedule of cash and cash equivalents 2022 £’000 2021 £’000 2020 £’000 Cash at bank available on demand 2,836 10,057 7,546 During 2022, 2021 and 2020, cash inflows arose from equity financing transactions, included within financing activities on the face of the cash flow statement. As part of the equity transaction in December 2022 warrants to the value of £Nil (July 2021: £nil; May 2020: £1.0m;) were issued as disclosed in note 19. Schedule of cash inflows from an equity financing transaction 2022 £’000 2021 £’000 2020 £’000 Gross proceeds 321 10,091 10,792 Transaction costs (78 ) (1,056 ) (1,050 ) Proceeds from issuing shares 243 9,035 9,742 The following changes in loans and borrowings arose as a result of financing activities during the year: Schedule of changes in bank loan liabilities Non-current £’000 Current £’000 Total £’000 At 1 January 2022 620 699 1,319 Cash flows – (178 ) (178 ) Non-cashflows: – – – Loans and borrowings classified as non-current 31 December 2021 becoming current in 2022 (178 ) 178 – Gain/(loss) in finance income within the consolidated statement of comprehensive income – (468 ) (468 ) Interest accruing in period 21 15 36 At 31 December 2022 463 246 709 Non-current £’000 Current £’000 Total £’000 At 1 January 2021 60 1,759 1,819 Cash flows – (215 ) (215 ) Non-cashflows: Foreign Exchange – (4 ) (4 ) New leases 715 5 720 Effect of modification to lease term – IFRS 16 – (24 ) (24 ) Loans and borrowings classified as non-current 31 December 2020 becoming current in 2021 (178 ) 178 – Transfer to share premium on exercise of warrants – (70 ) (70 ) Gain/(loss) recognised in finance income within the consolidated statement of comprehensive income – (936 ) (936 ) Interest accruing in period 23 6 29 At 31 December 2021 620 699 1,319 Non-current £’000 Current £’000 Total £’000 At 1 January 2020 5,670 1,076 6,746 Cash flows (6,182 ) (258 ) (6,440 ) Non-cashflows: Foreign Exchange 252 23 275 Fair value changes 1,176 – 1,176 Effect of modification to lease term – IFRS 16 (877 ) 89 (788 ) Reclassification portion government loan to non-current 51 (51 ) – Warrants issued – 997 997 Transfer to share premium on exercise of warrants – (499 ) (499 ) Gain/(loss) recognised in finance income within the consolidated statement of comprehensive income – 397 397 Interest accruing in period (30 ) (15 ) (45 ) At 31 December 2020 60 1,759 1,819

Trade and other payables

Trade and other payables	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Trade and other payables	16 Trade and other payables Schedule of trade and other payables Current 2022 £’000 2021 £’000 2020 £’000 Trade payables 339 485 337 Other payables 17 5 26 Accruals 817 546 768 Total financial liabilities, excluding loans and borrowings, 1,173 1,036 1,131 Tax and social security 77 56 31 Deferred revenue 197 – 68 Total trade and other payables 1,447 1,092 1,230 Book values approximate to fair value at 31 December 2022, 2021 and 2020. All current trade and other payables are payable within 3 months of the period end date shown above.

Provisions

Provisions	12 Months Ended
	Dec. 31, 2022
Disclosure Provisions Abstract
Provisions	18 Provisions Schedule of provisions 2022 £’000 2021 £’000 2020 £’000 Opening provision at 1 January 50 50 97 Utilisation of provision (43 ) – (97 ) Provision recognised in the year 200 – 50 At 31 December 207 50 50 Less: non-current portion – – (50 ) Current portion 207 50 – The provision as at 31 December 2021 and 2020 represents management’s best estimate of the ‘making good’ clause on the Cardiff office which was vacated during the fourth quarter of 2021. This liability was settled during 2022. Bioasis Loans On 19 December 2022 the Company entered into a Promissory Note and Security Agreement with Bioasis to assist in the short term with Bioasis’ working capital requirements. Under the agreement the Company agreed to advance Bioasis up to US$750,000 in three tranches payable on 19 December 2022, 3 January 2023 and 6 February 2023. The terms of the agreement are set out in note 14. The Company advanced US$250,000 to Bioasis in the year to 31 December 2022. A further advance of US$250,000 was made to Bioasis on 3 January 2023. Management considers recovery of the debt to be uncertain and have therefore recognised an impairment provision of £207,000 in the year against advance made to Bioasis in December 2022, see note 14. A further provision has been of £207,000 against the future credit losses resulting from the Promissory Note. On 3 February 2023 Bioasis announced they were ‘urgently exploring and evaluating all financing and strategic alternatives that may be available to address its liquidity requirements’ which triggered an event of default. As a result of this the 3rd payment under the agreement was not made in the post year end period. On 5 March 2023 Bioasis were served with a notice of an event of default.

Financial instruments _ risk ma

Financial instruments – risk management	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Financial instruments – risk management	20 Financial instruments – risk management The Group is exposed through its operations to the following financial risks: · Credit risk · Foreign exchange risk · Liquidity risk This note describes the Group’s policies and processes for managing those risks. The policy for managing these risks is reviewed and agreed with the Board, however it has delegated the authority for designing and operating processes that ensure the effective management of the risks to the Group’s management. . Principal financial instruments The principal financial instruments used by the Group, from which financial instrument risk arises, are as follows: · Trade and other receivables · Cash and cash equivalents · Trade and other payables · Accruals · Loans and borrowings · Derivative financial liability A summary of the financial instruments held by category is provided below: Financial assets – amortised cost Schedule of consolidated derivative financial instruments 2022 £’000 2021 £’000 2020 £’000 Cash and cash equivalents 2,836 10,057 7,546 Trade receivables 329 33 95 Other receivables – – – Total financial assets 3,165 10,090 7,641 Financial liabilities – amortised cost 2022 £’000 2021 £’000 2020 £’000 Trade payables 339 485 337 Other payables 17 5 26 Accruals 817 546 768 Borrowings 624 766 260 Total financial liabilities – amortised cost 1,797 1,802 1,391 Financial liabilities – fair value through profit and loss – current 2022 £’000 2021 £’000 2020 £’000 Equity settled derivative financial liability 85 553 1,559 Fair value hierarchy The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique: · Level 1: quoted (unadjusted) prices in active markets for identical assets and liabilities; · Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and · Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data. The fair value of the Group’s derivative financial liability is measured at fair value on a recurring basis. The following table gives information about how the fair value of this financial liability is determined, additional disclosure is given in note 19: Schedule of consolidated financial assets and liabilities at fair value Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 48,000 Level 3 Monte Carlo simulation model Volatility rate of 70.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.88 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.22% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability £ 37,000 Level 3 Monte Carlo simulation model Volatility rate of 70.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.5 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.32% determined using the expected life assumptions. The higher the risk-free rate Total £ 85,000 Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 467,000 Level 3 Monte Carlo simulation model Volatility rate of 95.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 3.88 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.31% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability £ 86,000 Level 3 Monte Carlo simulation model Volatility rate of 85.0% determined using historical volatility of comparable companies The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 3.5 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.71% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability – Level 3 Black-Scholes option pricing model Volatility rate of 85.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.10 and 0.9 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.71% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Total £ 553,000 Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 1,187,000 Level 3 Monte Carlo simulation model Volatility rate of 105.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 4.49 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.07% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability £ 372,000 Level 3 Monte Carlo simulation model Volatility rate of 105.0% determined using historical volatility of comparable companies The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 4.888 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.08% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability – Level 3 Black-Scholes option pricing model Volatility rate of 105.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 1.0 and 1.9 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.8% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Total £ 1,559,000 Changing the unobservable risk free rate input to the valuation model by 10% higher while all other variables were held constant, would not impact the carrying amount of shares (2021: nil ; 2020: nil). There were no transfers between Level 1 and 2 in the period. The financial liability measured at fair value on Level 3 fair value measurement represents consideration relating to warrants issued in May 2020 and October 2019 as part of Registered Direct offerings and also a business combination. Credit risk The Group is exposed to credit risk from amounts due from collaborative partners and from cash and cash equivalents and deposits with banks and financial institutions. The risk from collaborative partners is deemed to be low. For banks and financial institutions, only independently rated parties with high credit status are accepted. The Group does not enter into derivatives to manage credit risk. The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. The total exposure to credit risk of the Group is equal to the total value of the financial assets held at each year end as noted above. Foreign exchange risk Foreign exchange risk arose because the Group had a material operation located in Bilbao, Spain. Given the levels of materiality, the Group did not hedge its net investments in overseas operations as the cost of doing so would be disproportionate to the exposure. The table below shows analysis of the Pounds Sterling equivalent of year-end cash and cash equivalent balances by currency: Schedule of foreign exchange risk 2022 £’000 2021 £’000 2020 £’000 Cash and cash equivalents: Pounds Sterling 2,588 10,057 7,247 US Dollar 248 – 120 Euro – – 179 Total 2,836 10,057 7,546 The table below shows the foreign currency exposure that gives rise to net currency gains and losses recognised in the consolidated statement of comprehensive income. As at 31 December, these exposures were as follows: 2022 £’000 2021 £’000 2020 £’000 Net Foreign Currency Assets/(Liabilities): US Dollar 248 – 120 Euro 17 22 54 Other – – 1 Total 265 22 175 Foreign exchange risk also arises when individual Group entities enter into transactions denominated in a currency other than their functional currency; the Group’s transactions outside the UK to the US and Europe drive foreign exchange movements where suppliers invoice in currency other than sterling. These transactions are not hedged because the cost of doing so is disproportionate to the risk. Foreign currency sensitivity analysis The most significant currencies in which the Group transacts, other than Pounds Sterling, are the US Dollar and the Euro. The Group also trades in other currencies in small amounts as necessary. The following table details the Group’s sensitivity to a 10% change in year-end exchange rates, which the Group feels is the maximum likely change in rate based upon recent currency movements, in the key foreign currency exchange rates against Pounds Sterling: Schedule of foreign currency exchange rates Year ended 31 December 2022 US Dollar £’000 Euro £’000 Other £’000 Loss before tax 25 (1 ) – Total equity 25 (1 ) – Year ended 31 December 2021 US Dollar £’000 Euro £’000 Other £’000 Loss before tax – 2 – Total equity – 2 – Year ended 31 December 2020 US Dollar £’000 Euro £’000 Other £’000 Loss before tax 12 (293 ) (4 ) Total equity 12 (293 ) (4 ) Liquidity risk Liquidity risk arises from the Group’s management of working capital. It is the risk that the Group will encounter difficulty in meeting its financial obligations as they fall due. It is the Group’s aim to settle balances as they become due. In December 2022, the Company completed a Registered Direct Offering in the US which raised £0.3 million before expenses. In February 2021, previously issued warrants were exercised resulting in the Company receiving £0.13 million before expenses. In July 2021, the Company completed a UK placing which raised £10.0 million before expenses. The Directors have prepared cash flow forecasts and considered the cash flow requirement for the Company for the next three years including the period twelve months from the date of approval of the consolidated financial statements. These forecasts show that further financing will be required during the fourth quarter of 2023 assuming, inter alia, that certain development programs and other operating activities continue as currently planned. This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group and parent company’s ability to continue as a going concern. In our opinion, the environment for financing of small and micro-cap biotech companies is as challenging as it has been since the financial crisis of 2008-2010. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, any attendant financings by Biodexa are likely to be dilutive. We and our advisors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group, including fundraising and the partnering of assets and technologies of the Company. The alternatives being considered are all at an early stage and are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any of the alternative courses of action to finance the Company will be successful. This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt about our ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would stated at net realizable value and all liabilities would be accelerated to current liabilities. As a result of the foregoing, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended 31 December 2022 with respect to this uncertainty. We believe there are adequate options and time and available to secure additional financing for the Company and after considering the uncertainties, we considered it is appropriate to continue to adopt the going concern basis in preparing these financial information. The following table sets out the contractual maturities (representing undiscounted contractual cash-flows) of financial liabilities: Schedule of contractual maturities of financial liabilities 2022 Up to 3 £’000 Between 3 and 12 months £’000 Between years £’000 Between £’000 Over £’000 Trade and other payables 1,173 – – – – Lease liabilities 49 140 188 254 – Total 1,222 140 188 254 – 2021 Up to 3 £’000 Between 3 and 12 months £’000 Between years £’000 Between £’000 Over £’000 Trade and other payables 1,036 – – – – Lease liabilities 46 171 195 442 – Total 1,082 171 195 442 – 2020 Up to 3 £’000 Between 3 and 12 months £’000 Between years £’000 Between £’000 Over £’000 Trade and other payables 1,131 – – – – Lease liabilities 25 75 61 8 – Government research loans 107 – – – – Total 1,263 75 61 8 – More details with regard to the line items above are included in the respective notes: Trade and other payables – note 16 Borrowings – note 17 As a result of the Strategic Review undertaken in March 2020 the Group repaid all Government Research loans during 2020 and 2021. Capital risk management The Group monitors capital which comprises all components of equity (i.e. share capital, share premium, foreign exchange reserve and accumulated deficit). The Group’s objectives when maintaining capital are: · to safeguard the entity’s ability to continue as a going concern; and · to have sufficient resource to take development projects forward towards commercialisation. The Group continues to incur substantial operating expenses. Until the Group generates positive net cash inflows from the commercialisation of its products it remains dependent upon additional funding through the injection of equity capital and government funding. The Group may not be able to generate positive net cash inflows in the future or to attract such additional required funding at all, or on suitable terms. In such circumstances the development programmes may be delayed or cancelled, and business operations cut back. The Group seeks to reduce this risk by keeping a tight control on expenditure, avoiding long term supplier contracts (other than clinical trials), prioritising development spend on products closest to potential revenue generation, obtaining government grants (where applicable), maintaining a focussed portfolio of products under development and keeping shareholders informed of progress. There have been no changes to the Group’s processes for managing capital risk since the previous year.

Deferred tax

Deferred tax	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Deferred tax	21 Deferred tax Deferred tax is calculated in full on temporary differences under the liability method using tax rates applicable in the tax jurisdictions where the tax asset or liability would arise. The movement on the deferred tax account in 2022 is £nil (2021: £nil, 2020: £nil) as the net credit arising on the amortisation of intangible assets and other timing differences has been matched by a reduction in the deferred tax asset recognised on the losses offsetting the liability remaining. Unused tax losses carried forward, subject to agreement with local tax authorities, were as follows: Schedule of unused tax losses carried forward Gross losses £’000 Potential £’000 31 December 2022 71,139 17,867 31 December 2021 67,210 16,925 31 December 2020 63,183 13,076 During 2020 the remaining deferred tax asset and liability arising on the business combination of Midatech Pharma (Wales) Ltd (2019: £ 1.6 The remaining potential deferred tax asset of £17.9m (2021: £16.9m, 2020: £13.1m) has not been provided in these accounts due to uncertainty as to whether the asset would be recovered. The losses have arisen as a result of accumulated trading losses. Deferred tax asset balances disclosed as at 31 December 2022 have been calculated at 25%. The Finance Bill 2021 enacted an increase in the tax rate to 25% from 1 April 2023.

Share capital

Share capital	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Share capital	8. Share capital and reserves Schedule of detailed information about share capital Authorised, allotted and As at 30 June Number As at 30 June £ As at 31 Number As at 31 £ Ordinary shares of 277,971,722 277,972 5,417,137 108,343 ‘A’ Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 ‘B’ Deferred shares of £0.001 4,063,321,418 4,063,321 – – Total 5,341,294 1,108,344 At a General Meeting on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result, the par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. The above table reflects the share consolidation in the comparative figures. At a General Meeting on 14 June 2023, shareholders approved the subdivision and redesignation of the Company’s Issued Ordinary Shares of £0.02 each into to one Ordinary Share of £0.001 each and 19 ‘B’ Deferred Shares of £0.001 each. The ‘B’ Deferred Shares have limited rights and are effectively valueless. The previously issued Deferred Shares were redesignated ‘A’ Deferred Shares. On 26 May 2023 the Company entered into private placement as set out in note 4. As no share premium was recognised in relation to this transaction the transaction costs allocated to the initial issue of shares have been charged to retained earnings. During the period the Company entered into two private placements as set out in note 4. The pre-funded, Series A, Series B, Series C and Investor warrants have been accounted for as equity warrants and the fair value on recognition allocated to the warrant reserve, net of transaction costs. On exercise of the warrants the fair value has been transferred to share capital and share premium. Ordinary and deferred shares were recorded as equity. Rights attaching to the shares of Biodexa Pharmaceuticals PLC Shares classified as equity The holders of ordinary shares in the capital of the Company have the following rights: (a) to receive notice of, to attend and to vote at all general meetings of the Company, in which case shareholders shall have one vote for each share of which he is the holder; and, (b) to receive such dividend as is declared by the Board on each share held. The holders of deferred shares in the capital of the Company: (a) shall not be entitled to receive notice of or to attend or speak at any general meeting of the Company or to vote on any resolution to be proposed at any general meeting of the Company; and (b) shall not be entitled to receive any dividend or other distribution of out of the profits of the Company. In the event of a distribution of assets, the deferred shareholders shall receive the nominal amount paid up on such share after the holder of each ordinary share shall have received (in cash or specie) the amount paid up or credited as paid up on such ordinary share together with an additional payment of £100 per share. The Company has the authority to purchase the deferred shares and may require the holder of the deferred shares to sell them for a price not exceeding 1p for all the deferred shares. Schedule Of Ordinary and Deferred Shares 2023 Ordinary Number ‘A’ Number ‘B’ Deferred Share £ Total £’000 At 1 January 2023 5,417,137 1,000,001 - 15 February 2023 Private Placements 3,250,200 - - 0.0505 164 26 May 2023 Registered Direct Offering 110,679,610 - - 0.0097 1,076 April – June 2023 Exercise February 2023 pre-funded warrants 62,184,525 - - 0.0505 3,139 March 2023 Exercise Series ‘A’ warrants 12,931,020 - - 0.0505 653 March 2023 Exercise Series ‘B’ warrants 19,396,530 - - 0.0505 979 15 June 2023 Exercise Investor warrants 625,000 - - 0.0505 32 14 June 2023 Share sub-division and re-designation - - 4,063,321,418 n/a n/a 30 June 2023 Exercise ‘C’ warrants 63,487,700 - - 0.0097 617 At 30 June 2023 (unaudited) 277,971,722 1,000,001 4,063,321,418 2022 At 1 January 2022 4,923,420 1,000,001 - 22 March 2022 Exercise of warrants 1 - - 200.000 - 3 May 2022 Share issue to SIPP trustee* 1,250 - - 0.001 - 19 December 2022 Registered Direct Offering 492,466 - - 0.6660 321 At 31 December 2022 5,417,137 1,000,001 - *Share issued to Biodexa Pharmaceuticals PLC employee benefit trust	22 Share capital Schedule of detailed information about share capital Authorised, allotted and fully 2022 Number 2022 £ 2021 Number 2021 £ 2020 Number 2020 £ At 31 December Ordinary shares of 5,417,137 108,343 4,923,420 98,468 3,153,694 63,074 Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 Total 1,108,344 1,098,469 1,063,075 At a General Meeting on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result the par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. At the same time, the ratio of the Company’s Ordinary Shares to ADSs was changed from each ADS representing 25 Ordinary Shares to each ADS representing 5 Ordinary Shares. The above table reflects the share consolidation. In accordance with the Articles of Association for the Company adopted on 13 November 2014, the share capital of the Company consists of an unlimited number of ordinary shares of nominal value £0.001 each. Ordinary and deferred shares were recorded as equity. Rights attaching to the shares following the incorporation of Biodexa Pharmaceuticals plc Shares classified as equity The holders of ordinary shares in the capital of the Company have the following rights: (a) to receive notice of, to attend and to vote at all general meetings of the Company, in which case shareholders shall have one vote for each share of which he is the holder; and, (b) to receive such dividend as is declared by the Board on each share held. The holders of deferred shares in the capital of the Company: (a) shall not be entitled to receive notice of or to attend or speak at any general meeting of the Company or to vote on any resolution to be proposed at any general meeting of the Company; and (b) shall not be entitled to receive any dividend or other distribution of out of the profits of the Company. In the event of a distribution of assets, the deferred shareholders shall receive the nominal amount paid up on such share after the holder of each ordinary share shall have received (in cash or specie) the amount paid up or credited as paid up on such ordinary share together with an additional payment of £100 per share. The Company has the authority to purchase the deferred shares and may require the holder of the deferred shares to sell them for a price not exceeding 1p for all the deferred shares. Schedule Of Ordinary and Deferred Shares Ordinary Number Deferred Number Share £ Total £’000 At 1 January 2020 1,174,752 1,000,001 2020 18 May 2020 Placing & Registered Direct Offering 787,878 5.4000 4,255 27 July 2020 Placing 1,064,814 5.4000 5,750 19 August 2020 Exercise of warrants 125,000 6.2642 783 30 September 2020 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – At 31 December 2020 3,153,694 1,000,001 19 February 2021 Exercise of warrants 15,340 5.9600 91 6 July 2021 Placing 1,754,386 5.7000 10,000 At 31 December 2021 4,923,420 1,000,001 22 March 2022 Exercise of warrants 1 200.0000 – 3 May 2022 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – 19? December 2022 Registered Direct Offering 492,466 0.6660 321 At 31 December 2022 5,417,137 1,000,001

Reserves

Reserves	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Reserves	23 Reserves The following describes the nature and purpose of each reserve within equity: Schedule of reserves Reserve Description and purpose Share capital Nominal value of subscribed share capital Share premium Amount subscribed for share capital in excess of nominal value. Merger reserve Represents the difference between the fair value and nominal value of shares issued on the acquisition of subsidiary companies where the Company has elected to take advantage of merger accounting. Foreign exchange reserve Gains/losses arising on retranslating the net assets of overseas operations into sterling. Warrant reserve Represents the fair value of warrants denominated in £ at the date of grant. The number and price is fixed at the date of grant. The warrants expire in November 2025. Accumulated deficit All other net gains and losses and transactions with owners (e.g. dividends) not recognised elsewhere.

Retirement benefits

Retirement benefits	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Retirement benefits	24 Retirement benefits The Group operates a defined contribution pension scheme for the benefit of its employees. The assets of the scheme are administered by trustees in funds independent from those of the Group. The annual charge for the year was £ 98,000 71,000

Share-based payments

Share-based payments	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Share-based payments	25 Share-based payments Share Options The Group has issued options over ordinary shares under the 2014 Biodexa Pharmaceuticals plc Enterprise Management Incentive Scheme, the Biodexa Pharmaceuticals plc 2016 U.S. Option Plan, which is a sub-plan of the approved UK plan, and unapproved share options awarded to non-UK or non-US staff. In addition, certain share options originally issued over shares in Midatech Limited under the Midatech Limited 2008 unapproved share option scheme or Midatech Limited 2013 approved Enterprise Incentive scheme were reissued in 2015 over shares in Biodexa Pharmaceuticals plc under the 2014 Biodexa Pharmaceuticals plc Enterprise Management Incentive Scheme. Exercise of an option is subject to continued employment. At a General Meeting on 24 March 2023, shareholders approved a consolidation of the Company’s Ordinary Shares on a one for 20 basis. As a result the par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. The following tables reflects the share consolidation. The options granted in 2022 were made under the 2014 Biodexa Pharmaceuticals plc Enterprise Management Incentive Scheme. Details of all share options granted under the Schemes are set out below: Details of all share options granted under the Schemes are set out below: Date of grant At 1 January Granted in Lapsed in Forfeited in At 31 December Exercise Price 20 April 2012 79 – (79 ) – – £ 1,676.00 9 May 2014 500 – (500 ) – – £ 30.00 30 June 2014 25 – – – 25 £ 30.00 31 October 2016 352 – (352 ) – – £ 1,072.00 19 December 2016 396 – (383 ) – 13 £ 484.00 15 December 2017 59 – – (19 ) 40 £ 184.00 24 April 2019 625 – – (313 ) 312 £ 29.20 2 October 2019 1,500 – – – 1,500 £ 21.00 17 April 2020 5,000 – – – 5,000 £ 4.80 17 June 2020 43,175 – (5,625 ) (3,950 ) 33,600 £ 4.04 15 July 2021 71,450 – – (7,100 ) 64,350 £ 5.55 2 August 2021 2,500 – – – 2,500 £ 5.30 1 September 2021 6,000 – – – 6,000 £ 5.10 7 February 2022 – 18,750 – – 18,750 £ 3.05 12 August 2022 – 12,500 – – 12,500 £ 2.10 131,661 31,250 (6,939 ) (11,382 ) 144,590 Options exercisable at 31 December 2022 55,932 Weighted average exercise price of outstanding options at 31 December 2022 £ 4.836 Weighted average exercise price of options exercised in 2022 n/a Weighted average exercise price of options lapsed in 2022 £ 105.612 Weighted average exercise price of options forfeited in 2022 £ 5.974 Weighted average exercise price of options granted in 2022 £ 2.670 Weighted average remaining contractual life of outstanding options at 31 December 2022 8.1 Date of grant At 1 January Granted in Lapsed in Forfeited in At 31 December Exercise Price 13 September 2011 8 – (8 ) – – £ 1,676.00 20 April 2012 79 – – – 79 £ 1,676.00 9 May 2014 500 – – – 500 £ 30.00 30 June 2014 25 – – – 25 £ 30.00 31 October 2016 397 – – (45 ) 352 £ 1,072.00 19 December 2016 499 – – (103 ) 396 £ 484.00 15 December 2017 164 – – (105 ) 59 £ 184.00 24 April 2019 2,275 – – (1,650 ) 625 £ 29.20 2 October 2019 1,500 – – – 1,500 £ 21.00 17 April 2020 5,000 – – – 5,000 £ 4.80 17 June 2020 63,700 – – (20,525 ) 43,175 £ 4.04 15 July 2021 – 85,450 – (14,000 ) 71,450 £ 5.55 2 August 2021 – 2,500 – – 2,500 £ 5.30 1 September 2021 – 6,000 – – 6,000 £ 5.10 74,147 93,950 (8 ) (36,428 ) 131,661 Options exercisable at 31 December 2021 8,982 Weighted average exercise price of outstanding options at 31 December 2021 £ 10.759 Weighted average exercise price of options exercised in 2021 n/a Weighted average exercise price of options lapsed in 2021 £ 1,676.000 Weighted average exercise price of options forfeited in 2021 £ 8.955 Weighted average exercise price of options granted in 2021 £ 5.515 Weighted average remaining contractual life of outstanding options at 31 December 2021 9.0 Date of grant At 1 January Granted in Lapsed in Forfeited in At 31 December Exercise Price 1 April 2010 63 – (63 ) – – £ 1,600.00 20 August 2010 104 – (104 ) – – £ 1,676.00 13 September 2011 8 – – – 8 £ 1,676.00 20 April 2012 79 – – – 79 £ 1,676.00 9 May 2014 500 – – – 500 £ 30.00 30 June 2014 925 – – (9,000 ) 25 £ 30.00 11 July 2014 6 – (3 ) (3 ) – £ 30.00 31 October 2016 815 – (43 ) (375 ) 397 £ 1,072.00 14 December 2016 20 – (20 ) – – £ 620.00 14 December 2016 25 – (25 ) – – £ 680.00 14 December 2016 100 – (100 ) – – £ 748.00 14 December 2016 81 – (81 ) – – £ 752.00 15 December 2016 230 – (230 ) – – £ 484.00 19 December 2016 1,118 – (78 ) (541 ) 499 £ 484.00 15 December 2017 1,478 – (666 ) (648 ) 164 £ 184.00 2 April 2018 50 – (50 ) – – £ 332.00 2 April 2018 225 – (225 ) – – £ 484.00 24 April 2019 8,475 – – (6,200 ) 2,275 £ 29.20 2 October 2019 2,500 – – (1,000 ) 1,500 £ 21.00 17 April 2020 – 5,000 – – 5,000 £ 4.80 17 June 2020 – 68,150 – (4,450 ) 63,700 £ 4.04 16,802 73,150 (1,688 ) (14,117 ) 74,147 Options exercisable at 31 December 2020 9,759 Weighted average exercise price of outstanding options at 31 December 2020 £ 16.698 Weighted average exercise price of options exercised in 2020 n/a Weighted average exercise price of options lapsed in 2020 £ 523.411 Weighted average exercise price of options forfeited in 2020 £ 72.975 Weighted average exercise price of options granted in 2020 £ 4.092 Weighted average remaining contractual life of outstanding options at 31 December 2020 9.2 The following information is relevant in the determination of the fair value of options granted during the year 2022 under the equity share based remuneration schemes operated by the Group. Schedule of fair value of options granted February 2022 August 2022 August 2022 Number of options 18,750 5,000 7,500 Option pricing models used Black-Scholes Black-Scholes Black-Scholes Share price £ 3.05 £ 2.10 £ 2.10 Exercise price of options issued in year £ 3.05 £ 2.10 £ 2.10 Contractual life 10 10 10 Expected life 5 5 5 Volatility 87.88 %** 91.78 %** 91.66 %** Expected dividend yield 0 % 0 % 0 % Risk free rate 1.28 % 1.92 % 1.92 % The share price used in the determination of the fair value of the options granted in 2022 was the share price on the date of grant. ** Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period. The following information is relevant in the determination of the fair value of options granted during the year 2021 under the equity share based remuneration schemes operated by the Group. July 2021 August 2021 September 2021 Number of options 85,450 2,500 6,000 Option pricing models used Black-Scholes Black-Scholes Black-Scholes Share price £ 5.55 * £ 5.30 * £ 5.10 * Exercise price of options issued in year £ 5.55 £ 5.30 £ 5.10 Contractual life 10 10 10 Expected life 5 5 5 Volatility 88.63 %** 88.59 %** 88.11 %** Expected dividend yield 0 % 0 % 0 % Risk free rate 0.38 % 0.26 % 0.32 % * The share price used in the determination of the fair value of the options granted in 2021 was the share price on the date of grant. ** Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period. The following information is relevant in the determination of the fair value of options granted during the year 2020 under the equity share based remuneration schemes operated by the Group. April 2020 June 2020 Number of options 5,000 68,150 Option pricing models used Black-Scholes Black-Scholes Share price £ 4.80 * £ 4.04 * Exercise price of options issued in year £ 4.80 £ 4.04 Contractual life 10 10 Expected life 5 5 Volatility 84.76 %** 92.55 %** Expected dividend yield 0 % 0 % Risk free rate 0.11 % 0.10 % * The share price used in the determination of the fair value of the options granted in 2020 was the share price on the date of grant. ** Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period. All other share options relate to the Midatech Limited 2008 unapproved share option scheme. Share Incentive Plan In April 2017 the Group set up the Biodexa Pharmaceuticals Share Incentive Plan (MPSIP). Under the BPSIP, Group employees and Directors can acquire ordinary shares in the Company via a salary sacrifice arrangement. Biodexa grants matching shares for every share bought. In order to retain these shares, scheme participants must remain employed by the Group for three years from the date of acquisition. All shares purchased by the BPSIP are held by an Employee Benefit Trust that is not under the control of Biodexa. Shares must be left in the plan for 5 years to qualify for full income tax and NIC relief.

Capital commitments

Capital commitments	12 Months Ended
	Dec. 31, 2022
Capital Commitments
Capital commitments	26 Capital commitments The Group had no capital commitments at 31 December 2022, 31 December 2021 and 31 December 2020.

Related party transactions

Related party transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Related party transactions	9. Related party transaction The Directors consider there to be no related party transactions during the periods reported other than Directors Remuneration.	27 Related party transactions Trading Transactions The Directors consider BioConnection BV to be a related party by virtue of the fact that there is a common Director with the Company and the Director is identified as having significant influence over the entity. 2019 was the first year where this relationship existed. During the year Group companies entered into the following transactions with related parties who are not members of the Group. Schedule of related party transactions Purchase of good Amounts owed by related parties 2022 €’000 2021 €’000 2020 €’000 2022 €’000 2021 €£’000 2020 €’000 BioConnection BV – – 296 – – – During 2019 Midatech Pharma (Espana) SL entered into a commercial contract with BioConnection BV in connection with the Group’s MTD201 program, this contract was subsequently terminated in 2020 as a result of the termination of the program. The Group has not made any allowances for bad or doubtful debts in respect of related party debtors nor has any guarantee been given or received during 2022, 2021 or 2020 regarding related party transactions.

Ultimate controlling party

Ultimate controlling party	12 Months Ended
	Dec. 31, 2022
Ultimate Controlling Party
Ultimate controlling party	29 Ultimate controlling party The Directors do not consider that there is an ultimate controlling party.

Results of Midatech Pharma (Esp

Results of Midatech Pharma (Espa?a) SL	12 Months Ended
	Dec. 31, 2022
Results Of Midatech Pharma Espaa Sl
Results of Midatech Pharma (Espa?a) SL	30 Results of Midatech Pharma (España) SL Included within the Group Consolidated Statements of Comprehensive Income for the year to 31 December 2020 are the results of the Group’s Spanish operation that was closed on 3 June 2020. The Group appointed a Liquidator to liquidate the company with documentation submitted to the Spanish Authorities in February 2021. Management assessed whether Midatech Pharma (España) SL should be accounted for as a discontinued operation under IFRS 5 and concluded that it did not meet the criteria as it did not meet the definition of a cash generating unit. The unaudited results of Midatech Pharma (España) SL for the year to 31 December are as follows: Schedule Of Unaudited Results Explanatory Year ended 31 £’000 Grant revenue 163 Total revenue 163 Research and development costs (2,820 ) Administrative costs (1,146 ) Loss from operations (3,803 ) Finance expense (11 ) Loss before tax (3,814 ) Taxation (21 ) Loss from operations after tax (3,835 )

Post Balance Sheet Events

Post Balance Sheet Events	12 Months Ended
	Dec. 31, 2022
Post Balance Sheet Events
Post Balance Sheet Events	31 Post Balance Sheet Events On 3 January 2023 the Company provided a further advance to Bioasis under the Promissory Note and Security Agreement it entered into on 19 December 2022 of US$ 250,000 On 5 January 2023 the Company issued a Circular containing details of the Company’s proposed acquisition of Bioasis, an equity raise of US$ 9.6 225,000 On 9 February 2023 the Company announced it had entered into definitive binding agreements with institutional US investors to raise aggregate gross proceeds of US$ 6.0 10,344,822 On 8 March 2023 the Company announced that it sent a circular to shareholders convening a General Meeting to effect a share consolidation on a one for 20 basis, give the Directors authority to allot shares, disapply pre-emption rights, adopt new Articles, cancel the admission of the Company’s Ordinary Shares to trading on the AIM market and change the name of the Company to Biodexa Pharmaceuticals PLC. The Company also notified shareholders that the Ordinary Share to ADS ratio was being changed from 25 Ordinary Shares per ADS to 5 Ordinary Shares per ADS. At the General Meeting on 24 March 2023, all resolutions were duly passed. The share consolidation will have an impact on the ordinary shares, any employee share option plans as well as warrants. As a result of share consolidation: Schedule of share consolidation Pre-Split Post-Split Weighted average number of shares outstanding - basic and diluted 98,835,849 4,941,793 Ordinary shares outstanding 108,342,738 5,417,137 Outstanding employee share options over ordinary shares 2,891,875 144,590 Outstanding DARA options over ordinary shares 2,822 138 Outstanding warrants over ordinary shares 17,221,973 861,075 The financial statements reflect the effects of the reverse stock split (share consolidation) for all periods presented. On 26 April 2023, the admission of the Company’s Ordinary Shares to trading on AIM was cancelled.

Accounting policies (Policies)

Accounting policies (Policies)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Basis for consolidation	Basis for consolidation The Group financial statements consolidate those of the parent company and all of its subsidiaries. The parent controls a subsidiary if it has power over the investee to significantly direct the activities, exposure, or rights to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor’s returns. All subsidiaries have a reporting date of 31 December. All transactions and balances between Group companies are eliminated on consolidation, including unrealised gains and losses on transactions between Group companies. Where unrealised losses on intra-Group asset sales are reversed on consolidation, the underlying asset is also tested for impairment from a Group perspective. Amounts reported in the financial statements of subsidiaries have been adjusted where necessary to ensure consistency with the accounting policies adopted by the Group. The consolidated financial statements consist of the results of the following entities: Schedule of entities Entity Summary description Biodexa Pharmaceuticals plc Ultimate holding company Midatech Limited Trading company Midatech Pharma (Espana) SL (formerly Midatech Biogune SL) Liquidated - 2021 PharMida AG Dormant Midatech Pharma (Wales) Limited (formerly Q Chip Limited) Trading company Midatech Pharma Pty Dissolved - 2020 Biodexa Limited (formerly Bioadexa Pharmaceuticals Limited) Dormant – incorporated October 2022
Going concern	Going concern The Group and Company are subject to a number of risks similar to those of other development and early-commercial stage pharmaceutical companies. These risks include, amongst others, generation of revenue from the development portfolio and risks associated with research, development, testing and obtaining related regulatory approvals of our pipeline products. Ultimately, the attainment of profitable operations is dependent on future uncertain events which include obtaining adequate financing to fulfill our commercial and development activities and generating a level of revenue adequate to support our cost structure. We have experienced net losses and significant cash outflows from cash used in operating activities over the past years as we develop our portfolio. For the year ended 31 December 2022, the Group incurred a consolidated loss from operations of £7.7 million and negative cash flows from operating activities of £7.0 million. As of 31 December 2022, the Group had an accumulated deficit of £135.3 million. Our future viability is dependent on our ability to raise cash from financing activities to finance our development plans until commercialisation, generate cash from operating activities and to successfully obtain regulatory approval to allow marketing of our development products. Our failure to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue its business strategies. Our consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at 31 December 2022, we had cash and cash equivalents of £2.8 million. On 9 February 2023 the Company completed a Private Placement in which it raised US$5.2 million (approximately £4.3 million), after deducting the placement agent’s fees and other estimated expenses. We forecast that the Group currently has enough cash to fund its planned operations into the fourth quarter of 2023. We believe we currently have enough cash to fund our planned operations into the fourth quarter of 2023. Failure to secure additional funding before the fourth quarter of 2023 could result in the Company being placed into administration. We have prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period twelve months from the date of approval of the consolidated financial statements. These forecasts show that further financing will be required during the course of the next 12 months assuming, inter alia, that certain development programs and other operating activities continue as currently planned. In our opinion, the environment for financing of small and micro-cap biotech companies is as challenging as it has been since the financial crisis of 2008-2010. While this may present acquisition and/or merger opportunities with other companies with limited or no access to financing, any attendant financings by Biodexa are likely to be dilutive. We and our advisors continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to the Group, including fundraising and the partnering of assets and technologies of the Company. The alternatives being considered are all at an early stage and are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any of the alternative courses of action to finance the Company will be successful. This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt about our ability to continue as a going concern. Should it become evident in the future that there are no realistic financing options available to the Company which are actionable before its cash resources run out then the Company will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to current liabilities. As a result of the foregoing, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended 31 December 2022 with respect to this uncertainty. We believe there are adequate options and time and available to secure additional financing for the Company and after considering the uncertainties, we considered it is appropriate to continue to adopt the going concern basis in preparing these financial information. Our ability to continue as a going concern is dependent upon our ability to obtain additional capital and/or dispose of assets, for which there can be no assurance we will be able to do on a timely basis, on favourable terms or at all.
Revenue	Revenue Revenue is accounted for in line with principles of IFRS 15 ‘Revenue from contracts with customers’ Supply of Research and Development Services Revenue from the supply of services is subject to specific agreement. This is recognised over the contract term, proportionate to the progress in overall satisfaction of the performance obligations (the services performed by the Group), measured by cost incurred to date out of total estimate of costs. The primary input of substantially all work performed under these arrangements is labour. There is normally a direct relationship between costs incurred and the proportion of the contract performed to date. Where the Group supplies services to a client it generally bills an agreed percentage in advance of the commencement of any work and the balance on completion. Invoices to clients are payable under normal commercial terms. Grant revenue Where grant income is received, which is not a direct re-imbursement of related costs, revenue is recognised at the point at which the conditions have been met, this has been recognised within grant revenue. Where grants are received as a re-imbursement of directly related costs they are credited to research and development expense in the same period as the expenditure towards which they are intended to contribute. The Group previously received government loans that had a below-market rate of interest. These loans were recognised and measured in accordance with IFRS 9. The benefit of the below-market rate of interest was measured as the difference between the initial carrying value of the loan discounted at a market rate of interest and the proceeds received. The difference was held within deferred revenue as a government grant and released as a credit to grant income or to research and development expense in line with the expenditure to which it related. In a situation where the proceeds were invested in plant and equipment, the deferred revenue was credited to research and development within the income statement in line with the depreciation of the acquired asset.
Business combinations and externally acquired intangible assets	Business combinations and externally acquired intangible assets Business combinations are accounted for using the acquisition method at the acquisition date, which is the date at which the Group obtains control over the entity. The cost of an acquisition is measured as the amount of the consideration transferred to the seller, measured at the acquisition date fair value, and the amount of any non-controlling interest in the acquiree. The Group measures goodwill initially at cost at the acquisition date, being: · the fair value of the consideration transferred to the seller, plus; · the amount of any non-controlling interest in the acquiree, plus; · if the business combination is achieved in stages, the fair value of the existing equity interest in the acquiree re-measured at the acquisition date, less; · the fair value of the net identifiable assets acquired and assumed liabilities. Acquisition costs incurred are expensed and included in administrative costs. Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration, whether it is an asset or liability, will be recognised through the consolidated statement of comprehensive income. If the contingent consideration is classified as equity, it is not re-measured. An intangible asset, which is an identifiable non-monetary asset without physical substance, is recognised to the extent that it is probable that the expected future economic benefits attributable to the asset will flow to the Group and that its cost can be measured reliably. The asset is deemed to be identifiable when it is separable or when it arises from contractual or other legal rights. Externally acquired intangible assets other than goodwill are initially recognised at cost and subsequently amortised on a straight-line basis over their useful economic lives where they are in use. Goodwill is stated at cost less any accumulated impairment losses. The amounts ascribed to intangibles recognised on business combinations are arrived at by using appropriate valuation techniques. In-process research and development (‘IPRD’) programmes acquired in business combinations are recognised as assets even if subsequent expenditure is written off because the criteria specified in the policy for development costs below are not met. IPRD is subject to annual impairment testing until the completion or abandonment of the related project. No further costs are capitalised in respect of this IPRD unless they meet the criteria for research and development capitalisation as set out below. As per IFRS 3, once the research and development of each defined project is completed, the carrying value of the acquired IPRD is reclassified as a finite-lived asset and amortised over its useful life. The significant intangibles recognised by the Group and their useful economic lives are as follows: Schedule of intangibles assets useful economic lives Goodwill – Indefinite life IPRD – In process, not yet amortising IT and website costs – 4 years The useful economic life of IPRD will be determined when the in-process research projects are completed.
Internally generated intangible assets (development costs)	Internally generated intangible assets (development costs) Expenditure on the research phase of an internal project is recognised as an expense in the period in which it is incurred. Development costs incurred on specific projects are capitalised when all the following conditions are satisfied: · completion of the asset is technically feasible so that it will be available for use or sale; · the Group intends to complete the asset and use or sell it; · the Group has the ability to use or sell the asset and the asset will generate probable future economic benefits (over and above cost); · there are adequate technical, financial and other resources to complete the development and to use or sell the asset; and · the expenditure attributable to the asset during its development can be measured reliably. All internal activities related to the research and development of new projects are continuously monitored by the Directors. The Directors consider that the criteria to capitalise development expenditure are not met for a product prior to that product receiving regulatory approval in at least one country. Development expenditure not satisfying the above criteria, and expenditure on the research phase of internal projects are included in research and development costs recognised in the Consolidated Statement of Comprehensive Income as incurred. No projects have yet reached the point of capitalisation.
Impairment of non-financial assets	Impairment of non-financial assets Assets that have an indefinite useful life, for example goodwill, or intangible assets not ready for use, such as IPRD, are not subject to amortisation and are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). The Group at 31 December 2022 had only one cash generating unit (2021: one, 2020: one), as set out in note 12. Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of impairment at each reporting date. Impairment charges are included in profit or loss, except, where applicable, to the extent they reverse gains previously recognised in other comprehensive income. An impairment loss recognised for goodwill is not reversed.
Patents and trademarks	Patents and trademarks The costs incurred in establishing patents and trademarks are either expensed in accordance with the corresponding treatment of the development expenditure for the product to which they relate or capitalised if the development expenditure to which they relate has reached the point of capitalisation as an intangible asset.
Foreign currency	Foreign currency Transactions entered into by subsidiary entities in a currency other than the currency of the primary economic environment, in which they operate, are recorded at the rates ruling when the transactions occur. Foreign currency monetary assets and liabilities are translated at the rates ruling at the reporting date. Exchange differences arising on the retranslation of unsettled monetary assets and liabilities are recognised immediately in profit or loss. The presentational currency of the Group is Pounds Sterling. Foreign subsidiaries use the local currencies of the country where the operate. On consolidation, the results of overseas operations are translated into Pounds Sterling at rates approximating to those ruling when the transactions took place. All assets and liabilities of overseas operations, including goodwill arising on the acquisition of those operations, are translated at the rate ruling at the reporting date. Exchange differences arising on translating the opening net assets at opening rate and the results of overseas operations at actual rate are recognised in other comprehensive income and accumulated in the foreign exchange reserve. Exchange differences recognised in the profit or loss of Group entities on the translation of long-term monetary items forming part of the Group’s net investment in the overseas operation concerned are reclassified to other comprehensive income and accumulated in the foreign exchange reserve on consolidation. On disposal of a foreign operation, the cumulative exchange differences recognised in the foreign exchange reserve relating to that operation up to the date of disposal are transferred to the consolidated statement of comprehensive income as part of the gain or loss on disposal.
Financial assets and liabilities	Financial assets and liabilities Assets at amortised cost The Group does not have any financial assets which it would classify as fair value through profit or loss. Therefore, all financial assets are classed as assets at amortised cost as defined below. These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise principally through the provision of goods and services to customers (e.g. trade receivables), but also incorporate other types of contractual monetary asset. They are initially recognised at fair value plus transaction costs that are directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment. For impairment provisions, the Group applies the IFRS 9 simplified approach to measure expected credit losses using a lifetime expected credit loss provision for trade receivables to measure expected credit losses on a collective basis. Trade receivables are grouped based on a similar credit risk and ageing The expected loss rates are based on the Group’s historic credit losses experienced over the three-year period prior to the period end. The historic loss rates are then adjusted for current and forward-looking information on macroeconomic factors. The Group’s assets at amortised costs comprise trade and other receivables and cash and cash equivalents in the consolidated statement of financial position. Cash and cash equivalents include cash in hand, deposits held at call with original maturities of three months or less. Financial liabilities The Group classifies its financial liabilities into one of two categories, depending on the purpose for which the liability was acquired. Fair value through profit and loss (‘FVTPL’) The Group has outstanding warrants in the ordinary share capital of the company. The number of ordinary shares to be issued when exercised is fixed, however the exercise price is denominated in US Dollars being different to the functional currency of the parent company. Therefore, the warrants are classified as equity settled derivative financial liabilities recognised at fair value through the profit and loss account. The financial liability is valued using the either the Monte Carlo model or the Black-Scholes option pricing model. Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on re-measurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the ‘finance income’ or ‘finance expense’ lines item in the income statement. Fair value is determined in the manner described in note 19. Other financial liabilities include the following items: · Borrowings are initially recognised at fair value net of any transaction costs directly attributable to the issue of the instrument. Such interest-bearing liabilities are subsequently measured at amortised cost using the effective interest rate method, which ensures that any interest expense over the period to repayment is at a constant rate on the balance of the liability carried in the consolidated statement of financial position. Interest expense in this context includes initial transaction costs and premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding. · Government loans received on favourable terms below market rate are discounted at a market rate of interest. The difference between the present value of the loan and the proceeds is held as a government grant within deferred revenue and is released to research and development expenditure or grant income in line with when the asset or expenditure is recognised in the income statement. · Trade payables and other short-term monetary liabilities are initially recognised at fair value and subsequently carried at amortised cost using the effective interest method.
Share capital	Share capital Financial instruments issued by the Group are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Group has two classes of share in existence: · ordinary shares of £ 0.001 · deferred shares of £1 each are classified as equity instruments.
Retirement benefits: defined contribution schemes	Retirement benefits: defined contribution schemes Contributions to defined contribution pension schemes are charged to the consolidated statement of comprehensive income in the year to which they relate.
Provisions	Provisions Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.
Share-based payments	Share-based payments The Group operates a number of equity-settled, share-based compensation plans, under which the entity receives services from employees as consideration for equity instruments (options) of the Group. The fair value of the employee services received in exchange for the grant of the options is recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted: · including any market performance conditions (including the share price); · excluding the impact of any service and non-market performance vesting conditions (for example, remaining an employee of the entity over a specified time period); and · including the impact of any non-vesting conditions (for example, the requirement for employees to save). Non-market performance and service conditions are included in assumptions about the number of options that are expected to vest. The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. Where vesting conditions are accelerated on the occurrence of a specified event, such as a change in control or initial public offering, such remaining unvested charge is accelerated to the income statement. In addition, in some circumstances employees may provide services in advance of the grant date and therefore the grant date fair value is estimated for the purposes of recognising the expense during the period between service commencement period and grant date. At the end of each reporting period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting conditions. It recognises the impact of the revision to original estimates, if any, in the income statement, with a corresponding adjustment to equity. When the options are exercised, the Company issues new shares. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium.
Leases	Leases Identifying Leases The Group accounts for a contract, or a portion of a contract, as a lease when it conveys the right to use an asset for a period of time in exchange for consideration. Leases are those contracts that satisfy the following criteria: (a) There is an identified asset; (b) The Group obtains substantially all the economic benefits from use of the asset; and (c) The Group has the right to direct use of the asset. The Group considers whether the supplier has substantive substitution rights. If the supplier does have those rights, the contract is not identified as giving rise to a lease. In determining whether the Group obtains substantially all the economic benefits from use of the asset, the Group considers only the economic benefits that arise from the use of the asset, not those incidental to legal ownership or other potential benefits. In determining whether the Group has the right to direct use of the asset, the Group considers whether it directs how and for what purpose the asset is used throughout the period of use. If there are no significant decisions to be made because they are pre-determined due to the nature of the asset, the Group considers whether it was involved in the design of the asset in a way that predetermines how and for what purpose the asset will be used throughout the period of use. If the contract or portion of a contract does not satisfy these criteria, the Group applies other applicable IFRSs rather than IFRS 16. All leases are accounted for by recognising a right-of-use asset and a lease liability except for: · Leases of low value assets; and · Leases with a duration of 12 months or less. Lease liabilities are measured at the present value of the contractual payments due to the lessor over the lease term, with the discount rate determined by reference to the group’s incremental borrowing rate on commencement of the lease. Right of use assets are initially measured at the amount of the lease liability, reduced for any lease incentives received, and increased for lease payments made at or before commencement of the lease. The Group has taken advantage of the practical expedient to ignore the requirement to separate non-lease components and instead account for the entire contract as a single lease. Subsequent to initial measurement lease liabilities increase as a result of interest charged at a constant rate on the balance outstanding and are reduced for lease payments made. Right-of-use assets are amortised on a straight-line basis over the remaining term of the lease. When the group revises its estimate of the term of any lease (because, for example, it re-assesses the probability of a lessee extension or termination option being exercised), it adjusts the carrying amount of the lease liability to reflect the payments to make over the revised term, which are discounted using a revised discount rate. An equivalent adjustment is made to the carrying value of the right-of-use asset, with the revised carrying amount being amortised over the remaining (revised) lease term. If the carrying amount of the right-of-use asset is adjusted to zero, any further reduction is recognised in profit or loss. Nature of leasing activities (in the capacity as lessee) As at 31 December 2022 the Group had one property lease in place in the UK.
Taxation	Taxation Tax is recognised in the Comprehensive Statement of Income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax credit is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the country where the Company operates and generates income.
Deferred taxation	Deferred taxation Deferred tax assets and liabilities are recognised where the carrying amount of an asset or liability in the consolidated statement of financial position differs from its tax base, except for differences arising on: · the initial recognition of goodwill; · the initial recognition of an asset or liability in a transaction which is not a business combination and at the time · investments in subsidiaries and jointly controlled entities where the Group is able to control the timing of the reversal of the difference and it is probable that the difference will not reverse in the foreseeable future. Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profit will be available against which the difference can be utilised. The amount of the asset or liability is determined using tax rates that have been enacted or substantively enacted by the reporting date and are expected to apply when the deferred tax assets or liabilities are recovered or settled.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses. Depreciation is provided on all items of property, plant and equipment so as to write off their carrying value over their expected useful economic lives. It is provided at the following rates: Schedule of depreciation rates of property, plant and equipment Fixtures and fittings – 20%- 25% per annum straight line Leasehold improvements – the shorter of 10% per annum straight line or over the lease term Computer equipment – 25% per annum straight line Laboratory equipment – 15% – 25% per annum straight line Right of use asset – Economic life of contractual relationship

Finance income and expense (Tab

Finance income and expense (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of finance income	Schedule of finance income Six months unaudited £’000 Six months unaudited £’000 Finance income Interest received on bank deposits 24 6 Gain on equity settled derivative financial liability 386 398 Total finance income 410 404 The gain on the equity settled derivative financial liability in 1H23 and 1H22 arose as a result of the fall in the Biodexa share price. Six months unaudited £’000 Six months unaudited £’000 Finance expense Interest expense on lease liabilities 15 24 Other loans 7 - Total finance expense 22 24	Schedule of finance income 2022 £’000 2021 £’000 2020 £’000 Finance income Interest received on bank deposits 29 – 1 Gain on equity settled derivative financial liability 468 936 – Total finance income 497 936 1 2022 £’000 2021 £’000 2020 £’000 Finance expense Interest expense on lease liabilities 43 36 20 Other loans 10 8 14 Loss on equity settled derivative financial liability – – 397 Total finance expense 53 44 431

Taxation (Tables)

Taxation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of components of income tax expense (benefit)	Schedule of components of income tax expense (benefit) Six months unaudited £’000 Six months unaudited £’000 Income tax credit 288 337	Schedule of components of income tax expense (benefit) 2022 £’000 2021 £’000 2020 £’000 Current tax credit Current tax credited to the income statement 825 646 1,144 Taxation payable in respect of foreign subsidiary – – (21 ) Adjustment in respect of prior year 7 – 158 Current tax credit 832 646 1,281 Deferred tax credit Reversal of temporary differences – – – Total tax credit 832 646 1,281
Schedule of difference between actual tax charge and the standard rate of corporation tax		Schedule of difference between actual tax charge and the standard rate of corporation tax 2022 £’000 2021 £’000 2020 £’000 Loss before tax (8,488 ) (6,106 ) (23,470 ) Expected tax credit based on the standard rate of United Kingdom corporation tax at the domestic rate of 19% (2021: 19%; 2020: 19%) (1,613 ) (1,160 ) (4,459 ) Expenses not deductible for tax purposes 392 75 596 Income not taxable (4 ) (2 ) (75 ) Adjustment in respect of prior period (7 ) – (158 ) Surrender of tax losses for R&D tax refund (357 ) (280 ) (491 ) Deferred tax not recognised 757 721 3,306 Total tax credited to the income statement (832 ) (646 ) (1,281 )

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of loss per share	Schedule of loss per share Six months unaudited £’000 Six months unaudited £’000 Numerator Loss used in basic EPS and diluted EPS: (3,568 ) (3,061 ) Denominator Weighted average number of ordinary shares used in basic EPS 99,191,082 4,923,828 Basic and diluted loss per share: (4 )p (62 )p	Schedule of loss per share 2022 £’000 2021 £’000 2020 £’000 Numerator Loss used in basic EPS and diluted EPS: Continuing operations (7,656 ) (5,460 ) (22,189 ) Denominator Weighted average number of ordinary shares used in basic EPS: 4,941,793 4,027,345 2,142,000 Basic and diluted loss per share: Continuing operations – £ (1.55 ) (1.36 ) (10.36 )

Borrowings (Tables)

Borrowings (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of borrowings	Schedule of borrowings As at 30 £’000 As at 31 £’000 Current Lease liabilities 164 161 Total 164 161 Non-current Lease liabilities 380 463 Total 380 463	Schedule of borrowings 2020 £’000 2021 £’000 2020 £’000 Current Lease liabilities 161 146 93 Government and research loans – – 107 Total 161 146 200 Non-current Lease liabilities 463 620 60 Total 463 620 60

Provision (Tables)

Provision (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Provision
Schedule of provisions	Schedule of provisions As at 30 £’000 As at 31 £’000 Opening provision at 1 January 207 50 Utilisation of provision (207 ) (43 ) Provision recognised during the period - 200 - 207	Schedule of provisions 2022 £’000 2021 £’000 2020 £’000 Opening provision at 1 January 50 50 97 Utilisation of provision (43 ) – (97 ) Provision recognised in the year 200 – 50 At 31 December 207 50 50 Less: non-current portion – – (50 ) Current portion 207 50 –

Derivative financial liabilit_2

Derivative financial liability – current (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Derivative Financial Liability Current
Schedule of derivative financial liability	Schedule of derivative financial liability As at 30 £’000 As at 31 £’000 At 1 January 85 553 Warrants issued 665 - Gain recognised in finance income within the consolidated statement of comprehensive income (386 ) (468 ) 364 85	Schedule of derivative financial liability 2022 £’000 2021 £’000 2020 £’000 Equity settled derivative financial liability At 1 January 553 1,559 664 Warrants issued – – 997 Transfer to share premium on exercise of warrants – (70 ) (499 ) (Gain)/loss recognised in finance (income)/expense within the consolidated statement of comprehensive income (468 ) (936 ) 397 At 31 December 85 553 1,559
Schedule of warrants outstanding	Schedule of warrants outstanding ADS Warrants Original price New price per Equivalent Ordinary Number October 2019 warrants 375 $10,000 $320 150,000 May 2020 warrants 406 $3,280 $320 162,400 * Number and original price of warrants have been adjusted to reflect the share consolidation and ratio change of ADS’s to ordinary shares that occurred on 2 March 2020 and 24 March 2023 and the ratio change of ADS’s to ordinary shares on 26 September 2022 and 5 July 2023.	Schedule of warrants outstanding At 1 Granted Exercised At 31 Lapsed Exercised At 31 Lapsed At 31 May 2020 grant – 477,255 (125,000 ) 352,255 – (15,340 ) 336,915 – 336,915 October 19 grant 157,495 – – 157,495 – – 157,495 – 157,495 DARA Warrants 231 – – 231 (27 ) – 204 (204 ) – DARA Options 138 – – 138 – – 138 – 138
Schedule of warrants and options recognised	Schedule of warrants and options recognised At 1 Lapsed At 31 2022 Granted Lapsed Exercised At 30 June ADSs May 2023 grant ‘D’ warrants – – – 276,689 – – 276,689 May 2020 grant 838 – 838 – – – 838 October 2019 grant 392 – 392 – – – 392 Ordinary Shares DARA Warrants 204 (204) – – – – – DARA Options 138 – 138 (4) – 134
Schedule of consolidated financial assets and liabilities at fair value	Schedule of consolidated financial assets and liabilities at fair value Financial Fair value as at 30 June 2023 Fair value as 2022 Fair value Valuation Significant unobservable input(s) Relationship of Equity settled financial derivative liability – June 2023 £ 364,000 - Level 3 2023 - Black-Scholes Model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life of 4.98 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.13% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability – May 2020 Warrants – £48,000 Level 3 2023 – Black- Scholes Model 2022 - Monte Carlo simulation model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.38 years determined using the remaining life of the share options The shorter the expected life the lower the fair value. Risk-free rate of 4.68% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability – October 2019 Warrants – £37,000 Level 3 2023 – Black- Scholes Model 2022 - Monte Carlo simulation model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.00 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.87% determined using the expected life assumptions. The higher the risk-free rate Total £364,000 £85,000 Changing the unobservable risk-free rate input to the valuation model by 10% higher while all other variables were held constant, would not impact the carrying amount of shares (2022: nil). There were no transfers between Level 1 and 2 in the period. The financial liability measured at fair value on Level 3 fair value measurement represents consideration relating to warrants issued in June 2023, May 2020 and October 2019 as part of Private Placements and Registered Direct offerings.	Schedule of consolidated financial assets and liabilities at fair value Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 48,000 Level 3 Monte Carlo simulation model Volatility rate of 70.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.88 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.22% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability £ 37,000 Level 3 Monte Carlo simulation model Volatility rate of 70.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.5 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.32% determined using the expected life assumptions. The higher the risk-free rate Total £ 85,000 Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 467,000 Level 3 Monte Carlo simulation model Volatility rate of 95.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 3.88 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.31% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability £ 86,000 Level 3 Monte Carlo simulation model Volatility rate of 85.0% determined using historical volatility of comparable companies The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 3.5 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.71% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability – Level 3 Black-Scholes option pricing model Volatility rate of 85.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.10 and 0.9 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.71% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Total £ 553,000 Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 1,187,000 Level 3 Monte Carlo simulation model Volatility rate of 105.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 4.49 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.07% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability £ 372,000 Level 3 Monte Carlo simulation model Volatility rate of 105.0% determined using historical volatility of comparable companies The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 4.888 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.08% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability – Level 3 Black-Scholes option pricing model Volatility rate of 105.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 1.0 and 1.9 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.8% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Total £ 1,559,000
Schedule of warrant exercise price		Schedule of warrant exercise price ADR Warrants Equivalent Ordinary Number* Original Price New Price per Number October 2019 ADR warrants 30,000 $ 125.00 $ 4.00 150,000 May 2020 ADR warrants 32,550 $ 41.00 $ 4.00 162,750

Share capital and reserves (Tab

Share capital and reserves (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of detailed information about share capital	Schedule of detailed information about share capital Authorised, allotted and As at 30 June Number As at 30 June £ As at 31 Number As at 31 £ Ordinary shares of 277,971,722 277,972 5,417,137 108,343 ‘A’ Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 ‘B’ Deferred shares of £0.001 4,063,321,418 4,063,321 – – Total 5,341,294 1,108,344	Schedule of detailed information about share capital Authorised, allotted and fully 2022 Number 2022 £ 2021 Number 2021 £ 2020 Number 2020 £ At 31 December Ordinary shares of 5,417,137 108,343 4,923,420 98,468 3,153,694 63,074 Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 Total 1,108,344 1,098,469 1,063,075
Schedule Of Ordinary and Deferred Shares	Schedule Of Ordinary and Deferred Shares 2023 Ordinary Number ‘A’ Number ‘B’ Deferred Share £ Total £’000 At 1 January 2023 5,417,137 1,000,001 - 15 February 2023 Private Placements 3,250,200 - - 0.0505 164 26 May 2023 Registered Direct Offering 110,679,610 - - 0.0097 1,076 April – June 2023 Exercise February 2023 pre-funded warrants 62,184,525 - - 0.0505 3,139 March 2023 Exercise Series ‘A’ warrants 12,931,020 - - 0.0505 653 March 2023 Exercise Series ‘B’ warrants 19,396,530 - - 0.0505 979 15 June 2023 Exercise Investor warrants 625,000 - - 0.0505 32 14 June 2023 Share sub-division and re-designation - - 4,063,321,418 n/a n/a 30 June 2023 Exercise ‘C’ warrants 63,487,700 - - 0.0097 617 At 30 June 2023 (unaudited) 277,971,722 1,000,001 4,063,321,418 2022 At 1 January 2022 4,923,420 1,000,001 - 22 March 2022 Exercise of warrants 1 - - 200.000 - 3 May 2022 Share issue to SIPP trustee* 1,250 - - 0.001 - 19 December 2022 Registered Direct Offering 492,466 - - 0.6660 321 At 31 December 2022 5,417,137 1,000,001 - *Share issued to Biodexa Pharmaceuticals PLC employee benefit trust	Schedule Of Ordinary and Deferred Shares Ordinary Number Deferred Number Share £ Total £’000 At 1 January 2020 1,174,752 1,000,001 2020 18 May 2020 Placing & Registered Direct Offering 787,878 5.4000 4,255 27 July 2020 Placing 1,064,814 5.4000 5,750 19 August 2020 Exercise of warrants 125,000 6.2642 783 30 September 2020 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – At 31 December 2020 3,153,694 1,000,001 19 February 2021 Exercise of warrants 15,340 5.9600 91 6 July 2021 Placing 1,754,386 5.7000 10,000 At 31 December 2021 4,923,420 1,000,001 22 March 2022 Exercise of warrants 1 200.0000 – 3 May 2022 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – 19? December 2022 Registered Direct Offering 492,466 0.6660 321 At 31 December 2022 5,417,137 1,000,001

Accounting policies (Tables)

Accounting policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of entities	Schedule of entities Entity Summary description Biodexa Pharmaceuticals plc Ultimate holding company Midatech Limited Trading company Midatech Pharma (Espana) SL (formerly Midatech Biogune SL) Liquidated - 2021 PharMida AG Dormant Midatech Pharma (Wales) Limited (formerly Q Chip Limited) Trading company Midatech Pharma Pty Dissolved - 2020 Biodexa Limited (formerly Bioadexa Pharmaceuticals Limited) Dormant – incorporated October 2022
Schedule of intangibles assets useful economic lives	Schedule of intangibles assets useful economic lives Goodwill – Indefinite life IPRD – In process, not yet amortising IT and website costs – 4 years
Schedule of depreciation rates of property, plant and equipment	Schedule of depreciation rates of property, plant and equipment Fixtures and fittings – 20%- 25% per annum straight line Leasehold improvements – the shorter of 10% per annum straight line or over the lease term Computer equipment – 25% per annum straight line Laboratory equipment – 15% – 25% per annum straight line Right of use asset – Economic life of contractual relationship

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of revenue by geographical analysis	Schedule of revenue by geographical analysis 2022 £’000 2021 £’000 2020 £’000 Revenue: United Kingdom – – 4 Belgium 699 578 114 Rest of the World – – 62 699 578 180
Schedule of performance obligations	Schedule of performance obligations Contractual Assets Contractual Liabilities 2022 £’000 2021 £’000 2020 £’000 2022 £’000 2021 £’000 2020 £’000 At 1 January – 71 – – (68 ) – Transfers in the period from contract assets to trade receivables – (71 ) – – – – Amounts included in contract liabilities that was recognised as revenue during the period – – – – (68 ) – Excess of revenue recognised over cash – – 71 – – – Cash received in advance of performance and not recognised as revenue during the period – – – (197 ) – (68 ) At 31 December – – 71 (197 ) – (68 )
Schedule of commercial segment	Schedule of commercial segment 2022 £’000 2021 £’000 2020 £’000 Customer A 100 % 100 % 64 % Customer B – – 34 % Customer C – – 2 %

Loss from operations (Tables)

Loss from operations (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of loss from operations	Schedule of loss from operations Note 2022 £’000 2021 £’000 2020 £’000 Loss from operations is stated after charging/(crediting): Depreciation of property, plant and equipment - Research and development costs 9 162 198 1,064 - Administrative costs 9 12 15 25 Depreciation of right of use asset - Research and development costs 9 151 165 110 - Administrative costs 9 15 25 8 Amortisation of intangible assets – software - Research and development costs 11 3 – 8 - Administrative costs 11 – – 2 Impairment of intangible assets 11 – – 12,369 Impairment of financial asset 14 207 – – Provision against future loss on loan agreement 18 207 – – Fees payable to the Company’s auditor for the audit of the parent Company financial statements 106 88 87 Fees payable to the Company’s auditors for the audits of the subsidiary financial statements 44 44 43 Fees payable to the Company’s auditor for: – Audit related services 70 – 7 Fees payable to the Company’s previous auditor for the audit of the parent Company financial statements – – 15 Fees payable to the Company’s previous auditor for: - Audit related services 67 41 171 Foreign exchange loss 9 12 96 Profit/(Loss) 14 (42 ) (226 ) Equity settled share-based payment* 123 89 (404 )

Staff costs (Tables)

Staff costs (Tables)	12 Months Ended
	Dec. 31, 2022
Staff Costs
Schedule of staff costs	Schedule of staff costs 2022 £’000 2021 £’000 2020 £’000 Wages and salaries 2,033 1,354 2,727 Defined contribution pension cost (note 24) 98 71 75 Social security contributions and similar taxes 269 152 397 Share-based payment charge/(credit) 123 89 (404 ) Staff costs gross 2,523 1,666 2,795
Schedule for average number of employed staff	Schedule for average number of employed staff 2022 2021 2020 Research and development 22 15 31 General and administration 5 5 9 27 20 40
Schedule of Management Personnel Compensation	Schedule of Management Personnel Compensation 2022 £’000 2021 £’000 2020 £’000 Short term employee benefits 668 658 472 Post-employment benefits 21 27 24 Termination benefits – – 30 Share-based payment 53 61 (472 ) Total 742 746 54

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of detailed information about property, plant and equipment	Schedule of detailed information about property, plant and equipment Fixtures and fittings £’000 Leasehold improvements £’000 Computer equipment £’000 Laboratory equipment £’000 Right of use asset £’000 Total £’000 Cost At 1 January 2020 248 2,038 403 3,738 1,124 7,551 Additions – 58 16 135 – 209 Effect of modification to lease terms – – – – (678 ) (678 ) Disposal (202 ) (2,184 ) (185 ) (2,323 ) (316 ) (5,210 ) Exchange differences 7 92 2 112 58 271 At 31 December 2020 53 4 236 1,662 188 2,143 Additions 57 53 16 194 720 1,040 Transfer – – – (155 ) 155 – Effect of modification to lease terms – – – – (24 ) (24 ) Disposal (50 ) (4 ) (10 ) (138 ) (164 ) (366 ) At 31 December 2021 60 53 242 1,563 875 2,793 Additions 3 – 14 45 – 62 Transfer to intangibles – – (122 ) – – (122 ) Disposal – – (46 ) (174 ) (51 ) (271 ) At 31 December 2022 63 53 88 1,434 824 2,462 Fixtures and fittings £’000 Leasehold improvements £’000 Computer equipment £’000 Laboratory equipment £’000 Right of use asset £’000 Total £’000 Accumulated depreciation At 1 January 2020 235 1,794 332 2,740 296 5,397 Charge for the year 9 310 50 720 118 1,207 Disposal (202 ) (2,183 ) (185 ) (2,300 ) (316 ) (5,186 ) Exchange differences 7 81 2 79 14 183 At 31 December 2020 49 2 199 1,239 112 1,601 Transfer – – – (74 ) 74 – Charge for the year 8 5 22 178 190 403 Disposal (50 ) (3 ) (8 ) (138 ) (164 ) (363 ) At 31 December 2021 7 4 213 1,205 212 1,641 Transfer to intangibles – – (113 ) – – (113 ) Charge for the year 12 11 12 139 166 340 Disposal – – (41 ) (155 ) (41 ) (237 ) At 31 December 2022 19 15 71 1,189 337 1,631 Net book value At 31 December 2022 44 38 17 245 487 831 At 31 December 2021 53 49 29 358 663 1,152 At 31 December 2020 4 2 37 423 76 542

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of market rental rates	Schedule of market rental rates Lease Liabilities 2022 £’000 2021 £’000 2020 £’000 At 1 January 766 76 907 Additions – 720 – Transfer – 77 – Effect of modification to lease terms – (24 ) (788 ) Interest expenses 36 29 15 Lease payments (178 ) (112 ) (105 ) Exchange differences – – 47 At 31 December 624 766 76
Low value leases expensed in year	Low value leases expensed in year 2022 £’000 2021 £’000 2020 £’000 Low value leases expensed 3 2 10 3 2 10

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of reconciliation of changes in intangible assets and goodwill	Schedule of reconciliation of changes in intangible assets and goodwill In-process £’000 Goodwill £’000 IT/Website £’000 Total £’000 Cost At 1 January 2020 13,378 2,291 35 15,704 Disposal – – (36 ) (36 ) Foreign exchange – – 1 1 At 31 December 2020 13,378 2,291 – 15,669 At 31 December 2021 13,378 2,291 – 15,669 Transfer from property, plant and equipment – – 122 122 Disposal – – (12 ) (12 ) At 31 December 2022 13,378 2,291 110 15,779 In-process research and development £’000 Goodwill £’000 IT/Website Costs £’000 Total £’000 Accumulated amortisation and impairment At 1 January 2020 3,300 – 25 3,325 Amortisation charge for the year – – 10 10 Disposal – – (36 ) (36 ) Impairment 10,078 2,291 – 12,369 Foreign exchange – – 1 1 At 31 December 2020 13,378 2,291 – 15,669 At 31 December 2021 13,378 2,291 – 15,669 Amortisation charge for the year – – 3 3 Transfer from property, plant and equipment – – 113 113 Disposal – – (12 ) (12 ) At 31 December 2022 13,378 2,291 104 15,773 Net book value At 31 December 2022 – – 6 6 At 31 December 2021 – – – – At 31 December 2020 – – – –

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of subsidiaries	Schedule of subsidiaries Name Registered Office Nature of Business Notes Midatech Limited 1 Caspian Point, Caspian Way, Cardiff, Trading company PharMida AG c/o Kellerhals, Hirschgässlein 11, 4051 Basel, Switzerland Dormant (a) (b) Midatech Pharma (Wales) Limited 1 Caspian Point, Caspian Way, Cardiff, Trading company Biodexa Limited (formerly Biodexa Pharmaceuticals Limited) 1 Caspian Point, Caspian Way, Cardiff, Dormant

Trade and other receivables (Ta

Trade and other receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of trade and other receivables	Schedule of trade and other receivables 2022 £’000 2021 £’000 2020 £’000 Trade receivables 329 33 95 Prepayments 376 607 258 Other receivables 301 394 219 Total trade and other receivables 1,006 1,034 572 Less: non-current portion – – – Current portion 1,006 1,034 572

Cash and cash equivalents and_2

Cash and cash equivalents and cash flow supporting notes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of cash and cash equivalents	Schedule of cash and cash equivalents 2022 £’000 2021 £’000 2020 £’000 Cash at bank available on demand 2,836 10,057 7,546
Schedule of cash inflows from an equity financing transaction	Schedule of cash inflows from an equity financing transaction 2022 £’000 2021 £’000 2020 £’000 Gross proceeds 321 10,091 10,792 Transaction costs (78 ) (1,056 ) (1,050 ) Proceeds from issuing shares 243 9,035 9,742
Schedule of changes in bank loan liabilities	Schedule of changes in bank loan liabilities Non-current £’000 Current £’000 Total £’000 At 1 January 2022 620 699 1,319 Cash flows – (178 ) (178 ) Non-cashflows: – – – Loans and borrowings classified as non-current 31 December 2021 becoming current in 2022 (178 ) 178 – Gain/(loss) in finance income within the consolidated statement of comprehensive income – (468 ) (468 ) Interest accruing in period 21 15 36 At 31 December 2022 463 246 709 Non-current £’000 Current £’000 Total £’000 At 1 January 2021 60 1,759 1,819 Cash flows – (215 ) (215 ) Non-cashflows: Foreign Exchange – (4 ) (4 ) New leases 715 5 720 Effect of modification to lease term – IFRS 16 – (24 ) (24 ) Loans and borrowings classified as non-current 31 December 2020 becoming current in 2021 (178 ) 178 – Transfer to share premium on exercise of warrants – (70 ) (70 ) Gain/(loss) recognised in finance income within the consolidated statement of comprehensive income – (936 ) (936 ) Interest accruing in period 23 6 29 At 31 December 2021 620 699 1,319 Non-current £’000 Current £’000 Total £’000 At 1 January 2020 5,670 1,076 6,746 Cash flows (6,182 ) (258 ) (6,440 ) Non-cashflows: Foreign Exchange 252 23 275 Fair value changes 1,176 – 1,176 Effect of modification to lease term – IFRS 16 (877 ) 89 (788 ) Reclassification portion government loan to non-current 51 (51 ) – Warrants issued – 997 997 Transfer to share premium on exercise of warrants – (499 ) (499 ) Gain/(loss) recognised in finance income within the consolidated statement of comprehensive income – 397 397 Interest accruing in period (30 ) (15 ) (45 ) At 31 December 2020 60 1,759 1,819

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of trade and other payables	Schedule of trade and other payables Current 2022 £’000 2021 £’000 2020 £’000 Trade payables 339 485 337 Other payables 17 5 26 Accruals 817 546 768 Total financial liabilities, excluding loans and borrowings, 1,173 1,036 1,131 Tax and social security 77 56 31 Deferred revenue 197 – 68 Total trade and other payables 1,447 1,092 1,230

Provisions (Tables)

Provisions (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure Provisions Abstract
Schedule of provisions	Schedule of provisions As at 30 £’000 As at 31 £’000 Opening provision at 1 January 207 50 Utilisation of provision (207 ) (43 ) Provision recognised during the period - 200 - 207	Schedule of provisions 2022 £’000 2021 £’000 2020 £’000 Opening provision at 1 January 50 50 97 Utilisation of provision (43 ) – (97 ) Provision recognised in the year 200 – 50 At 31 December 207 50 50 Less: non-current portion – – (50 ) Current portion 207 50 –

Financial instruments _ risk _2

Financial instruments – risk management (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of consolidated derivative financial instruments		Schedule of consolidated derivative financial instruments 2022 £’000 2021 £’000 2020 £’000 Cash and cash equivalents 2,836 10,057 7,546 Trade receivables 329 33 95 Other receivables – – – Total financial assets 3,165 10,090 7,641 Financial liabilities – amortised cost 2022 £’000 2021 £’000 2020 £’000 Trade payables 339 485 337 Other payables 17 5 26 Accruals 817 546 768 Borrowings 624 766 260 Total financial liabilities – amortised cost 1,797 1,802 1,391 Financial liabilities – fair value through profit and loss – current 2022 £’000 2021 £’000 2020 £’000 Equity settled derivative financial liability 85 553 1,559
Schedule of consolidated financial assets and liabilities at fair value	Schedule of consolidated financial assets and liabilities at fair value Financial Fair value as at 30 June 2023 Fair value as 2022 Fair value Valuation Significant unobservable input(s) Relationship of Equity settled financial derivative liability – June 2023 £ 364,000 - Level 3 2023 - Black-Scholes Model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life of 4.98 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.13% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability – May 2020 Warrants – £48,000 Level 3 2023 – Black- Scholes Model 2022 - Monte Carlo simulation model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.38 years determined using the remaining life of the share options The shorter the expected life the lower the fair value. Risk-free rate of 4.68% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability – October 2019 Warrants – £37,000 Level 3 2023 – Black- Scholes Model 2022 - Monte Carlo simulation model Volatility rate of 90% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.00 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.87% determined using the expected life assumptions. The higher the risk-free rate Total £364,000 £85,000 Changing the unobservable risk-free rate input to the valuation model by 10% higher while all other variables were held constant, would not impact the carrying amount of shares (2022: nil). There were no transfers between Level 1 and 2 in the period. The financial liability measured at fair value on Level 3 fair value measurement represents consideration relating to warrants issued in June 2023, May 2020 and October 2019 as part of Private Placements and Registered Direct offerings.	Schedule of consolidated financial assets and liabilities at fair value Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 48,000 Level 3 Monte Carlo simulation model Volatility rate of 70.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.88 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.22% determined using the expected life assumptions. The higher the risk-free rate Equity settled financial derivative liability £ 37,000 Level 3 Monte Carlo simulation model Volatility rate of 70.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 2.5 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 4.32% determined using the expected life assumptions. The higher the risk-free rate Total £ 85,000 Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 467,000 Level 3 Monte Carlo simulation model Volatility rate of 95.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 3.88 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.31% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability £ 86,000 Level 3 Monte Carlo simulation model Volatility rate of 85.0% determined using historical volatility of comparable companies The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 3.5 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.71% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability – Level 3 Black-Scholes option pricing model Volatility rate of 85.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.10 and 0.9 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.71% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Total £ 553,000 Financial Fair value Fair Valuation Significant unobservable Relationship of Equity settled financial derivative liability £ 1,187,000 Level 3 Monte Carlo simulation model Volatility rate of 105.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 4.49 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.07% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability £ 372,000 Level 3 Monte Carlo simulation model Volatility rate of 105.0% determined using historical volatility of comparable companies The higher the volatility the higher the fair value. Expected life between a range of 0.1 and 4.888 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.08% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Equity settled financial derivative liability – Level 3 Black-Scholes option pricing model Volatility rate of 105.0% determined using historical volatility of comparable companies. The higher the volatility the higher the fair value. Expected life between a range of 1.0 and 1.9 years determined using the remaining life of the share options. The shorter the expected life the lower the fair value. Risk-free rate of 0.8% determined using the expected life assumptions. The higher the risk-free rate the higher the fair value. Total £ 1,559,000
Schedule of foreign exchange risk		Schedule of foreign exchange risk 2022 £’000 2021 £’000 2020 £’000 Cash and cash equivalents: Pounds Sterling 2,588 10,057 7,247 US Dollar 248 – 120 Euro – – 179 Total 2,836 10,057 7,546 The table below shows the foreign currency exposure that gives rise to net currency gains and losses recognised in the consolidated statement of comprehensive income. As at 31 December, these exposures were as follows: 2022 £’000 2021 £’000 2020 £’000 Net Foreign Currency Assets/(Liabilities): US Dollar 248 – 120 Euro 17 22 54 Other – – 1 Total 265 22 175
Schedule of foreign currency exchange rates		Schedule of foreign currency exchange rates Year ended 31 December 2022 US Dollar £’000 Euro £’000 Other £’000 Loss before tax 25 (1 ) – Total equity 25 (1 ) – Year ended 31 December 2021 US Dollar £’000 Euro £’000 Other £’000 Loss before tax – 2 – Total equity – 2 – Year ended 31 December 2020 US Dollar £’000 Euro £’000 Other £’000 Loss before tax 12 (293 ) (4 ) Total equity 12 (293 ) (4 )
Schedule of contractual maturities of financial liabilities		Schedule of contractual maturities of financial liabilities 2022 Up to 3 £’000 Between 3 and 12 months £’000 Between years £’000 Between £’000 Over £’000 Trade and other payables 1,173 – – – – Lease liabilities 49 140 188 254 – Total 1,222 140 188 254 – 2021 Up to 3 £’000 Between 3 and 12 months £’000 Between years £’000 Between £’000 Over £’000 Trade and other payables 1,036 – – – – Lease liabilities 46 171 195 442 – Total 1,082 171 195 442 – 2020 Up to 3 £’000 Between 3 and 12 months £’000 Between years £’000 Between £’000 Over £’000 Trade and other payables 1,131 – – – – Lease liabilities 25 75 61 8 – Government research loans 107 – – – – Total 1,263 75 61 8 –

Deferred tax (Tables)

Deferred tax (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of unused tax losses carried forward	Schedule of unused tax losses carried forward Gross losses £’000 Potential £’000 31 December 2022 71,139 17,867 31 December 2021 67,210 16,925 31 December 2020 63,183 13,076

Share capital (Tables)

Share capital (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of detailed information about share capital	Schedule of detailed information about share capital Authorised, allotted and As at 30 June Number As at 30 June £ As at 31 Number As at 31 £ Ordinary shares of 277,971,722 277,972 5,417,137 108,343 ‘A’ Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 ‘B’ Deferred shares of £0.001 4,063,321,418 4,063,321 – – Total 5,341,294 1,108,344	Schedule of detailed information about share capital Authorised, allotted and fully 2022 Number 2022 £ 2021 Number 2021 £ 2020 Number 2020 £ At 31 December Ordinary shares of 5,417,137 108,343 4,923,420 98,468 3,153,694 63,074 Deferred shares of £1 each 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 1,000,001 Total 1,108,344 1,098,469 1,063,075
Schedule Of Ordinary and Deferred Shares	Schedule Of Ordinary and Deferred Shares 2023 Ordinary Number ‘A’ Number ‘B’ Deferred Share £ Total £’000 At 1 January 2023 5,417,137 1,000,001 - 15 February 2023 Private Placements 3,250,200 - - 0.0505 164 26 May 2023 Registered Direct Offering 110,679,610 - - 0.0097 1,076 April – June 2023 Exercise February 2023 pre-funded warrants 62,184,525 - - 0.0505 3,139 March 2023 Exercise Series ‘A’ warrants 12,931,020 - - 0.0505 653 March 2023 Exercise Series ‘B’ warrants 19,396,530 - - 0.0505 979 15 June 2023 Exercise Investor warrants 625,000 - - 0.0505 32 14 June 2023 Share sub-division and re-designation - - 4,063,321,418 n/a n/a 30 June 2023 Exercise ‘C’ warrants 63,487,700 - - 0.0097 617 At 30 June 2023 (unaudited) 277,971,722 1,000,001 4,063,321,418 2022 At 1 January 2022 4,923,420 1,000,001 - 22 March 2022 Exercise of warrants 1 - - 200.000 - 3 May 2022 Share issue to SIPP trustee* 1,250 - - 0.001 - 19 December 2022 Registered Direct Offering 492,466 - - 0.6660 321 At 31 December 2022 5,417,137 1,000,001 - *Share issued to Biodexa Pharmaceuticals PLC employee benefit trust	Schedule Of Ordinary and Deferred Shares Ordinary Number Deferred Number Share £ Total £’000 At 1 January 2020 1,174,752 1,000,001 2020 18 May 2020 Placing & Registered Direct Offering 787,878 5.4000 4,255 27 July 2020 Placing 1,064,814 5.4000 5,750 19 August 2020 Exercise of warrants 125,000 6.2642 783 30 September 2020 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – At 31 December 2020 3,153,694 1,000,001 19 February 2021 Exercise of warrants 15,340 5.9600 91 6 July 2021 Placing 1,754,386 5.7000 10,000 At 31 December 2021 4,923,420 1,000,001 22 March 2022 Exercise of warrants 1 200.0000 – 3 May 2022 Share issue to SIPP trustee (see note 25) 1,250 0.0200 – 19? December 2022 Registered Direct Offering 492,466 0.6660 321 At 31 December 2022 5,417,137 1,000,001

Reserves (Tables)

Reserves (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of reserves	Schedule of reserves Reserve Description and purpose Share capital Nominal value of subscribed share capital Share premium Amount subscribed for share capital in excess of nominal value. Merger reserve Represents the difference between the fair value and nominal value of shares issued on the acquisition of subsidiary companies where the Company has elected to take advantage of merger accounting. Foreign exchange reserve Gains/losses arising on retranslating the net assets of overseas operations into sterling. Warrant reserve Represents the fair value of warrants denominated in £ at the date of grant. The number and price is fixed at the date of grant. The warrants expire in November 2025. Accumulated deficit All other net gains and losses and transactions with owners (e.g. dividends) not recognised elsewhere.

Share-based payments (Tables)

Share-based payments (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Details of all share options granted under the Schemes are set out below:	Details of all share options granted under the Schemes are set out below: Date of grant At 1 January Granted in Lapsed in Forfeited in At 31 December Exercise Price 20 April 2012 79 – (79 ) – – £ 1,676.00 9 May 2014 500 – (500 ) – – £ 30.00 30 June 2014 25 – – – 25 £ 30.00 31 October 2016 352 – (352 ) – – £ 1,072.00 19 December 2016 396 – (383 ) – 13 £ 484.00 15 December 2017 59 – – (19 ) 40 £ 184.00 24 April 2019 625 – – (313 ) 312 £ 29.20 2 October 2019 1,500 – – – 1,500 £ 21.00 17 April 2020 5,000 – – – 5,000 £ 4.80 17 June 2020 43,175 – (5,625 ) (3,950 ) 33,600 £ 4.04 15 July 2021 71,450 – – (7,100 ) 64,350 £ 5.55 2 August 2021 2,500 – – – 2,500 £ 5.30 1 September 2021 6,000 – – – 6,000 £ 5.10 7 February 2022 – 18,750 – – 18,750 £ 3.05 12 August 2022 – 12,500 – – 12,500 £ 2.10 131,661 31,250 (6,939 ) (11,382 ) 144,590 Options exercisable at 31 December 2022 55,932 Weighted average exercise price of outstanding options at 31 December 2022 £ 4.836 Weighted average exercise price of options exercised in 2022 n/a Weighted average exercise price of options lapsed in 2022 £ 105.612 Weighted average exercise price of options forfeited in 2022 £ 5.974 Weighted average exercise price of options granted in 2022 £ 2.670 Weighted average remaining contractual life of outstanding options at 31 December 2022 8.1 Date of grant At 1 January Granted in Lapsed in Forfeited in At 31 December Exercise Price 13 September 2011 8 – (8 ) – – £ 1,676.00 20 April 2012 79 – – – 79 £ 1,676.00 9 May 2014 500 – – – 500 £ 30.00 30 June 2014 25 – – – 25 £ 30.00 31 October 2016 397 – – (45 ) 352 £ 1,072.00 19 December 2016 499 – – (103 ) 396 £ 484.00 15 December 2017 164 – – (105 ) 59 £ 184.00 24 April 2019 2,275 – – (1,650 ) 625 £ 29.20 2 October 2019 1,500 – – – 1,500 £ 21.00 17 April 2020 5,000 – – – 5,000 £ 4.80 17 June 2020 63,700 – – (20,525 ) 43,175 £ 4.04 15 July 2021 – 85,450 – (14,000 ) 71,450 £ 5.55 2 August 2021 – 2,500 – – 2,500 £ 5.30 1 September 2021 – 6,000 – – 6,000 £ 5.10 74,147 93,950 (8 ) (36,428 ) 131,661 Options exercisable at 31 December 2021 8,982 Weighted average exercise price of outstanding options at 31 December 2021 £ 10.759 Weighted average exercise price of options exercised in 2021 n/a Weighted average exercise price of options lapsed in 2021 £ 1,676.000 Weighted average exercise price of options forfeited in 2021 £ 8.955 Weighted average exercise price of options granted in 2021 £ 5.515 Weighted average remaining contractual life of outstanding options at 31 December 2021 9.0 Date of grant At 1 January Granted in Lapsed in Forfeited in At 31 December Exercise Price 1 April 2010 63 – (63 ) – – £ 1,600.00 20 August 2010 104 – (104 ) – – £ 1,676.00 13 September 2011 8 – – – 8 £ 1,676.00 20 April 2012 79 – – – 79 £ 1,676.00 9 May 2014 500 – – – 500 £ 30.00 30 June 2014 925 – – (9,000 ) 25 £ 30.00 11 July 2014 6 – (3 ) (3 ) – £ 30.00 31 October 2016 815 – (43 ) (375 ) 397 £ 1,072.00 14 December 2016 20 – (20 ) – – £ 620.00 14 December 2016 25 – (25 ) – – £ 680.00 14 December 2016 100 – (100 ) – – £ 748.00 14 December 2016 81 – (81 ) – – £ 752.00 15 December 2016 230 – (230 ) – – £ 484.00 19 December 2016 1,118 – (78 ) (541 ) 499 £ 484.00 15 December 2017 1,478 – (666 ) (648 ) 164 £ 184.00 2 April 2018 50 – (50 ) – – £ 332.00 2 April 2018 225 – (225 ) – – £ 484.00 24 April 2019 8,475 – – (6,200 ) 2,275 £ 29.20 2 October 2019 2,500 – – (1,000 ) 1,500 £ 21.00 17 April 2020 – 5,000 – – 5,000 £ 4.80 17 June 2020 – 68,150 – (4,450 ) 63,700 £ 4.04 16,802 73,150 (1,688 ) (14,117 ) 74,147 Options exercisable at 31 December 2020 9,759 Weighted average exercise price of outstanding options at 31 December 2020 £ 16.698 Weighted average exercise price of options exercised in 2020 n/a Weighted average exercise price of options lapsed in 2020 £ 523.411 Weighted average exercise price of options forfeited in 2020 £ 72.975 Weighted average exercise price of options granted in 2020 £ 4.092 Weighted average remaining contractual life of outstanding options at 31 December 2020 9.2
Schedule of fair value of options granted	Schedule of fair value of options granted February 2022 August 2022 August 2022 Number of options 18,750 5,000 7,500 Option pricing models used Black-Scholes Black-Scholes Black-Scholes Share price £ 3.05 £ 2.10 £ 2.10 Exercise price of options issued in year £ 3.05 £ 2.10 £ 2.10 Contractual life 10 10 10 Expected life 5 5 5 Volatility 87.88 %** 91.78 %** 91.66 %** Expected dividend yield 0 % 0 % 0 % Risk free rate 1.28 % 1.92 % 1.92 % The share price used in the determination of the fair value of the options granted in 2022 was the share price on the date of grant. ** Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period. The following information is relevant in the determination of the fair value of options granted during the year 2021 under the equity share based remuneration schemes operated by the Group. July 2021 August 2021 September 2021 Number of options 85,450 2,500 6,000 Option pricing models used Black-Scholes Black-Scholes Black-Scholes Share price £ 5.55 * £ 5.30 * £ 5.10 * Exercise price of options issued in year £ 5.55 £ 5.30 £ 5.10 Contractual life 10 10 10 Expected life 5 5 5 Volatility 88.63 %** 88.59 %** 88.11 %** Expected dividend yield 0 % 0 % 0 % Risk free rate 0.38 % 0.26 % 0.32 % * The share price used in the determination of the fair value of the options granted in 2021 was the share price on the date of grant. ** Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period. The following information is relevant in the determination of the fair value of options granted during the year 2020 under the equity share based remuneration schemes operated by the Group. April 2020 June 2020 Number of options 5,000 68,150 Option pricing models used Black-Scholes Black-Scholes Share price £ 4.80 * £ 4.04 * Exercise price of options issued in year £ 4.80 £ 4.04 Contractual life 10 10 Expected life 5 5 Volatility 84.76 %** 92.55 %** Expected dividend yield 0 % 0 % Risk free rate 0.11 % 0.10 % * The share price used in the determination of the fair value of the options granted in 2020 was the share price on the date of grant. ** Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period.

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Notes and other explanatory information [abstract]
Schedule of related party transactions	Schedule of related party transactions Purchase of good Amounts owed by related parties 2022 €’000 2021 €’000 2020 €’000 2022 €’000 2021 €£’000 2020 €’000 BioConnection BV – – 296 – – –

Results of Midatech Pharma (E_2

Results of Midatech Pharma (Espa?a) SL (Tables)	12 Months Ended
	Dec. 31, 2022
Results Of Midatech Pharma Espaa Sl
Schedule Of Unaudited Results Explanatory	Schedule Of Unaudited Results Explanatory Year ended 31 £’000 Grant revenue 163 Total revenue 163 Research and development costs (2,820 ) Administrative costs (1,146 ) Loss from operations (3,803 ) Finance expense (11 ) Loss before tax (3,814 ) Taxation (21 ) Loss from operations after tax (3,835 )

Post Balance Sheet Events (Tabl

Post Balance Sheet Events (Tables)	12 Months Ended
	Dec. 31, 2022
Post Balance Sheet Events
Schedule of share consolidation	Schedule of share consolidation Pre-Split Post-Split Weighted average number of shares outstanding - basic and diluted 98,835,849 4,941,793 Ordinary shares outstanding 108,342,738 5,417,137 Outstanding employee share options over ordinary shares 2,891,875 144,590 Outstanding DARA options over ordinary shares 2,822 138 Outstanding warrants over ordinary shares 17,221,973 861,075

Basis of preparation (Details N

Basis of preparation (Details Narrative) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Basis Of Preparation
Loss from operations	£ 3,570	£ 3,060	£ 7,700
Negative cash flows from operating activities	3,880	£ 3,540	7,000
Accumulated deficit	138,970		135,300
Cash and cash equivalents	£ 5,230		£ 2,800

Finance income and expense (Det

Finance income and expense (Details) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finance income
Interest received on bank deposits	£ 24	£ 6	£ 29		£ 1
Gain on equity settled derivative financial liability	386	398	468	936
Total finance income	410	404	497	936	1
Finance expense
Interest expense on lease liabilities	15	24	43	36	20
Other loans	7		10	8	14
Loss on equity settled derivative financial liability					397
Total finance expense	£ 22	£ 24	£ 53	£ 44	£ 431

Taxation (Details)

Taxation (Details) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes and other explanatory information [abstract]
Total tax credit	£ 288	£ 337	£ 832	£ 646	£ 1,281
Current tax credit
Current tax credited to the income statement			825	646	1,144
Taxation payable in respect of foreign subsidiary					(21)
Adjustment in respect of prior year			7		158
Current tax credit			832	646	1,281
Deferred tax credit
Reversal of temporary differences

Loss per share (Details)

Loss per share (Details) - GBP (£) £ / shares in Units, £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator
Loss used in basic EPS and diluted EPS:	£ (3,568)	£ (3,061)	£ (7,656)	£ (5,460)	£ (22,189)
Denominator
Weighted average number of ordinary shares used in basic EPS:	99,191,082	4,923,828	4,941,793	4,027,345	2,142,000
Basic and diluted loss per share:	£ (4)	£ (62)	£ (1.55)	£ (1.36)	£ (10.36)
Loss used in basic EPS and diluted EPS:
Continuing operations			£ (7,656)	£ (5,460)	£ (22,189)
Basic and diluted loss per share:
Continuing operations – £			£ (1.55)	£ (1.36)	£ (10.36)

Borrowings (Details)

Borrowings (Details) - GBP (£) £ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Current borriwings	£ 164	£ 161	£ 146	£ 200
Non current borriwings	380	463	620	60
Finance Lease [Member]
IfrsStatementLineItems [Line Items]
Current borriwings		161	146	93
Non current borriwings		463	620	60
Government and Research Loans [Member]
IfrsStatementLineItems [Line Items]
Current borriwings				£ 107
Lease liabilities [member]
IfrsStatementLineItems [Line Items]
Current borriwings	164	161
Non current borriwings	£ 380	£ 463

Loss per share (Details Narrati

Loss per share (Details Narrative) - £ / shares			1 Months Ended		6 Months Ended	12 Months Ended
	Jun. 14, 2023	Mar. 14, 2023	May 26, 2023	Mar. 24, 2023	Jun. 30, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Ordinary Shares, issued price	£ 0.02	£ 0.02
Private placemnet descriiption					company completed a private placement for the sale of (i)8,125 ADSs (3,250,200 Ordinary Shares), (ii) 32,327 ADSs (12,931,020 Ordinary Shares) issuable upon the exercise of Series A warrants, (iii) 48,491 ADSs (19,396,530 Ordinary Shares) issuable upon the exercise of Series B warrants, and (iv) 155,461 ADSs (62,184,525 Ordinary Shares) issuable upon the exercise of pre-funded warrants, subject to certain reset provisions set forth in the Pre-Funded Warrants, at an initial purchase price of $185.60 per ADS, for aggregate gross proceeds of approximately $6.0 million.
Direct Offering description			company completed a Registered Direct Offering for the sale of (i) 276,699 ADSs (110,679,610 Ordinary Shares), (ii) 415,043 ADSs (166,017,300 Ordinary Shares) issuable upon the exercise of Series C warrants, and (iii) 276,689 ADSs (110,675,600 Ordinary Shares) issuable upon the exercise of Series C warrants, at an initial price per ADS of $12.00, for aggregate gross proceeds of $3.32 million. The issuance of the Series C warrants and Series D warrants issuable was subject to shareholder approval at a general meeting on 14 June 2023.
Description of stock split						Ordinary Shares on a one for 20 basis. As a result the par value of the Ordinary Shares was changed from £0.001 per share to £0.02 per share. The denominator has been calculated to reflect the share consolidation.
Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Warrant issue				1,562
Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Warrant issue				625,000

Provision (Details)

Provision (Details) - GBP (£) £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Provision
Provisions at beginning	£ 207	£ 50
Utilisation of provision	(207)	(43)		£ (97)
Provision released during the period		200
Provisions at ending		£ 207	£ 50

Provision (Details Narrative)

Provision (Details Narrative) - Bioasis [Member] - GBP (£) £ in Thousands		1 Months Ended
	Jan. 03, 2023	Dec. 31, 2022	Dec. 19, 2022
IfrsStatementLineItems [Line Items]
Advance to related party	£ 250	£ 250	£ 750
Impairment of provision		207
Provision of promissory note		£ 207

Derivative financial liabilit_3

Derivative financial liability - current (Details) - GBP (£) £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Financial Liability Current
Balance at beginning	£ 85	£ 553	£ 1,559	£ 664
Warrants issued	665			997
Gain recognised in finance income within the consolidated statement of comprehensive income	(386)	(468)	(936)	397
Balance at ending	£ 364	85	553	1,559
Transfer to share premium on exercise of warrants			£ (70)	£ (499)

Derivative financial liabilit_4

Derivative financial liability - current (Details 1) - GBP (£)		6 Months Ended		12 Months Ended
		Jun. 30, 2023		Dec. 31, 2022
Warrants [member]
IfrsStatementLineItems [Line Items]
ADS Warrants Number		375
Original price per ads	[1]	£ 10,000
New price per ADS		£ 320
Equivalent Ordinary Shares Number		150,000
Warrant One [Member]
IfrsStatementLineItems [Line Items]
ADS Warrants Number		406
Original price per ads		£ 3,280	[1]	£ 125
New price per ADS		£ 320
Equivalent Ordinary Shares Number		162,400
Adr warrants number				30,000
New price per adr				£ 4
Equivalent ordinary shares				150,000
Warrant Two [Member]
IfrsStatementLineItems [Line Items]
Original price per ads				£ 41
Adr warrants number				32,550
New price per adr				£ 4
Equivalent ordinary shares				162,750
[1]Number and original price of warrants have been adjusted to reflect the share consolidation and ratio change of ADS’s to ordinary shares that occurred on 2 March 2020 and 24 March 2023 and the ratio change of ADS’s to ordinary shares on 26 September 2022 and 5 July 2023.

Derivative financial liabilit_5

Derivative financial liability - current (Details 2) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Warrants [member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding, at beginning
Shares lapsed
Granted		276,689
Shares exercised
Number of shares outstanding, at ending	276,689
Number of shares outstanding	276,689
Warrant Three [Member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding, at beginning	838	838
Shares lapsed
Granted
Shares exercised
Number of shares outstanding, at ending	838	838	838
Number of shares outstanding	838	838	838
Warrant Four [Member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding, at beginning	392	392
Shares lapsed
Granted
Shares exercised
Number of shares outstanding, at ending	392	392	392
Number of shares outstanding	392	392	392
D A R A Warrant [Member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding, at beginning		204	231
Shares lapsed		(204)
Granted
Shares exercised
Number of shares outstanding, at ending			204
Number of shares outstanding			204	231	231
Lapsed			(27)
D A R A Options [Member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding, at beginning	138	138	138
Shares lapsed	(4)
Shares exercised
Number of shares outstanding, at ending	134	138	138
Number of shares outstanding	134	138	138	138	138
Lapsed		(204)
Warrant One [Member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding, at beginning	336,915	336,915	352,255
Granted			477,255
Number of shares outstanding, at ending		336,915	336,915
Number of shares outstanding		336,915	336,915	352,255
Exercised				(125,000)
Warrant Two [Member]
IfrsStatementLineItems [Line Items]
Number of shares outstanding, at beginning	157,495	157,495	157,495
Number of shares outstanding, at ending		157,495	157,495
Number of shares outstanding		157,495	157,495	157,495	157,495
Exercised			(15,340)

Derivative financial liabilit_6

Derivative financial liability - current (Details 3) - GBP (£) £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Equity settled financial derivative liability	£ 364	£ 85	£ 553	£ 1,559	£ 85	£ 664
Level 3 of fair value hierarchy [member]
IfrsStatementLineItems [Line Items]
Equity settled financial derivative liability	364	85
Level 3 of fair value hierarchy [member] | Black-Scholes option pricing model [member]
IfrsStatementLineItems [Line Items]
Equity settled financial derivative liability	£ 364
Significant unobservable input(s)			Volatility rate of 85.0% determined using historical volatility of comparable companies.	Volatility rate of 105.0% determined using historical volatility of comparable companies.
Relationship of unobservable inputs to fair value	The shorter the expected life the lower the fair value.		The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.
Description of inputs used in fair value measurement			Expected life between a range of 0.10 and 0.9 years determined using the remaining life of the share options.	Expected life between a range of 1.0 and 1.9 years determined using the remaining life of the share options.
Description of inputs used in fair value measurement	Expected life of 4.98 years determined using the remaining life of the share options.
Description of inputs used in fair value measurement assets	Risk-free rate of 4.13% determined using the expected life assumptions.		Risk-free rate of 0.71% determined using the expected life assumptions.	Risk-free rate of 0.8% determined using the expected life assumptions.
Description of reasons for fair value measurement	The higher the risk-free rate the higher the fair value.
Valuation technique (s) and key input(s)			Black-Scholes option pricing model	Black-Scholes option pricing model
Description of reasons for fair value measurement assets			The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.
Description of reasons for fair value measurement			The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.
Level 3 of fair value hierarchy [member] | Black Scholes Option Pricing Model One [Member]
IfrsStatementLineItems [Line Items]
Equity settled financial derivative liability		48
Significant unobservable input(s)	2023 - Black-Scholes Model
Relationship of unobservable inputs to fair value	Volatility rate of 90% determined using historical volatility of comparable companies.
Description of inputs used in fair value measurement	The higher the volatility the higher the fair value.
Level 3 of fair value hierarchy [member] | Black Scholes Option Pricing Model Two [Member]
IfrsStatementLineItems [Line Items]
Equity settled financial derivative liability		£ 37
Significant unobservable input(s)	2023 – Black- Scholes Model
Relationship of unobservable inputs to fair value	Volatility rate of 90% determined using historical volatility of comparable companies.
Description of inputs used in fair value measurement	The higher the volatility the higher the fair value.
Level 3 of fair value hierarchy [member] | Monte Carlo simulation model [member]
IfrsStatementLineItems [Line Items]
Equity settled financial derivative liability				£ 1,187
Significant unobservable input(s)	2022 - Monte Carlo simulation model	Volatility rate of 70.0% determined using historical volatility of comparable companies.	Volatility rate of 95.0% determined using historical volatility of comparable companies.	Volatility rate of 105.0% determined using historical volatility of comparable companies.
Relationship of unobservable inputs to fair value	The shorter the expected life the lower the fair value.	The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.
Description of inputs used in fair value measurement		Expected life between a range of 0.1 and 2.88 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 3.88 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 4.49 years determined using the remaining life of the share options.
Description of inputs used in fair value measurement	Expected life between a range of 0.1 and 2.38 years determined using the remaining life of the share options
Description of inputs used in fair value measurement assets	Risk-free rate of 4.68% determined using the expected life assumptions.	Risk-free rate of 4.22% determined using the expected life assumptions.	Risk-free rate of 0.31% determined using the expected life assumptions.	Risk-free rate of 0.07% determined using the expected life assumptions.
Description of reasons for fair value measurement	The higher the risk-free rate the higher the fair value.
Valuation technique (s) and key input(s)		Monte Carlo simulation model	Monte Carlo simulation model	Monte Carlo simulation model
Description of reasons for fair value measurement assets		The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.
Description of reasons for fair value measurement		The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.
Level 3 of fair value hierarchy [member] | Black Scholes Option Pricing Model Three [Member]
IfrsStatementLineItems [Line Items]
Significant unobservable input(s)	2023 – Black- Scholes Model
Relationship of unobservable inputs to fair value	Volatility rate of 90% determined using historical volatility of comparable companies.
Description of inputs used in fair value measurement	The higher the volatility the higher the fair value.
Level 3 of fair value hierarchy [member] | Number of shares lapsed [Default Label]
IfrsStatementLineItems [Line Items]
Significant unobservable input(s)		Volatility rate of 70.0% determined using historical volatility of comparable companies.	Volatility rate of 85.0% determined using historical volatility of comparable companies	Volatility rate of 105.0% determined using historical volatility of comparable companies
Relationship of unobservable inputs to fair value		The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.
Description of inputs used in fair value measurement	Expected life between a range of 0.1 and 2.00 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 2.5 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 3.5 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 4.888 years determined using the remaining life of the share options.
Description of inputs used in fair value measurement assets	Risk-free rate of 4.87% determined using the expected life assumptions.	Risk-free rate of 4.32% determined using the expected life assumptions.	Risk-free rate of 0.71% determined using the expected life assumptions.	Risk-free rate of 0.08% determined using the expected life assumptions.
Valuation technique (s) and key input(s)	2022 - Monte Carlo simulation model	Monte Carlo simulation model	Monte Carlo simulation model	Monte Carlo simulation model
Description of reasons for fair value measurement assets	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.
Description of reasons for fair value measurement	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.

Derivative financial liabilit_7

Derivative financial liability – current (Details Narrative) - GBP (£)		1 Months Ended		6 Months Ended
	Dec. 13, 2022	May 31, 2020	Oct. 30, 2019	Jun. 30, 2023
D A R A Warrant [Member]
IfrsStatementLineItems [Line Items]
Number of warrants issued				276,689
Warrants [member]
IfrsStatementLineItems [Line Items]
Number of warrants issued		838	392
Number of warrants issued price	£ 320		£ 10,000
Warrants [member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Share Price		£ 3,280
Warrants [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Share Price		£ 3,300

Share capital and reserves (Det

Share capital and reserves (Details) - GBP (£)	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Issued Capitals	£ 5,341,294	£ 1,108,344
Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Number of authorised shares	277,971,722	5,417,137	4,923,420	3,153,694
Issued Capitals	£ 277,972	£ 108,343
A Deferred Shares [Member]
IfrsStatementLineItems [Line Items]
Number of authorised shares	1,000,001	1,000,001
Issued Capitals	£ 1,000,001	£ 1,000,001
B Deferred Shares [Member]
IfrsStatementLineItems [Line Items]
Number of authorised shares	4,063,321,418
Issued Capitals	£ 4,063,321

Share capital and reserves (D_2

Share capital and reserves (Details 1) - £ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Private Placements	164,000
Registered Direct Offering	1,076,000	321,000
Registered Direct Offering, share price		£ 0.6660
Exercise February 2023 pre-funded warrants	3,139,000
Exercise sries warrants	653,000
Exercise series b Warrants	979,000
Exercise Investor warrants	32,000
Exercise c warrant	617,000
Exercise of warrants
Exercise of warrants, share price		£ 200	£ 5.9600	£ 6.2642
Share issue to SIPP trustee
ShareIssue for SIPP trustee, share price		£ 0.0200		£ 0.0200
Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Number of shares issued for consideraton at end	277,971,722	5,417,137	4,923,420
Private Placements	3,250,200
Private placements, share price	£ 0.0505
Registered Direct Offering	110,679,610	492,466
Registered Direct Offering, share price	£ 0.0097	£ 0.6660
Exercise February 2023 pre-funded warrants	62,184,525
Exercise February 2023 pre-funded warrants, share price	£ 0.0505
Exercise sries warrants	12,931,020
Exercise series warrants share price	£ 0.0505
Exercise series b Warrants	19,396,530
Exercise series B warrants share price	£ 0.0505
Exercise Investor warrants	625,000
Exercise Investor warrants, share price	£ 0.0505
Share sub-division and re-designation
Exercise c warrant	63,487,700
Exercise c warrants share price	£ 0.0097
Exercise of warrants		1	15,340	125,000
Exercise of warrants, share price		£ 200
Share issue to SIPP trustee		1,250		1,250
ShareIssue for SIPP trustee, share price		£ 0.001
A Deferred Shares [Member]
IfrsStatementLineItems [Line Items]
Number of shares issued for consideraton at end	1,000,001	1,000,001	1,000,001
Private Placements
Registered Direct Offering
Exercise February 2023 pre-funded warrants
Exercise sries warrants
Exercise series b Warrants
Exercise Investor warrants
Share sub-division and re-designation
Exercise c warrant
Exercise of warrants
Share issue to SIPP trustee
B Deferred Shares [Member]
IfrsStatementLineItems [Line Items]
Number of shares issued for consideraton at end	4,063,321,418
Private Placements
Registered Direct Offering
Exercise February 2023 pre-funded warrants
Exercise sries warrants
Exercise series b Warrants
Exercise Investor warrants
Share sub-division and re-designation	4,063,321,418
Exercise c warrant
Exercise of warrants
Share issue to SIPP trustee

Contingent liabilities (Details

Contingent liabilities (Details Narrative) - GBP (£)	1 Months Ended	6 Months Ended	12 Months Ended
	Jan. 23, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 18, 2022
Notes and other explanatory information [abstract]
Reimbursement expenses	£ 225,000	£ 225,000
Contingent liabilites		£ 225,000	£ 225,000
Aggregate consideration				£ 7,400,000
Contingent liability				£ 225,000
Requested for reimbursement	£ 225,000

Accounting policies (Details)

Accounting policies (Details)	12 Months Ended
	Dec. 31, 2022
Biodexa Pharmaceuticalsplc [Member]
IfrsStatementLineItems [Line Items]
Entity	Biodexa Pharmaceuticals plc
Summary description	Ultimate holding company
Midatech limited [member]
IfrsStatementLineItems [Line Items]
Entity	Midatech Limited
Summary description	Trading company
Midatech pharma (espana) SL (formerly midatech biogune SL) [member]
IfrsStatementLineItems [Line Items]
Entity	Midatech Pharma (Espana) SL (formerly Midatech Biogune SL)
Summary description	Liquidated - 2021
PharMida AG [member]
IfrsStatementLineItems [Line Items]
Entity	PharMida AG
Summary description	Dormant	[1],[2]
Midatech Pharma Wale Limited [Member]
IfrsStatementLineItems [Line Items]
Entity	Midatech Pharma (Wales) Limited (formerly Q Chip Limited)
Summary description	Trading company
Midatech pharma PTY [member]
IfrsStatementLineItems [Line Items]
Entity	Midatech Pharma Pty
Summary description	Dissolved - 2020
Biodexa Limited [Member]
IfrsStatementLineItems [Line Items]
Entity	Biodexa Limited (formerly Bioadexa Pharmaceuticals Limited)
Summary description	Dormant – incorporated October 2022
[1]PharMida AG became dormant in January 2016.[2]Wholly owned subsidiary of Midatech Limited.

Accounting policies (Details 1)

Accounting policies (Details 1)	12 Months Ended
	Dec. 31, 2022
Goodwill [member]
IfrsStatementLineItems [Line Items]
Useful economic lives	Indefinite life
Intangible assets under development [member]
IfrsStatementLineItems [Line Items]
Useful economic lives	In process, not yet amortising
IT and website costs [member]
IfrsStatementLineItems [Line Items]
Useful economic lives	4 years

Events after the reporting da_2

Events after the reporting date (Details Narrative)	Jul. 05, 2023 shares
Notes and other explanatory information [abstract]
Number of shares	400

Accounting policies (Details 2)

Accounting policies (Details 2)	12 Months Ended
	Dec. 31, 2022
Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
Description of useful life, property, plant and equipment	20%- 25% per annum straight line
Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
Description of useful life, property, plant and equipment	the shorter of 10% per annum straight line or over the lease term
Computer equipment [member]
IfrsStatementLineItems [Line Items]
Description of useful life, property, plant and equipment	25% per annum straight line
Laboratory equipment [member]
IfrsStatementLineItems [Line Items]
Description of useful life, property, plant and equipment	15% – 25% per annum straight line
Right of use asset [member]
IfrsStatementLineItems [Line Items]
Description of useful life, property, plant and equipment	Economic life of contractual relationship

Accounting policies (Details Na

Accounting policies (Details Narrative)	Mar. 02, 2020 £ / shares
Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Share par value (in dollars per share)	£ 0.001

Critical accounting estimates_2

Critical accounting estimates and judgements (Details Narrative) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Critical Accounting Estimates And Judgements
Unutilised tax losses			£ 71,600	£ 67,200	£ 63,200
Loss from operations	£ 3,570	£ 3,060	7,700
Negative cash flows from operations	3,880	£ 3,540	7,000
Accumulated deficit	138,970		135,300
Cash and cash equivalents	£ 5,230		£ 2,800

Revenue (Details)

Revenue (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Revenue	£ 699	£ 578	£ 180
United Kingdom [Member]
IfrsStatementLineItems [Line Items]
Revenue			4
Belgium [Member]
IfrsStatementLineItems [Line Items]
Revenue	699		114
Belgium [Member] | Continuing operations [member]
IfrsStatementLineItems [Line Items]
Revenue		578
Rest of the world [member]
IfrsStatementLineItems [Line Items]
Revenue			£ 62

Revenue (Details 1)

Revenue (Details 1) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes and other explanatory information [abstract]
Contractual assets, beginning		£ 71
Contractual liabilities, beginning		(68)
Transfers in the period from contract assets to trade receivables		(71)
Transfers in the period from contract assets to trade receivables
Amounts included in contract liabilities that was recognised as revenue during the period
Amounts included in contract liabilities that was recognised as revenue during the period		(68)
Excess of revenue recognised over cash			71
Excess of revenue recognised over cash
Cash received in advance of performance and not recognised as revenue during the period
Cash received in advance of performance and not recognised as revenue during the period	(197)		(68)
Contractual assets, ending			71
Contractual liabilities, ending	£ (197)		£ (68)

Revenue (Details 2)

Revenue (Details 2)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Customers A [Member]
IfrsStatementLineItems [Line Items]
Percentage of revenue in excess of 10%	100%	100%	64%
Customers B [Member]
IfrsStatementLineItems [Line Items]
Percentage of revenue in excess of 10%			34%
Customers C [Member]
IfrsStatementLineItems [Line Items]
Percentage of revenue in excess of 10%			2%

Loss from operations (Details)

Loss from operations (Details) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Impairment of intangible assets							£ 12,369
Impairment of financial asset			207
Provision against future loss on loan agreement			207
Fee and commission income (expense)			106		88		87
Fees payable to the Company's subsidiary auditors for the audits of the susidiary accounts			44		44		43
Other services			70				7
Fee and commission income expense 2							15
Fee payable other services 1			67		41		171
Foreign exchange loss			9		12		96
Profit/(Loss) on disposal of property, plant and equipment			14		(42)		(226)
Equity settled share-based payment*	£ 15	£ 100	123	[1]	89	[1]	(404)	[1]
Research and Development [Member]
IfrsStatementLineItems [Line Items]
Depreciation of property, plant and equipment			162		198		1,064
Depreciation of right of use asset			151		165		110
Amortisation of intangible assets software			3				8
Administrative Costs [Member]
IfrsStatementLineItems [Line Items]
Depreciation of property, plant and equipment			12		15		25
Depreciation of right of use asset			15		25		8
Amortisation of intangible assets software							£ 2
[1]credit recognised in 2020 due to employees leaving the company and the subsequent reversal of the cumulative share based payment charge relating to share options under the 2014 Biodexa Pharmaceuticals plc Enterprise Management Incentive Scheme.

Staff costs (Details)

Staff costs (Details) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Staff Costs
Wages and salaries			£ 2,033		£ 1,354		£ 2,727
Defined contribution pension cost (note 24)			98		71		75
Social security contributions and similar taxes			269		152		397
Share-based payment charge/(credit)	£ 15	£ 100	123	[1]	89	[1]	(404)	[1]
Staff costs gross			£ 2,523		£ 1,666		£ 2,795
[1]credit recognised in 2020 due to employees leaving the company and the subsequent reversal of the cumulative share based payment charge relating to share options under the 2014 Biodexa Pharmaceuticals plc Enterprise Management Incentive Scheme.

Staff costs (Details 1)

Staff costs (Details 1) - Number	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Average number of staff employee	27	20	40
Research and Development [Member]
IfrsStatementLineItems [Line Items]
Average number of staff employee	22	15	31
General and Administration [Member]
IfrsStatementLineItems [Line Items]
Average number of staff employee	5	5	9

Staff costs (Details 2)

Staff costs (Details 2) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Staff Costs
Short term employee benefits	£ 668	£ 658	£ 472
Post-employment benefits	21	27	24
Termination benefits			30
Share-based payment	53	61	(472)
Total	£ 742	£ 746	£ 54

Taxation (Details 1)

Taxation (Details 1) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Staff Costs
Loss before tax	£ (8,488)	£ (6,106)	£ (23,470)
Expected tax credit based on the standard rate of United Kingdom corporation tax at the domestic rate of 19% (2021: 19%; 2020: 19%)	(1,613)	(1,160)	(4,459)
Expenses not deductible for tax purposes	392	75	596
Income not taxable	(4)	(2)	(75)
Adjustment in respect of prior period	(7)		(158)
Surrender of tax losses for R&D tax refund	(357)	(280)	(491)
Deferred tax not recognised	757	721	3,306
Total tax credited to the income statement	£ (832)	£ (646)	£ (1,281)

Staff costs (Details Narrative)

Staff costs (Details Narrative)	12 Months Ended
	Dec. 31, 2022
Staff Costs
Disclosure of information about key management personnel	Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, including the Directors of the Company listed on page 25, including the Chief Executive Officer and Chief Scientific Officer.

Property, plant and equipment_2

Property, plant and equipment (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2023
IfrsStatementLineItems [Line Items]
Balance at beginning	£ 1,152	£ 542
Balance at ending	831	1,152	£ 542
Net book value	831	1,152	542	£ 693
Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	2,793	2,143	7,551
Additions	62	1,040	209
Effect of modification to lease terms		(24)	(678)
Disposals	271	(366)	(5,210)
Exchange differences			271
Transfer	(122)
Disposals	(271)	366	5,210
Balance at ending	2,462	2,793	2,143
Net book value	2,462	2,793	2,143
Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Exchange differences			183
Balance at beginning	1,631	1,641	1,601
Charge for the year	340	403	1,207
Disposals	(237)	(363)	(5,186)
Balance at beginning	1,641	1,601	5,397
Transfer	(113)
Balance at end	1,631	1,641	1,601
Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
Balance at beginning	53	4
Balance at ending	44	53	4
Net book value	44	53	4
Fixtures and fittings [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	60	53	248
Additions	3	57
Effect of modification to lease terms
Disposals		(50)	(202)
Exchange differences			7
Transfer
Disposals		50	202
Balance at ending	63	60	53
Net book value	63	60	53
Fixtures and fittings [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Exchange differences			7
Balance at beginning	19	7	49
Charge for the year	12	8	9
Disposals		(50)	(202)
Balance at beginning	7	49	235
Transfer
Balance at end	19	7	49
Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
Balance at beginning	49	2
Balance at ending	38	49	2
Net book value	38	49	2
Leasehold improvements [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	53	4	2,038
Additions		53	58
Effect of modification to lease terms
Disposals		(4)	(2,184)
Exchange differences			92
Transfer
Disposals		4	2,184
Balance at ending	53	53	4
Net book value	53	53	4
Leasehold improvements [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Exchange differences			81
Balance at beginning	15	4	2
Charge for the year	11	5	310
Disposals		(3)	(2,183)
Balance at beginning	4	2	1,794
Transfer
Balance at end	15	4	2
Computer equipment [member]
IfrsStatementLineItems [Line Items]
Balance at beginning	29	37
Balance at ending	17	29	37
Net book value	17	29	37
Computer equipment [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	242	236	403
Additions	14	16	16
Effect of modification to lease terms
Disposals	(46)	(10)	(185)
Exchange differences			2
Transfer	(122)
Disposals	46	10	185
Balance at ending	88	242	236
Net book value	88	242	236
Computer equipment [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Exchange differences			2
Balance at beginning	71	213	199
Charge for the year	12	22	50
Disposals	(41)	(8)	(185)
Balance at beginning	213	199	332
Transfer	(113)
Balance at end	71	213	199
Laboratory equipment [member]
IfrsStatementLineItems [Line Items]
Balance at beginning	358	423
Balance at ending	245	358	423
Net book value	245	358	423
Laboratory equipment [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	1,563	1,662	3,738
Additions	45	194	135
Effect of modification to lease terms
Disposals	(174)	(138)	(2,323)
Exchange differences			112
Transfer		(155)
Disposals	174	138	2,323
Balance at ending	1,434	1,563	1,662
Net book value	1,434	1,563	1,662
Laboratory equipment [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Exchange differences			79
Balance at beginning	1,189	1,205	1,239
Charge for the year	139	178	720
Disposals	(155)	(138)	(2,300)
Balance at beginning	1,205	1,239	2,740
Transfer		(74)
Balance at end	1,189	1,205	1,239
Right-of-use assets [member]
IfrsStatementLineItems [Line Items]
Balance at beginning	663	76
Balance at ending	487	663	76
Net book value	487	663	76
Right-of-use assets [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	875	188	1,124
Additions		720
Effect of modification to lease terms		(24)	(678)
Disposals	51	(164)	(316)
Exchange differences			58
Transfer		155
Disposals	(51)	164	316
Balance at ending	824	875	188
Net book value	824	875	188
Right-of-use assets [member] | Accumulated depreciation and amortisation [member]
IfrsStatementLineItems [Line Items]
Exchange differences			14
Balance at beginning	337	212	112
Charge for the year	166	190	118
Disposals	(41)	(164)	(316)
Balance at beginning	212	112	296
Transfer		74
Balance at end	£ 337	£ 212	£ 112

Leases (Details)

Leases (Details) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Interest expenses	£ 15	£ 24	£ 43	£ 36	£ 20
Lease payments	(95)	(73)	(178)	(112)	(258)
Land and buildings [member]
IfrsStatementLineItems [Line Items]
Balance at beginning	£ 624	£ 766	766	76	907
Additions				720
Transfer				77
Effect of modification to lease terms				(24)	(788)
Interest expenses			36	29	15
Lease payments			(178)	(112)	(105)
Exchange differences					47
Balance at ending			£ 624	£ 766	£ 76

Leases (Details 1)

Leases (Details 1) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes and other explanatory information [abstract]
Low value leases expensed	£ 3	£ 2	£ 10
Total	£ 3	£ 2	£ 10

Intangible assets (Details)

Intangible assets (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Balance at beginning
Balance at end	6
Net book value	6
Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	15,669	15,704
Disposal	(12)	(36)
Foreign exchange		1
Balance at end	15,779	15,669
Transfer from property, plant and equipment	122
Net book value	15,779	15,669
Accumulated depreciation, amortisation and impairment [member]
IfrsStatementLineItems [Line Items]
Balance at beginning
Disposal	(12)	(36)
Foreign exchange		1
Balance at end	6
Transfer from property, plant and equipment	113
Balance at beginning	15,669	3,325
Amortisation charge for the year	3	10
Impairment		12,369
Balance at end	15,773	15,669
Net book value	6
Intangible assets under development [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	13,378	13,378
Disposal
Foreign exchange
Balance at end	13,378	13,378
Transfer from property, plant and equipment
Net book value	13,378	13,378
Intangible assets under development [member] | Accumulated depreciation, amortisation and impairment [member]
IfrsStatementLineItems [Line Items]
Balance at beginning
Disposal
Foreign exchange
Balance at end
Transfer from property, plant and equipment
Balance at beginning	13,378	3,300
Amortisation charge for the year
Impairment		10,078
Balance at end	13,378	13,378
Net book value
Goodwill [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning	2,291	2,291
Disposal
Foreign exchange
Balance at end	2,291	2,291
Transfer from property, plant and equipment
Net book value	2,291	2,291
Goodwill [member] | Accumulated depreciation, amortisation and impairment [member]
IfrsStatementLineItems [Line Items]
Balance at beginning
Disposal
Foreign exchange
Balance at end
Transfer from property, plant and equipment
Balance at beginning	2,291
Amortisation charge for the year
Impairment		2,291
Balance at end	2,291	2,291
Net book value
IT and website costs [member] | Gross Gross Gross Carrying Amount [Member]
IfrsStatementLineItems [Line Items]
Balance at beginning		35
Disposal	(12)	(36)
Foreign exchange		1
Balance at end	110
Transfer from property, plant and equipment	122
Net book value	110
IT and website costs [member] | Accumulated depreciation, amortisation and impairment [member]
IfrsStatementLineItems [Line Items]
Balance at beginning
Disposal	(12)	(36)
Foreign exchange		1
Balance at end	6
Transfer from property, plant and equipment	113
Balance at beginning		25
Amortisation charge for the year	3	10
Impairment
Balance at end	104
Net book value	£ 6

Subsidiaries (Details)

Subsidiaries (Details)	12 Months Ended
	Dec. 31, 2022
Midatech limited [member]
IfrsStatementLineItems [Line Items]
Entity name	Midatech Limited
Principal place of business of subsidiary	1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ
Description of nature of entity's operations and principal activities	Trading company
PharMida AG [member]
IfrsStatementLineItems [Line Items]
Entity name	PharMida AG
Principal place of business of subsidiary	c/o Kellerhals, Hirschgässlein 11, 4051 Basel, Switzerland	[1],[2]
Description of nature of entity's operations and principal activities	Dormant	[1],[2]
Midatech pharma (wales) limited [member]
IfrsStatementLineItems [Line Items]
Entity name	Midatech Pharma (Wales) Limited	[1],[2]
Principal place of business of subsidiary	1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ
Description of nature of entity's operations and principal activities	Trading company
Biodexa Limited 1 [Member]
IfrsStatementLineItems [Line Items]
Entity name	Biodexa Limited (formerly Biodexa Pharmaceuticals Limited)
Principal place of business of subsidiary	1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ
Description of nature of entity's operations and principal activities	Dormant
[1]PharMida AG became dormant in January 2016.[2]Wholly owned subsidiary of Midatech Limited.

Trade and other receivables (De

Trade and other receivables (Details) - GBP (£) £ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes and other explanatory information [abstract]
Trade receivables		£ 329	£ 33	£ 95
Prepayments		376	607	258
Other receivables		301	394	219
Total trade and other receivables		1,006	1,034	572
Less: non-current portion
Current portion	£ 903	£ 1,006	£ 1,034	£ 572

Cash and cash equivalents and_3

Cash and cash equivalents and cash flow supporting notes (Details) - GBP (£) £ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Notes and other explanatory information [abstract]
Cash at bank available on demand	£ 5,227	£ 2,836	£ 6,423	£ 10,057	£ 7,546	£ 10,928

Cash and cash equivalents and_4

Cash and cash equivalents and cash flow supporting notes (Details 1) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes and other explanatory information [abstract]
Gross proceeds			£ 321	£ 10,091	£ 10,792
Transaction costs			(78)	(1,056)	(1,050)
Proceeds from issuing shares	£ 6,354		£ 243	£ 9,035	£ 9,742

Cash and cash equivalents and_5

Cash and cash equivalents and cash flow supporting notes (Details 2) - GBP (£) £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Beginning	£ 709	£ 1,319	£ 1,819	£ 6,746
Cash Flows		(178)	(215)	(6,440)
Loans and borrowings classified as non-current 31 December 2018 becoming current in 2019
Gain/(loss) in finance income within the consolidated statement of comprehensive income		(468)	(936)	397
Interest accruing in period		36	29	(45)
Ending		709	1,319	1,819
Foreign Exchange			(4)	275
New leases			720
Effect of modification to lease term - IFRS 16			(24)	(788)
Transfer to share premium on exercise of warrants			(70)	(499)
Fair value changes				1,176
Reclassification portion government loan to non-current
Warrants issued	665			997
Long-term borrowings [member]
IfrsStatementLineItems [Line Items]
Beginning	463	620	60	5,670
Cash Flows				(6,182)
Loans and borrowings classified as non-current 31 December 2018 becoming current in 2019		(178)	(178)
Gain/(loss) in finance income within the consolidated statement of comprehensive income
Interest accruing in period		21	23	(30)
Ending		463	620	60
Foreign Exchange				252
New leases			715
Effect of modification to lease term - IFRS 16				(877)
Transfer to share premium on exercise of warrants
Fair value changes				1,176
Reclassification portion government loan to non-current				51
Warrants issued
Short-term borrowings [member]
IfrsStatementLineItems [Line Items]
Beginning	£ 246	699	1,759	1,076
Cash Flows		(178)	(215)	(258)
Loans and borrowings classified as non-current 31 December 2018 becoming current in 2019		178	178
Gain/(loss) in finance income within the consolidated statement of comprehensive income		(468)	(936)	397
Interest accruing in period		15	6	(15)
Ending		£ 246	699	1,759
Foreign Exchange			(4)	23
New leases			5
Effect of modification to lease term - IFRS 16			(24)	89
Transfer to share premium on exercise of warrants			£ (70)	(499)
Fair value changes
Reclassification portion government loan to non-current				(51)
Warrants issued				£ 997

Trade and other payables (Detai

Trade and other payables (Details) - GBP (£) £ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current
Trade payables	£ 339	£ 485	£ 337
Other payables	17	5	26
Accruals	817	546	768
Total financial liabilities, excluding loans and borrowings, classified as financial liabilities measured at amortised cost	1,173	1,036	1,131
Tax and social security	77	56	31
Deferred revenue	197		68
Total trade and other payables	£ 1,447	£ 1,092	£ 1,230

Impairment testing (Details Nar

Impairment testing (Details Narrative) - GBP (£) £ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Impairment charge on non financial assets		£ 2,300
Intangible assets under development [member] | Midatech pharma (wales) limited [member]
IfrsStatementLineItems [Line Items]
Impairment charge on non financial assets	£ 11,600	£ 9,300

Trade and other payables (Det_2

Trade and other payables (Details Narrative) - Midatech pharma (espana) SL (formerly midatech biogune SL) [member] - Spanish Government Reindustrialization Programme [Member] £ in Thousands	Sep. 30, 2019 GBP (£)
IfrsStatementLineItems [Line Items]
Government grants	£ 6,600
Cash Backed Guarantee [Member]
IfrsStatementLineItems [Line Items]
Government grants	£ 2,900

Provisions (Details)

Provisions (Details) - GBP (£) £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Provisions Abstract
Opening provision at 1 January	£ 207	£ 50	£ 50	£ 97
Utilisation of provision	(207)	(43)		(97)
Provision recognised/(released) in the year		200		50
At 31 December		207	50	50
Less: non-current portion				(50)
Current portion		£ 207	£ 50

Financial instruments - risk ma

Financial instruments - risk management (Details) - GBP (£) £ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Notes and other explanatory information [abstract]
Cash and cash equivalents	£ 5,227	£ 2,836	£ 6,423	£ 10,057	£ 7,546	£ 10,928
Trade receivables		329		33	95
Other receivables
Total financial assets		3,165		10,090	7,641
Trade payables		339		485	337
Other payables		17		5	26
Accruals		817		546	768
Borrowings		624		766	260
Total financial liabilities – amortised cost		1,797		1,802	1,391
Equity settled derivative financial liability	£ 364	£ 85	£ 85	£ 553	£ 1,559	£ 664

Financial instruments - risk _2

Financial instruments - risk management (Details 1) - GBP (£) £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Equity settled derivative financial liability		£ 85
Equity settled derivative financial liability	£ 364	85	£ 553	£ 1,559	£ 85	£ 664
Level 3 of fair value hierarchy [member]
IfrsStatementLineItems [Line Items]
Equity settled derivative financial liability	£ 364	85
Level 3 of fair value hierarchy [member] | Monte Carlo simulation model [member]
IfrsStatementLineItems [Line Items]
Equity settled derivative financial liability		£ 48	£ 467
Valuation technique (s) and key input(s)		Monte Carlo simulation model	Monte Carlo simulation model	Monte Carlo simulation model
Significant unobservable input(s)	2022 - Monte Carlo simulation model	Volatility rate of 70.0% determined using historical volatility of comparable companies.	Volatility rate of 95.0% determined using historical volatility of comparable companies.	Volatility rate of 105.0% determined using historical volatility of comparable companies.
Relationship of unobservable inputs to fair value	The shorter the expected life the lower the fair value.	The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.
Significant unobservable input(s)		Expected life between a range of 0.1 and 2.88 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 3.88 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 4.49 years determined using the remaining life of the share options.
Relationship of unobservable inputs to fair value		The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.
Significant unobservable input(s)	Risk-free rate of 4.68% determined using the expected life assumptions.	Risk-free rate of 4.22% determined using the expected life assumptions.	Risk-free rate of 0.31% determined using the expected life assumptions.	Risk-free rate of 0.07% determined using the expected life assumptions.
Relationship of unobservable inputs to fair value		The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.
Equity settled derivative financial liability				£ 1,187
Level 3 of fair value hierarchy [member] | Number of shares lapsed [Default Label]
IfrsStatementLineItems [Line Items]
Equity settled derivative financial liability		£ 37	£ 86	£ 372
Valuation technique (s) and key input(s)	2022 - Monte Carlo simulation model	Monte Carlo simulation model	Monte Carlo simulation model	Monte Carlo simulation model
Significant unobservable input(s)		Volatility rate of 70.0% determined using historical volatility of comparable companies.	Volatility rate of 85.0% determined using historical volatility of comparable companies	Volatility rate of 105.0% determined using historical volatility of comparable companies
Relationship of unobservable inputs to fair value		The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.
Significant unobservable input(s)	Expected life between a range of 0.1 and 2.00 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 2.5 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 3.5 years determined using the remaining life of the share options.	Expected life between a range of 0.1 and 4.888 years determined using the remaining life of the share options.
Relationship of unobservable inputs to fair value	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.
Significant unobservable input(s)	Risk-free rate of 4.87% determined using the expected life assumptions.	Risk-free rate of 4.32% determined using the expected life assumptions.	Risk-free rate of 0.71% determined using the expected life assumptions.	Risk-free rate of 0.08% determined using the expected life assumptions.
Relationship of unobservable inputs to fair value	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.
Level 3 of fair value hierarchy [member] | Black-Scholes option pricing model [member]
IfrsStatementLineItems [Line Items]
Valuation technique (s) and key input(s)			Black-Scholes option pricing model	Black-Scholes option pricing model
Significant unobservable input(s)			Volatility rate of 85.0% determined using historical volatility of comparable companies.	Volatility rate of 105.0% determined using historical volatility of comparable companies.
Relationship of unobservable inputs to fair value	The shorter the expected life the lower the fair value.		The higher the volatility the higher the fair value.	The higher the volatility the higher the fair value.
Significant unobservable input(s)			Expected life between a range of 0.10 and 0.9 years determined using the remaining life of the share options.	Expected life between a range of 1.0 and 1.9 years determined using the remaining life of the share options.
Relationship of unobservable inputs to fair value			The shorter the expected life the lower the fair value.	The shorter the expected life the lower the fair value.
Significant unobservable input(s)	Risk-free rate of 4.13% determined using the expected life assumptions.		Risk-free rate of 0.71% determined using the expected life assumptions.	Risk-free rate of 0.8% determined using the expected life assumptions.
Relationship of unobservable inputs to fair value			The higher the risk-free rate the higher the fair value.	The higher the risk-free rate the higher the fair value.
Equity settled derivative financial liability	£ 364

Financial instruments - risk _3

Financial instruments - risk management (Details 2) - GBP (£) £ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Cash and cash equivalents	£ 5,227	£ 2,836	£ 6,423	£ 10,057	£ 7,546	£ 10,928
Net Foreign Currency Assets Liabilities		265		22	175
Foreign exchange risk [member] | Pounds Sterling
IfrsStatementLineItems [Line Items]
Cash and cash equivalents		2,588		10,057	7,247
Foreign exchange risk [member] | US Dollar
IfrsStatementLineItems [Line Items]
Cash and cash equivalents		248			120
Net Foreign Currency Assets Liabilities		248			120
Foreign exchange risk [member] | Euro
IfrsStatementLineItems [Line Items]
Cash and cash equivalents					179
Net Foreign Currency Assets Liabilities		17		22	54
Foreign exchange risk [member] | Other
IfrsStatementLineItems [Line Items]
Net Foreign Currency Assets Liabilities					£ 1

Financial instruments - risk _4

Financial instruments - risk management (Details 3) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Loss before tax	£ (3,856)	£ (3,398)	£ (8,488)	£ (6,106)	£ (23,470)
Total equity	£ 5,299	£ 7,491	3,162	10,452	6,718	£ 19,558
Foreign currency sensitivity analysis [member] | US Dollar
IfrsStatementLineItems [Line Items]
Loss before tax			25		12
Total equity			25		12
Foreign currency sensitivity analysis [member] | Euro
IfrsStatementLineItems [Line Items]
Loss before tax			(1)	2	(293)
Total equity			(1)	2	(293)
Foreign currency sensitivity analysis [member] | Other
IfrsStatementLineItems [Line Items]
Loss before tax					(4)
Total equity					£ (4)

Financial instruments - risk _5

Financial instruments - risk management (Details 4) - Liquidity risk [member] - GBP (£) £ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Liquidity risk [member]
IfrsStatementLineItems [Line Items]
Total
Government and Research Loans [Member]
IfrsStatementLineItems [Line Items]
Total
Not later than three months [member]
IfrsStatementLineItems [Line Items]
Total	1,222	1,082	1,263
Not later than three months [member] | Trade and other payables [member]
IfrsStatementLineItems [Line Items]
Total	1,173	1,036	1,131
Not later than three months [member] | Finance Lease [Member]
IfrsStatementLineItems [Line Items]
Total	49	46	25
Not later than three months [member] | Government and Research Loans [Member]
IfrsStatementLineItems [Line Items]
Total			107
Later than three months and not later than one year [member]
IfrsStatementLineItems [Line Items]
Total	140	171	75
Later than three months and not later than one year [member] | Trade and other payables [member]
IfrsStatementLineItems [Line Items]
Total
Later than three months and not later than one year [member] | Finance Lease [Member]
IfrsStatementLineItems [Line Items]
Total	140	171	75
Later than three months and not later than one year [member] | Government and Research Loans [Member]
IfrsStatementLineItems [Line Items]
Total
Later than one year and not later than two years [member]
IfrsStatementLineItems [Line Items]
Total	188	195	61
Later than one year and not later than two years [member] | Trade and other payables [member]
IfrsStatementLineItems [Line Items]
Total
Later than one year and not later than two years [member] | Finance Lease [Member]
IfrsStatementLineItems [Line Items]
Total	188	195	61
Later than one year and not later than two years [member] | Government and Research Loans [Member]
IfrsStatementLineItems [Line Items]
Total
Later than two years and not later than five years [member]
IfrsStatementLineItems [Line Items]
Total	254	442	8
Later than two years and not later than five years [member] | Trade and other payables [member]
IfrsStatementLineItems [Line Items]
Total
Later than two years and not later than five years [member] | Finance Lease [Member]
IfrsStatementLineItems [Line Items]
Total	254	442	8
Later than two years and not later than five years [member] | Government and Research Loans [Member]
IfrsStatementLineItems [Line Items]
Total
Later than five years [member] | Trade and other payables [member]
IfrsStatementLineItems [Line Items]
Total
Later than five years [member] | Finance Lease [Member]
IfrsStatementLineItems [Line Items]
Total

Deferred tax (Details)

Deferred tax (Details) - GBP (£) £ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes and other explanatory information [abstract]
Gross losses	£ 71,139	£ 67,210	£ 63,183
Potential deferred tax asset	£ 17,867	£ 16,925	£ 13,076

Share capital (Details)

Share capital (Details) - GBP (£)	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Total		£ 1,108,344	£ 1,098,469	£ 1,063,075
Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Number of shares authorised, allotted and fully paid - classified as equity	277,971,722	5,417,137	4,923,420	3,153,694
Total		£ 108,343	£ 98,468	£ 63,074
Deferred Shares [member]
IfrsStatementLineItems [Line Items]
Number of shares authorised, allotted and fully paid - classified as equity		1,000,001	1,000,001	1,000,001
Total		£ 1,000,001	£ 1,000,001	£ 1,000,001

Share capital (Details 1)

Share capital (Details 1) - GBP (£) £ / shares in Units, £ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Placing & Registered Direct Offering, share price				£ 5.4000
Consideration for Placing & Registered Direct Offering				£ 4,255
Placing, share price			£ 5.7000	£ 5.4000
Consideration for Placing			£ 10,000	£ 5,750
Exercise of warrants
Exercise of warrants, share price		£ 200	£ 5.9600	£ 6.2642
Consideration for Exercise of warrants			£ 91	£ 783
Share issue to SIPP trustee
Share issue to SIPP trustee, share price		£ 0.0200		£ 0.0200
Consideration Share issue to SIPP trustee
Registered Direct Offering	1,076,000	321,000
Registered Direct Offering Share Price		£ 0.6660
Consideration for Registered Direct Offering		£ 321
Ordinary shares [member]
IfrsStatementLineItems [Line Items]
Beginning balance, shares	5,417,137	4,923,420	3,153,694	1,174,752
Placing & Registered Direct Offering				787,878
Placing			1,754,386	1,064,814
Exercise of warrants		1	15,340	125,000
Exercise of warrants, share price		£ 200
Share issue to SIPP trustee		1,250		1,250
Share issue to SIPP trustee, share price		£ 0.001
Registered Direct Offering	110,679,610	492,466
Registered Direct Offering Share Price	£ 0.0097	£ 0.6660
Ending balance, shares		5,417,137	4,923,420	3,153,694
Deferred Shares [member]
IfrsStatementLineItems [Line Items]
Beginning balance, shares	1,000,001	1,000,001	1,000,001	1,000,001
Ending balance, shares		1,000,001	1,000,001	1,000,001

Reserves (Details)

Reserves (Details)	12 Months Ended
	Dec. 31, 2022
Share Capital [Member]
IfrsStatementLineItems [Line Items]
Description of nature and purpose of reserves within equity	Nominal value of subscribed share capital
Share premium [member]
IfrsStatementLineItems [Line Items]
Description of nature and purpose of reserves within equity	Amount subscribed for share capital in excess of nominal value.
Merger Reserve [member]
IfrsStatementLineItems [Line Items]
Description of nature and purpose of reserves within equity	Represents the difference between the fair value and nominal value of shares issued on the acquisition of subsidiary companies where the Company has elected to take advantage of merger accounting.
Reserve of exchange differences on translation [member]
IfrsStatementLineItems [Line Items]
Description of nature and purpose of reserves within equity	Gains/losses arising on retranslating the net assets of overseas operations into sterling.
Warrant reserve [member]
IfrsStatementLineItems [Line Items]
Description of nature and purpose of reserves within equity	Represents the fair value of warrants denominated in £ at the date of grant. The number and price is fixed at the date of grant. The warrants expire in November 2025.
Retained earnings [member]
IfrsStatementLineItems [Line Items]
Description of nature and purpose of reserves within equity	All other net gains and losses and transactions with owners (e.g. dividends) not recognised elsewhere.

Deferred tax (Details Narrative

Deferred tax (Details Narrative) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020
Notes and other explanatory information [abstract]
Net deferred tax assets		£ 1,600
Description of deferred tax asset	Deferred tax asset balances disclosed as at 31 December 2022 have been calculated at 25%. The Finance Bill 2021 enacted an increase in the tax rate to 25% from 1 April 2023.

Share-based payments (Details)

Share-based payments (Details)	1 Months Ended								12 Months Ended
	Aug. 31, 2022 Number	Aug. 31, 2022 Number	Feb. 28, 2022 Number	Sep. 30, 2021 Number	Aug. 31, 2021 Number	Jul. 31, 2021 Number	Jun. 30, 2020 Number	Apr. 30, 2020 Number	Dec. 31, 2022 Number £ / shares	Dec. 31, 2021 Number £ / shares	Dec. 31, 2020 Number £ / shares
IfrsStatementLineItems [Line Items]
Beginning of the year									131,661	74,147	16,802
Granted	7,500	5,000	18,750	6,000	2,500	85,450	68,150	5,000	31,250	93,950	73,150
Lapsed									(6,939)	(8)	(1,688)
Forfeited									(11,382)	(36,428)	(14,117)
Beginning of the year									144,590	131,661	74,147
Options exercisable									55,932	8,982	9,759
Weighted average exercise price of outstanding options | £ / shares									£ 4.836	£ 10.759	£ 16.698
Weighted average exercise price of options lapsed | £ / shares									105.612	1,676	523.411
Weighted average exercise price of options forfeited | £ / shares									5.974	8.955	72.975
Weighted average exercise price of options granted | £ / shares									£ 2.670	£ 5.515	£ 4.092
Weighted average remaining contractual life of outstanding options									8 years 1 month 6 days	9 years	9 years 2 months 12 days
Beginning of the year									144,590	131,661	74,147
Grant 1 [Member]
IfrsStatementLineItems [Line Items]
Grant date									20 April 2012	20 April 2012	20 April 2012
Beginning of the year									79	79	79
Granted
Lapsed									(79)
Forfeited
Beginning of the year										79	79
Exercise Price | £ / shares									£ 1,676	£ 1,676	£ 1,676
Beginning of the year										79	79
Grant 2 [Member]
IfrsStatementLineItems [Line Items]
Grant date									9 May 2014	9 May 2014	9 May 2014
Beginning of the year									500	500	500
Granted
Lapsed									(500)
Forfeited
Beginning of the year										500	500
Exercise Price | £ / shares									£ 30	£ 30	£ 30
Beginning of the year										500	500
Grant 3 [Member]
IfrsStatementLineItems [Line Items]
Grant date									30 June 2014	30 June 2014	30 June 2014
Beginning of the year									25	25	925
Granted
Lapsed
Forfeited											(9,000)
Beginning of the year									25	25	25
Exercise Price | £ / shares									£ 30	£ 30	£ 30
Beginning of the year									25	25	25
Grant 4 [Member]
IfrsStatementLineItems [Line Items]
Grant date									31 October 2016	31 October 2016	31 October 2016
Beginning of the year									352	397	815
Granted
Lapsed									(352)		(43)
Forfeited										(45)	(375)
Beginning of the year										352	397
Exercise Price | £ / shares									£ 1,072	£ 1,072	£ 1,072
Beginning of the year										352	397
Grant 5 [Member]
IfrsStatementLineItems [Line Items]
Grant date									19 December 2016	19 December 2016	19 December 2016
Beginning of the year									396	499	1,118
Granted
Lapsed									(383)		(78)
Forfeited										(103)	(541)
Beginning of the year									13	396	499
Exercise Price | £ / shares									£ 484	£ 484	£ 484
Beginning of the year									13	396	499
Grant 6 [Member]
IfrsStatementLineItems [Line Items]
Grant date									15 December 2017	15 December 2017	15 December 2017
Beginning of the year									59	164	1,478
Granted
Lapsed											(666)
Forfeited									(19)	(105)	(648)
Beginning of the year									40	59	164
Exercise Price | £ / shares									£ 184	£ 184	£ 184
Beginning of the year									40	59	164
Grant 7 [Member]
IfrsStatementLineItems [Line Items]
Grant date									24 April 2019	24 April 2019	24 April 2019
Beginning of the year									625	2,275	8,475
Granted
Lapsed
Forfeited									(313)	(1,650)	(6,200)
Beginning of the year									312	625	2,275
Exercise Price | £ / shares									£ 29.20	£ 29.20	£ 29.20
Beginning of the year									312	625	2,275
Grant 8 [Member]
IfrsStatementLineItems [Line Items]
Grant date									2 October 2019	2 October 2019	2 October 2019
Beginning of the year									1,500	1,500	2,500
Granted
Lapsed
Forfeited											(1,000)
Beginning of the year									1,500	1,500	1,500
Exercise Price | £ / shares									£ 21	£ 21	£ 21
Beginning of the year									1,500	1,500	1,500
Grant 9 [Member]
IfrsStatementLineItems [Line Items]
Grant date										17 April 2020	17 April 2020
Beginning of the year									5,000	5,000
Granted											5,000
Lapsed
Forfeited
Beginning of the year									5,000	5,000	5,000
Exercise Price | £ / shares									£ 4.80	£ 4.80	£ 4.80
Beginning of the year									5,000	5,000	5,000
Grant 10 [Member]
IfrsStatementLineItems [Line Items]
Grant date									17 June 2020	17 June 2020	17 June 2020
Beginning of the year									43,175	63,700
Granted											68,150
Lapsed									(5,625)
Forfeited									(3,950)	(20,525)	(4,450)
Beginning of the year									33,600	43,175	63,700
Exercise Price | £ / shares									£ 4.04	£ 4.04	£ 4.04
Beginning of the year									33,600	43,175	63,700
Grant 11 [Member]
IfrsStatementLineItems [Line Items]
Grant date									15 July 2021	15 July 2021
Beginning of the year									71,450
Granted										85,450
Lapsed
Forfeited									(7,100)	(14,000)
Beginning of the year									64,350	71,450
Exercise Price | £ / shares									£ 5.55	£ 5.55
Beginning of the year									64,350	71,450
Grant 12 [Member]
IfrsStatementLineItems [Line Items]
Grant date									2 August 2021	2 August 2021
Beginning of the year									2,500
Granted										2,500
Lapsed
Forfeited
Beginning of the year									2,500	2,500
Exercise Price | £ / shares									£ 5.30	£ 5.30
Beginning of the year									2,500	2,500
Grant 13 [Member]
IfrsStatementLineItems [Line Items]
Grant date									1 September 2021	1 September 2021	11 July 2014
Beginning of the year									6,000		6
Granted										6,000
Lapsed											(3)
Forfeited											(3)
Beginning of the year									6,000	6,000
Exercise Price | £ / shares									£ 5.10	£ 5.10	£ 30
Beginning of the year									6,000	6,000
Grant 14 [Member]
IfrsStatementLineItems [Line Items]
Grant date									7 February 2022	14 December 2016	1 April 2010
Beginning of the year											20
Granted									18,750
Lapsed										(20)
Forfeited
Beginning of the year									18,750
Exercise Price | £ / shares									£ 3.05	£ 620
Beginning of the year									18,750
Grant 15 [Member]
IfrsStatementLineItems [Line Items]
Grant date									12 August 2022	14 December 2016	20 August 2010
Beginning of the year											25
Granted									12,500
Lapsed										(25)
Forfeited
Beginning of the year									12,500
Exercise Price | £ / shares									£ 2.10	£ 680
Beginning of the year									12,500
Grants [Member]
IfrsStatementLineItems [Line Items]
Grant date										13 September 2011	13 September 2011
Beginning of the year										8	8
Granted
Lapsed										(8)
Forfeited
Beginning of the year											8
Exercise Price | £ / shares										£ 1,676	£ 1,676
Beginning of the year											8
Grant 21 [Member]
IfrsStatementLineItems [Line Items]
Beginning of the year											63
Granted
Lapsed											(63)
Forfeited
Beginning of the year
Exercise Price | £ / shares											£ 1,600
Beginning of the year
Grant 22 [Member]
IfrsStatementLineItems [Line Items]
Beginning of the year											104
Granted
Lapsed											(104)
Forfeited
Beginning of the year
Exercise Price | £ / shares											£ 1,676
Beginning of the year
Grant 16 [Member]
IfrsStatementLineItems [Line Items]
Grant date											14 December 2016
Beginning of the year											100
Granted
Lapsed											(100)
Forfeited
Beginning of the year
Exercise Price | £ / shares											£ 748
Beginning of the year
Grant 17 [Member]
IfrsStatementLineItems [Line Items]
Grant date											14 December 2016
Beginning of the year											81
Granted
Lapsed											(81)
Forfeited
Beginning of the year
Exercise Price | £ / shares											£ 752
Beginning of the year
Grant 18 [Member]
IfrsStatementLineItems [Line Items]
Grant date											15 December 2016
Beginning of the year											230
Granted
Lapsed											(230)
Forfeited
Beginning of the year
Exercise Price | £ / shares											£ 484
Beginning of the year
Grant 19 [Member]
IfrsStatementLineItems [Line Items]
Grant date											2 April 2018
Beginning of the year											50
Granted
Lapsed											(50)
Forfeited
Beginning of the year
Exercise Price | £ / shares											£ 332
Beginning of the year
Grant 20 [Member]
IfrsStatementLineItems [Line Items]
Grant date											2 April 2018
Beginning of the year											225
Granted
Lapsed											(225)
Forfeited
Beginning of the year
Exercise Price | £ / shares											£ 484
Beginning of the year

Share-based payments (Details 1

Share-based payments (Details 1)	1 Months Ended																12 Months Ended
	Aug. 31, 2022 Number £ / shares		Aug. 31, 2022 Number £ / shares		Feb. 28, 2022 Number £ / shares		Sep. 30, 2021 Number £ / shares		Aug. 31, 2021 Number £ / shares		Jul. 31, 2021 Number £ / shares		Jun. 30, 2020 Number £ / shares		Apr. 30, 2020 Number £ / shares		Dec. 31, 2022 Number	Dec. 31, 2021 Number	Dec. 31, 2020 Number
Notes and other explanatory information [abstract]
Number of options	7,500		5,000		18,750		6,000		2,500		85,450		68,150		5,000		31,250	93,950	73,150
Option pricing models used	Black-Scholes		Black-Scholes		Black-Scholes
Share price	2.10		2.10		3.05
Exercise price of options issued in year | £ / shares	£ 2.10		£ 2.10		£ 3.05		£ 5.10	[1]	£ 5.30	[1]	£ 5.55	[1]	£ 4.04	[2]	£ 4.80	[2]
Contractual life	10 years		10 years		10 years		10 years		10 years		10 years		10 years		10 years
Expected life	5 years		5 years		5 years		5 years		5 years		5 years		5 years		5 years
Volatility	91.66%	[3]	91.78%	[3]	87.88%	[3]	88.11%	[4]	88.59%	[4]	88.63%	[4]	92.55%	[5]	84.76%	[5]
Expected dividend yield	0%		0%		0%		0%		0%		0%		0%		0%
Risk free rate	1.92%		1.92%		1.28%		0.32%		0.26%		0.38%		0.10%		0.11%
[1]The share price used in the determination of the fair value of the options granted in 2021 was the share price on the date of grant.[2]The share price used in the determination of the fair value of the options granted in 2020 was the share price on the date of grant.[3]Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period.[4]Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period.[5]Volatility was calculated with reference to the historic share price volatility of comparable companies measured over a five-year period.

Related party transactions (Det

Related party transactions (Details) - Bio Connection [Member] - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Purchase of good			£ 296
Amounts owed by related parties

Retirement benefits (Details Na

Retirement benefits (Details Narrative) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Notes and other explanatory information [abstract]
Retirement benefits	£ 98	£ 71

Results of Midatech Pharma (E_3

Results of Midatech Pharma (Espana) SL (Details) - GBP (£) £ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Grant revenue					£ 163
Research and development costs	£ (2,251)	£ (2,413)	(5,111)	(4,654)	(6,068)
Administrative costs	(2,291)	(1,849)	(4,542)	(2,946)	(4,958)
Loss from operations	(4,244)	(3,778)	(8,932)	(6,998)	(23,040)
Finance expense	(22)	(24)	(53)	(44)	(431)
Loss before tax	(3,856)	(3,398)	(8,488)	(6,106)	(23,470)
Taxation	£ 288	£ 337	832	646	1,281
Loss from operations after tax			£ (7,656)	£ (5,460)	(22,189)
Discontinued operations [member]
IfrsStatementLineItems [Line Items]
Grant revenue					163
Total revenue					163
Research and development costs					(2,820)
Administrative costs					1,146
Loss from operations					(3,803)
Finance expense					11
Loss before tax					(3,814)
Taxation					(21)
Loss from operations after tax					£ (3,835)

Post Balance Sheet Events (Deta

Post Balance Sheet Events (Details) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Ordinary shares outstanding	99,191,082	4,923,828	4,941,793	4,027,345	2,142,000
Pre Split [Member]
IfrsStatementLineItems [Line Items]
Weighted average number of shares outstanding - basic and diluted			98,835,849
Ordinary shares outstanding			108,342,738
Outstanding employee share options over ordinary shares			2,891,875
Outstanding DARA options over ordinary shares			2,822
Outstanding warrants over ordinary shares			17,221,973
Post Split [Member]
IfrsStatementLineItems [Line Items]
Weighted average number of shares outstanding - basic and diluted			4,941,793
Ordinary shares outstanding			5,417,137
Outstanding employee share options over ordinary shares			144,590
Outstanding DARA options over ordinary shares			138
Outstanding warrants over ordinary shares			861,075

Post Balance Sheet Events (De_2

Post Balance Sheet Events (Details Narrative) - GBP (£)	Feb. 09, 2023	Jan. 23, 2023	Jan. 05, 2023	Dec. 19, 2022
Post Balance Sheet Events
Further advance				£ 250,000
Equity raise			£ 9,600,000
Requested for reimbursement		£ 225,000
Raise gross proceeds	£ 6,000,000
Units issued	10,344,822